
<html lang="en"     class="pb-page"  data-request-id="f29ba5d0-b958-4705-ae00-68452148821e"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.0c02153;wgroup:string:ACHS website Group;issue:issue:10.1021/jmcmar.2021.64.issue-6;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Identification of Novel Tricyclic Benzo[1,3]oxazinyloxazolidinones as Potent Antibacterial Agents with Excellent Pharmacokinetic Profiles against Drug-Resistant Pathogens" /></meta><meta name="dc.Creator" content="Yongqi  Wu" /></meta><meta name="dc.Creator" content="Bin  Wang" /></meta><meta name="dc.Creator" content="Haijia  Lu" /></meta><meta name="dc.Creator" content="Hongyi  Zhao" /></meta><meta name="dc.Creator" content="Beibei  Yang" /></meta><meta name="dc.Creator" content="Li  Li" /></meta><meta name="dc.Creator" content="Yu  Lu" /></meta><meta name="dc.Creator" content="Dongfeng  Zhang" /></meta><meta name="dc.Creator" content="Ning  Sun" /></meta><meta name="dc.Creator" content="Haihong  Huang" /></meta><meta name="dc.Description" content="A series of conformationally constrained novel benzo[1,3]oxazinyloxazolidinones were designed, synthesized, and evaluated on their activities against Mycobacterium tuberculosis, Gram-positive bacte..." /></meta><meta name="Description" content="A series of conformationally constrained novel benzo[1,3]oxazinyloxazolidinones were designed, synthesized, and evaluated on their activities against Mycobacterium tuberculosis, Gram-positive bacte..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="March 11, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c02153" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c02153" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c02153" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c02153" /></link>
        
    
    

<title>Identification of Novel Tricyclic Benzo[1,3]oxazinyloxazolidinones as Potent Antibacterial Agents with Excellent Pharmacokinetic Profiles against Drug-Resistant Pathogens | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c02153" /></meta><meta property="og:title" content="Identification of Novel Tricyclic Benzo[1,3]oxazinyloxazolidinones as Potent Antibacterial Agents with Excellent Pharmacokinetic Profiles against Drug-Resistant Pathogens" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/large/jm0c02153_0015.jpeg" /></meta><meta property="og:description" content="A series of conformationally constrained novel benzo[1,3]oxazinyloxazolidinones were designed, synthesized, and evaluated on their activities against Mycobacterium tuberculosis, Gram-positive bacteria, and Gram-negative bacteria. The studies identified a new compound 20aa that displayed good to excellent antibacterial and antitubercular profiles against drug-resistant TB strains (MIC = 0.48–0.82 μg/mL), MRSA (MIC = 0.25–0.5 μg/mL), MRSE (MIC = 1 μg/mL), VISA (MIC = 0.25 μg/mL), and VRE (MIC = 0.25 μg/mL) and some linezolid-resistant strains (MIC 1–2 μg/mL). Compound 20aa was demonstrated as a promising candidate through ADME/T evaluation including microsomal stability, cytotoxicity, and inhibition of hERG and monoamine oxidase. Notably, 20aa showed excellent mouse PK profile with high plasma exposure (AUC0–∞ = 78 669 h·ng/mL), high peak plasma concentration (Cmax = 10 253 ng/mL), appropriate half-life of 3.76 h, and superior oral bioavailability (128%). The present study not only successfully provides a novel benzo[1,3]oxazinyloxazolidinone scaffold with superior druggability but also lays a good foundation for new antibacterial drug development." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c02153"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02153">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c02153&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c02153&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c02153&amp;href=/doi/10.1021/acs.jmedchem.0c02153" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 6</span><span class="cit-fg-pageRange">, 3234-3248</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/6" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c02151" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c02156" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Identification of Novel Tricyclic Benzo[1,3]oxazinyloxazolidinones as Potent Antibacterial Agents with Excellent Pharmacokinetic Profiles against Drug-Resistant Pathogens</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Yongqi Wu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yongqi Wu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Beijing 100050, P. R. China</div><div class="loa-info-affiliations-info">Chinese Academy of Medical Sciences Key Laboratory of Anti-DR TB Innovative Drug Research, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Beijing 100050, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yongqi++Wu">Yongqi Wu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Bin Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Bin Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Department of Pharmacology, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, 97 Ma Chang Street, Beijing 101149, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Bin++Wang">Bin Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Haijia Lu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Haijia Lu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Beijing 100050, P. R. China</div><div class="loa-info-affiliations-info">Chinese Academy of Medical Sciences Key Laboratory of Anti-DR TB Innovative Drug Research, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Beijing 100050, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Haijia++Lu">Haijia Lu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hongyi Zhao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hongyi Zhao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Beijing 100050, P. R. China</div><div class="loa-info-affiliations-info">Chinese Academy of Medical Sciences Key Laboratory of Anti-DR TB Innovative Drug Research, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Beijing 100050, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hongyi++Zhao">Hongyi Zhao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Beibei Yang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Beibei Yang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Beijing 100050, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Beibei++Yang">Beibei Yang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Li Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Li Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Beijing 100050, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Li++Li">Li Li</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9496-2280" title="Orcid link">http://orcid.org/0000-0002-9496-2280</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yu Lu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yu Lu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Department of Pharmacology, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, 97 Ma Chang Street, Beijing 101149, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yu++Lu">Yu Lu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dongfeng Zhang</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dongfeng Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Beijing 100050, P. R. China</div><div class="loa-info-affiliations-info">Chinese Academy of Medical Sciences Key Laboratory of Anti-DR TB Innovative Drug Research, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Beijing 100050, P. R. China</div></div><span class="conrtib-corresp"><strong>*</strong>D.Z.: email, <a href="/cdn-cgi/l/email-protection#13697775537a7e7e3d72703d707d"><span class="__cf_email__" data-cfemail="85ffe1e3c5ece8e8abe4e6abe6eb">[email protected]</span></a>; phone, +86-10-63165254.</span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dongfeng++Zhang">Dongfeng Zhang</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0870-3782" title="Orcid link">http://orcid.org/0000-0003-0870-3782</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ning Sun</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ning Sun</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">The State Key Laboratory of Chemical Biology and Drug Discovery, Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong, P. R. China</div><div class="loa-info-affiliations-info">The Fifth Affiliated Hospital of Guangzhou Medical University, 621 Gang Wan Road, Guangzhou 440112, P. R. China</div></div><span class="conrtib-corresp"><strong>*</strong>N.S.: email, <a href="/cdn-cgi/l/email-protection#fc9295929bd28f8992bc9f939292999f88d28c93908589d29497"><span class="__cf_email__" data-cfemail="147a7d7a733a67617a54777b7a7a7177603a647b786d613a7c7f">[email protected]</span></a>; phone, +86-13312853311.</span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ning++Sun">Ning Sun</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Haihong Huang</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Haihong Huang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Beijing 100050, P. R. China</div><div class="loa-info-affiliations-info">Chinese Academy of Medical Sciences Key Laboratory of Anti-DR TB Innovative Drug Research, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Beijing 100050, P. R. China</div></div><span class="conrtib-corresp"><strong>*</strong>H.H.: email, <a href="/cdn-cgi/l/email-protection#1e7471677d7b5e777373307f7d307d70"><span class="__cf_email__" data-cfemail="f3999c8a9096b39a9e9edd9290dd909d">[email protected]</span></a>; phone, +86-10-63165244.</span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Haihong++Huang">Haihong Huang</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c02153&amp;href=/doi/10.1021%2Facs.jmedchem.0c02153" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 6</span><span class="cit-pageRange">, 3234–3248</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">March 11, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>14 December 2020</li><li><span class="item_label"><b>Published</b> online</span>11 March 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 25 March 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c02153" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c02153</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D3234%26pageCount%3D15%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DYongqi%2BWu%252C%2BBin%2BWang%252C%2BHaijia%2BLu%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D6%26contentID%3Dacs.jmedchem.0c02153%26title%3DIdentification%2Bof%2BNovel%2BTricyclic%2BBenzo%255B1%252C3%255Doxazinyloxazolidinones%2Bas%2BPotent%2BAntibacterial%2BAgents%2Bwith%2BExcellent%2BPharmacokinetic%2BProfiles%2Bagainst%2BDrug-Resistant%2BPathogens%26numPages%3D15%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D3248%26publicationDate%3DMarch%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c02153"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1173</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">2</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c02153" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Identification of Novel Tricyclic Benzo[1,3]oxazinyloxazolidinones as Potent Antibacterial Agents with Excellent Pharmacokinetic Profiles against Drug-Resistant Pathogens&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Yongqi&quot;,&quot;last_name&quot;:&quot;Wu&quot;},{&quot;first_name&quot;:&quot;Bin&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Haijia&quot;,&quot;last_name&quot;:&quot;Lu&quot;},{&quot;first_name&quot;:&quot;Hongyi&quot;,&quot;last_name&quot;:&quot;Zhao&quot;},{&quot;first_name&quot;:&quot;Beibei&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Li&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Yu&quot;,&quot;last_name&quot;:&quot;Lu&quot;},{&quot;first_name&quot;:&quot;Dongfeng&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Ning&quot;,&quot;last_name&quot;:&quot;Sun&quot;},{&quot;first_name&quot;:&quot;Haihong&quot;,&quot;last_name&quot;:&quot;Huang&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;03&quot;,&quot;day&quot;:&quot;11&quot;,&quot;issue&quot;:&quot;6&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;3234-3248&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c02153&quot;},&quot;abstract&quot;:&quot;A series of conformationally constrained novel benzo[1,3]oxazinyloxazolidinones were designed, synthesized, and evaluated on their activities against Mycobacterium tuberculosis, Gram-positive bacteria, and Gram-negative bacteria. The studies identified a new compound 20aa that displayed good to excellent antibacterial and antitubercular profiles against drug-resistant TB strains (MIC = 0.48–0.82 μg/mL), MRSA (MIC = 0.25–0.5 μg/mL), MRSE (MIC = 1 μg/mL), VISA (MIC = 0.25 μg/mL), and VRE (MIC = 0.25 μg/mL) and some linezolid-resistant strains (MIC 1–2 μg/mL). Compound 20aa was demonstrated as a promising candidate through ADME/T evaluation including microsomal stability, cytotoxicity, and inhibition of hERG and monoamine oxidase. Notably, 20aa showed excellent mouse PK profile with high plasma exposure (AUC0–∞ = 78 669 h·ng/mL), high peak plasma concentration (Cmax = 10 253 ng/mL), appropriate half-life of 3.76 h, and superior oral bioavailability (128%). The present study not only successfully provides a novel&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c02153&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02153" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c02153&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02153" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c02153&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02153" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c02153&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02153&amp;href=/doi/10.1021/acs.jmedchem.0c02153" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c02153" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c02153" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c02153%26sid%3Dliteratum%253Aachs%26pmid%3D33705128%26genre%3Darticle%26aulast%3DWu%26date%3D2021%26atitle%3DIdentification%2Bof%2BNovel%2BTricyclic%2BBenzo%255B1%252C3%255Doxazinyloxazolidinones%2Bas%2BPotent%2BAntibacterial%2BAgents%2Bwith%2BExcellent%2BPharmacokinetic%2BProfiles%2Bagainst%2BDrug-Resistant%2BPathogens%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D6%26spage%3D3234%26epage%3D3248%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291362" title="Antimicrobial agents">Antimicrobial agents</a>,</li><li><a href="/action/doSearch?ConceptID=291214" title="Bacteria">Bacteria</a>,</li><li><a href="/action/doSearch?ConceptID=292201" title="Scaffolds">Scaffolds</a>,</li><li><a href="/action/doSearch?ConceptID=291676" title="Antibacterial activity">Antibacterial activity</a>,</li><li><a href="/action/doSearch?ConceptID=291675" title="Stability">Stability</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/6" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/jmcmar.2021.64.issue-6/20210325/jmcmar.2021.64.issue-6.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/medium/jm0c02153_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/large/jm0c02153_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02153&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">A series of conformationally constrained novel benzo[1,3]oxazinyloxazolidinones were designed, synthesized, and evaluated on their activities against <i>Mycobacterium tuberculosis</i>, Gram-positive bacteria, and Gram-negative bacteria. The studies identified a new compound <b>20aa</b> that displayed good to excellent antibacterial and antitubercular profiles against drug-resistant TB strains (MIC = 0.48–0.82 μg/mL), MRSA (MIC = 0.25–0.5 μg/mL), MRSE (MIC = 1 μg/mL), VISA (MIC = 0.25 μg/mL), and VRE (MIC = 0.25 μg/mL) and some linezolid-resistant strains (MIC 1–2 μg/mL). Compound <b>20aa</b> was demonstrated as a promising candidate through ADME/T evaluation including microsomal stability, cytotoxicity, and inhibition of hERG and monoamine oxidase. Notably, <b>20aa</b> showed excellent mouse PK profile with high plasma exposure (AUC<sub>0–∞</sub> = 78 669 h·ng/mL), high peak plasma concentration (<i>C</i><sub>max</sub> = 10 253 ng/mL), appropriate half-life of 3.76 h, and superior oral bioavailability (128%). The present study not only successfully provides a novel benzo[1,3]oxazinyloxazolidinone scaffold with superior druggability but also lays a good foundation for new antibacterial drug development.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20746" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20746" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Spanning decades, the use and misuse of antibiotics have increased the occurrence of drug resistant bacterial strains. This occurrence and prevalence of multidrug resistance strains pose one of the greatest risks to human health<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> and will inevitably increase in the future. In 2017, the World Health Organization released a list of 12 bacteria or bacterial families that pose the greatest threat to human health and for which new antibiotics are desperately needed. The list included a range of bacteria. Among them a quarter of the bacteria were Gram-positive bacteria, including methicillin-resistant <i>Staphylococcus aureus</i> (MRSA), vancomycin-resistant <i>Enterococci</i> (VRE) and penicillin-resistant <i>Streptococcus pneumoniae</i> (PRSP). <i>Mycobacterium tuberculosis</i> (<i>M. tuberculosis</i>) was not added to the list due to the fact that it is a well-established priority for new drug discovery.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> In 2019 alone, there were estimated 0.5 million new cases that displayed resistance to rifampicin, the most effective first-line drug, of which 78% were multidrug-resistant TB.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> There is therefore a clear and urgent need to develop antibacterial agents bearing novel pharmacophores or new modes of action to combat these multidrug resistant bacteria.</div><div class="NLM_p">Oxazolidinones were developed as a new class of synthetic antibacterial agents and exhibited their antibacterial activity through a unique mode of action. The compounds bind to 23S rRNA of the bacterial 50S ribosomal subunit and inhibit the bacterial protein synthesis at the initiation step.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> As shown in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>, linezolid (<b>1</b>)<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> was the first approved (2000) oxazolidinone antibacterial drug for the treatment of Gram-positive bacterial infections and has been off-label used in the treatment of complicated MDR-TB and XDR-TB. As one component in the Nix-TB regimen, consisting of bedaquiline, pretomanid, and linezolid, for the treatment of XDR-TB or treatment-intolerant/nonresponsive MDR-TB,<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> linezolid plays a key role in the efficacy of the treatment. As such, much effort has been devoted to improving the activity and ADME/T properties of linezolid. Extensive structural modifications along with the structure–activity relationship (SAR) studies were focused on the C-ring and C5 side chain (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) of the parent scaffold.<a onclick="showRef(event, 'ref7 ref8 ref9 ref10 ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref7 ref8 ref9 ref10 ref11 ref12">(7−12)</a> Tedizolid phosphate (<b>2</b>) was the second oxazolidinone drug approved by FDA for the treatment of MRSA skin infections in 2014.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Contezolid (<b>3</b>), developed by MicuRx Pharmaceuticals, phase III clinical trials were recently finished and the New Drug Application was submitted to regulators.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Furthermore, three oxazolidinones have been evaluated on their clinical effects with varying success such as delpazolid (<b>4</b>) (for Gram-positive bacteria and TB),<a onclick="showRef(event, 'ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref15 ref16">(15,16)</a> sutezolid (<b>5</b>) (for TB),<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17,18)</a> and TBI-223 (<b>6</b>) (for TB).<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Oxazolidinones can therefore be described as the privileged scaffold in antibacterial drug discovery, and further diversification of this important pharmacophore shows the potential to lead to the discovery of new antibacterial agents against both Gram-positive bacteria and <i>M. tuberculosis</i>.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/medium/jm0c02153_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/large/jm0c02153_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Representative structure modifications of linezolid focused on the C-ring and C5 side chain.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/large/jm0c02153_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02153&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Recently, the conformationally unique benzoxazinyloxazolidinone tricyclic scaffold has undergone intensive investigation. Yang and co-workers reported a series of benzo[1,4]oxazinyloxazolidinones<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20,21)</a> as antibacterial agents (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). The SAR showed that the compound with aryl group as the C ring was more active against MRSA and MRSE than that with the corresponding alkyl group, while the derivatives with fluorine substitution on the B ring generated reduced activity. Interestingly, our previous work identified that the promising candidates exhibiting highly potent antitubercular activity contained an aliphatic heterocyclic group as the C ring of this interesting motif. The SAR expressed that F substitution on the B ring was beneficial for improving the antitubercular activity and significantly reducing overall cytotoxicity.<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22,23)</a> Although there are some differences in the SAR described between Yang’s work and our reported work, this conformationally constrained tricyclic scaffold exhibited good to excellent antibacterial activities, with notably superior PK properties. These prominent characteristics displayed by this aforementioned benzo[1,4]oxazinyloxazolidinones led us to conclude that the exploration of chemical space between the phenyl (B ring) and the oxazolidinone (A ring) motif would pay dividends in relation to the discovery of potentially novel antibacterial agents bearing novel scaffolds.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/medium/jm0c02153_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/large/jm0c02153_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Design of novel conformational constraint oxazolidinones.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/large/jm0c02153_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02153&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Herein, we disclose our design and synthesis of novel oxazolidinones containing unique benzo[<i>e</i>]oxazolo[4,3-<i>b</i>][1,3]oxazin-1-one scaffold (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>), and their subsequent evaluation for antibacterial and antitubercular properties. We aim to explore the effect of aromatic or nonaromatic groups and F substitution on the B ring, as well as the key methylene linkage between the B ring (phenyl ring) and A ring (oxazolidinone ring) on the antibacterial activity, cytotoxicity, and PK properties of this new type of molecule. Interestingly, the newly designed benzo[1,3]oxazinyloxazolidinone scaffold displayed differential SAR compared to that established by the benzo[1,4]oxazinyloxazolidinones and the traditional phenyloxazolidinones such as linezolid. In particular, this novel scaffold exhibited good to excellent activity against both Gram-positive bacteria and <i>M. tuberculosis</i>, particularly against drug-resistant bacteria including MRSA, MRSE, VISA, VRE, and TB strains. The present study demonstrated systematically that compound <b>20aa</b> exhibited not only highly potent antitubercular and antibacterial activities including moderate activity against linezolid-resistant isolated clinical strains but also superior PK profiles with oral bioavailability up to 128% in mice.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30787" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30787" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The synthetic route of the critical tricyclic fused benzo[1,3]oxazinyloxazolidinone intermediates <b>(±)-18a</b> and <b>(±)-18b</b> is depicted in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Compound <b>8a</b> was prepared from 4-fluoro-2-hydroxybenzoic acid (<b>7a</b>) according to the literature.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> After esterification, the amination of <b>8a</b> gave the desired amide <b>9a</b> in 83% yield. The amide group of <b>9a</b> was subsequently reduced with BH<sub>3</sub> and followed by the protection with benzyl chloroformate (CbzCl) to afford compound <b>10a</b> at room temperature. The key oxazolidinone fragment 5-(hydroxymethyl)-3-(4-methoxybenzyl)oxazolidin-2-one (<b>13</b>) was synthesized from 4-methoxybenzylamine (<b>11</b>) and 2-(chloromethyl)oxirane (<b>12</b>) in the presence of K<sub>2</sub>CO<sub>3</sub> as base.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> The key intermediate <b>14</b> was produced from <b>13</b> via a Swern oxidation.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> This was followed by a tandem condensation/cyclization strategy to construct the 1,3-oxazinane ring from <b>10a</b> and <b>14</b>.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> As compound <b>14</b> has a chiral center, the cyclization will produce four distinct stereoisomers: two racemic diastereomers, <b>(±)-15a</b> (<i>trans</i>) and <b>(±)-15b</b> (<i>cis</i>), which were isolated by silica gel column chromatography directly. After cleavage of the 4-methoxybenzyl (PMB) group, the nitrogen atom in the intermediates <b>(±)-16a</b> and <b>(±)-16b</b> was Boc-protected to give <b>(±)-17a</b> and <b>(±)-17b</b>, respectively.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/medium/jm0c02153_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/large/jm0c02153_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Benzo[1,3]oxazinyloxazolidinone Intermediates <b>(±)-18a</b> and <b>(±)-18b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/large/jm0c02153_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02153&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NBS, conc H<sub>2</sub>SO<sub>4</sub>, MeCN, rt, 1 h, 84%; (b) (i) conc H<sub>2</sub>SO<sub>4</sub>, MeOH, reflux, 32 h; (ii) NH<sub>4</sub>OH, MeOH, 55 °C, 6 h, 83% of two steps; (c) (i) BH<sub>3</sub>, THF, reflux, 5 h; (ii) CbzCl, NaHCO<sub>3</sub>, THF/H<sub>2</sub>O = 5:1, rt, 3 h, 72% of two steps; (d) K<sub>2</sub>CO<sub>3</sub>, TEA, MeOH, reflux, 12 h, 60%; (e) (COCl)<sub>2</sub>, DMSO, TEA, THF, −78 °C to rt, 90%; (f) TsOH·H<sub>2</sub>O, toluene, reflux, 6 h, 49% for <b>(±)-15a</b>, 25% for <b>(±)-15b</b>; (g) ceric ammonium nitrate (CAN), MeCN/H<sub>2</sub>O = 9:1, rt, 2 h, 78% for <b>(±)-16a</b>, 76% for <b>(±)-16b</b>; (h) (Boc)<sub>2</sub>O, TEA, DMAP, DCM, rt, 2 h, 78% for <b>(±)-17a</b>, 82% for <b>(±)-17b</b>; (i) Cs<sub>2</sub>CO<sub>3</sub>, MeOH, rt, 3h, 89% for <b>(±)-18a</b>, 91% for <b>(±)-18b</b>.</p></p></figure><div class="NLM_p">The benzo[<i>e</i>]oxazolo[4,3-<i>b</i>][1,3]oxazin-1-one scaffold was constructed by an ingenious tandem reaction. The oxazolidinone ring of <b>(±)-17a</b> and <b>(±)-17b</b> was opened in the presence of Cs<sub>2</sub>CO<sub>3</sub> to afford the required oxazolidinone ring immediately and gave the key intermediates <b>(±)-18a</b> and <b>(±)-18b</b> with the novel tricyclic scaffold, respectively.</div><div class="NLM_p">The coupling of <b>(±)-18a</b> or <b>(±)-18b</b> with boronic acid ester afforded compounds <b>(±)-19a</b> or <b>(±)-19b</b>. Finally, <b>(±)-20a</b> and <b>(±)-20b</b> were obtained via cleavage of the protective carbamate group, followed by acetylation with acetyl chloride (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). Compound <b>(±)-20a</b> was separated as the pure enantiomers <b>20aa</b> and <b>20ab</b> with chiral HPLC (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). The absolute configurations of the above prepared compounds <b>20aa</b> and <b>20ab</b> were determined by the comparison of the experimental ECD spectrum and the corresponding calculated ECD spectra of compounds <b>20aa</b> and <b>20ab</b> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). The ECD spectrum recorded for <b>20aa</b> matches the calculated ECD curve of <b>20aa</b> but is opposite to that of <b>20ab</b>. Therefore, compounds <b>20aa</b> and <b>20ab</b> were deduced to have the (3<i>S</i>,3a<i>S</i>) and (3<i>R</i>,3a<i>R</i>) absolute configuration, respectively.</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/medium/jm0c02153_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/large/jm0c02153_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>(±)-20a</b> and <b>(±)-20b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/large/jm0c02153_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02153&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)picolinonitrile, Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub>, DMSO/H<sub>2</sub>O = 6:1, 100 °C, 5 h, 84% for <b>(±)-19a</b>, 81% for <b>(±)-19b</b>; (b) (i) TFA, DCM, rt, 2 h; (ii) acetyl chloride, TEA, DCM, 0 °C, 2 h, 87% for <b>(±)-20a</b>, 80% for <b>(±)-20b</b>.</p></p></figure><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/medium/jm0c02153_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/large/jm0c02153_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Separation of Compound <b>(±)-20a</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/large/jm0c02153_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02153&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) CHIRALPAK IA column, MeOH/EtOAc = 80:20, 1.0 mL/min, λ = 254 nm, 25 °C.</p></p></figure><figure id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/medium/jm0c02153_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/large/jm0c02153_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. ECD spectra of compounds <b>20aa</b> and <b>20ab</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/large/jm0c02153_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02153&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The synthetic route of the fluoride-free compound <b>(±)-24</b> is outlined in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>. Compound <b>(±)-24</b> was prepared from 5-bromo-2-hydroxybenzamide (<b>9b</b>) in a similar procedure as shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. The synthesis of the chiral pure target compounds <b>20aa</b>, <b>30</b>–<b>38</b> are outlined in <a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>. First, the pure enantiomers <b>18a</b> and <b>24</b> were obtained by chiral HPLC separation and then reacted with arylboronate ester or morpholine to afford intermediates <b>25</b>–<b>29</b> followed by subsequent deprotection of the <i>N</i>-Boc group to deliver amine compounds <b>30</b>–<b>34</b>. The desired products, <b>20aa</b> and <b>35</b>–<b>38</b>, were obtained from compounds <b>30</b>–<b>34</b> via the acetylation of the NH<sub>2</sub> group with acetyl chloride. The absolute configuration of the synthetic target compound was determined by chiral HPLC compared with the optically pure <b>20aa</b> obtained by chiral chromatography separation (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02153/suppl_file/jm0c02153_si_001.pdf" class="ext-link">Figure S4</a>).</div><figure id="sch4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/medium/jm0c02153_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/large/jm0c02153_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Compound <b>(±)-24</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/large/jm0c02153_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02153&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (i) BH<sub>3</sub>, THF, reflux, 5 h; (ii) CbzCl, NaHCO<sub>3</sub>, THF/H<sub>2</sub>O = 5:1, rt, 3 h, 72% of two steps; (b) TsOH·H<sub>2</sub>O, toluene, reflux, 6 h, 50%; (c) CAN, MeCN/H<sub>2</sub>O = 9:1, rt, 2 h, 76%; (d) (Boc)<sub>2</sub>O, TEA, DMAP, DCM, rt, 2 h, 90%; (e) Cs<sub>2</sub>CO<sub>3</sub>, MeOH, rt, 3 h, 84%.</p></p></figure><figure id="sch5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/medium/jm0c02153_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/large/jm0c02153_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Target Compounds <b>20aa</b> and <b>30</b>–<b>38</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/large/jm0c02153_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02153&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) CHIRALPAK AD-H column, MeOH = 100%, 1.0 mL/min, λ = 214 nm, 35 °C, for <b>18a</b>; CHIRALPAK IA column, hexane/EtOH = 50:50, 1.0 mL/min, λ = 254 nm, 25 °C, for <b>24</b>; (b) (i) arylboronic acid ester, Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub>, DMSO/H<sub>2</sub>O = 6:1, 100 °C, 5 h, 57–89%, for <b>25</b>, <b>26</b>, and <b>28</b>; (ii) morpholine, X-PHOS, Pd(OAc)<sub>2</sub>, Cs<sub>2</sub>CO<sub>3</sub>, toluene, reflux, 100 °C, 6 h, 44–66%, for <b>27</b> and <b>29</b>; (c) TFA, DCM, rt, 3 h, 63–94%; (d) acetyl chloride, TEA, DCM, 0 °C, 2 h, 78–99%.</p></p></figure><div class="NLM_p">Our next goal was to produce compounds <b>(±)-45</b>–<b>48</b>, with the fluorine on the phenyl ring at the <i>para</i> position relative to the oxygen of benzo[<i>e</i>]oxazolo[4,3-<i>b</i>][1,3]oxazin-1-one scaffold. As illustrated in <a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>, 4-bromo-5-fluoro-2-hydroxybenzamide (<b>9c</b>) was used as the starting material and the target compounds <b>(±)-45</b>–<b>48</b> were prepared in a similar procedure as shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Compound <b>9c</b> was synthesized from 4-bromo-5-fluoro-2-hydroxybenzoic acid via esterification, amination nucleophilic substitution, and deprotection sequentially (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02153/suppl_file/jm0c02153_si_001.pdf" class="ext-link">Supporting Information, Scheme S1</a>).</div><figure id="sch6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/medium/jm0c02153_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/large/jm0c02153_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Target Compounds <b>(±)-45</b>–<b>48</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/large/jm0c02153_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02153&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (i) BH<sub>3</sub>, THF, reflux, 5 h; (ii) CbzCl, NaHCO<sub>3</sub>, THF/H<sub>2</sub>O = 5:1, rt, 3 h, 71% of two steps; (b) TsOH·H<sub>2</sub>O, toluene, reflux, 6 h, 51%; (c) CAN, MeCN/H<sub>2</sub>O = 9:1, rt, 2 h, 67%; (d) (Boc)<sub>2</sub>O, TEA, DMAP, DCM, rt, 2 h, 74%; (e) Cs<sub>2</sub>CO<sub>3</sub>, MeOH, rt, 3h, 82%; (f) (i) 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)picolinonitrile, Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub>, DMSO/H<sub>2</sub>O = 6:1, 100 °C, 5 h, 84%, for (±)-<b>43</b>; (ii) morpholine, X-PHOS, Pd(OAc)<sub>2</sub>, Cs<sub>2</sub>CO<sub>3</sub>, toluene, reflux, 100 °C, 6 h, 38%, for (±)-<b>44</b>; (g) TFA, DCM, rt, 3 h, 78–86%; (h) acetyl chloride, TEA, DCM, 0 °C, 2 h, 76–86%.</p></p></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34801" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34801" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">As mentioned, the benzo[1,3]oxazinyloxazolidinone scaffold was first designed to elucidate its antibacterial activity, with the aim to characterize the intrinsic ability of this novel tricyclic fused oxazolidinone as an antibacterial agent. Due to the <i>N</i>,<i>O</i>-acetal fragment within the benzo[1,3]oxazinyloxazolidinone scaffold, we initially explored its microsome stability, as this would determine the subsequent success of this scaffold. We subjected compound <b>49</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02153/suppl_file/jm0c02153_si_001.pdf" class="ext-link">Supporting Information, Scheme S2</a>) with the key pharmacophore in the scaffold to two stability tests. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, compound <b>49</b> exhibited excellent stability not only in mouse liver microsomes but also in human liver microsomes compared to the known compound benzo[1,4]oxazinyloxazolidinone <b>50</b>.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Microsome Stability of Compounds <b>49</b> and <b>50</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/medium/jm0c02153_0011.gif" alt="" id="gr11" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Mouse liver microsome.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Human liver microsome.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">Substrate concentrations were determined in incubations with NADPH after 30 min and normalized to concentrations at time zero.</p></div><div class="footnote" id="t1fn4"><sup><sup>d</sup></sup><p class="last">Stability was determined without the NADPH cofactor.</p></div><div class="footnote" id="t1fn5"><sup><sup>e</sup></sup><p class="last">Compound <b>50</b> was prepared according to the literature.<a onclick="showRef(event, 'ref23 ref28'); return false;" href="javascript:void(0);" class="ref ref23 ref28">(23,28)</a></p></div></div><div></div></div><div class="NLM_p">Supported by the positive results of the above microsomal stability assay, the target compounds with the benzo[<i>e</i>]oxazolo[4,3-<i>b</i>][1,3]oxazin-1-one scaffold were synthesized and screened for their <i>in vitro</i> activities against Mtb H37Rv to confirm our molecular design strategy (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Compound <i>trans</i><b>(±)-20a</b> displayed good MIC (1.58 μg/mL) against Mtb H37Rv, while compound <i>cis</i><b>(±)-20b</b> showed low activity. These results clearly indicated that the <i>trans</i> configuration was optimal for anti-TB activity. Subsequently, compound <i>trans</i><b>(±)-20a</b> was separated into optical isomers <b>20aa</b> and <b>20ab</b> through chiral resolution. To our delight, compound <b>20aa</b> (3<i>S</i>,3a<i>S</i>) showed more potent <i>in vitro</i> anti-TB activity than linezolid. By contrast, compound <b>20ab</b> (3<i>R</i>,3a<i>R</i>) was found to be virtually inactive (MIC > 32 μg/mL). The results disclosed that the absolute configuration (3<i>S</i>,3a<i>S</i>) for this novel tricyclic fused oxazolidinone was essential for potency in accordance with that previously observed for the benzo[1,4]oxazinyloxazolidinone scaffold.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Compounds <b>20aa</b> and <b>20ab</b> were also evaluated for their antibacterial activities against Gram-positive bacteria <i>S. aureus</i> ATCC 29213. As anticipated, compound <b>20aa</b> displayed potent antibacterial activity (MIC = 0.125 μg/mL), while its enantiomer, <b>20ab</b>, showed no activity (MIC > 64 μg/mL). This result further demonstrated that the 3<i>S</i>,3a<i>S</i>-configuration is essential for maintaining potency.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Antibacterial Activities of Different Isomers of <b>20a</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/medium/jm0c02153_0012.gif" alt="" id="GRAPHIC-d7e1345-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">configuration (3,3a)</th><th class="colsep0 rowsep0" align="center">chiral purity</th><th class="colsep0 rowsep0" align="center">MIC (μg/mL), Mtb H37Rv</th><th class="colsep0 rowsep0" align="center">MIC (μg/mL), <i>S. aureus</i> 29213</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>(±)-20a</b></td><td class="colsep0 rowsep0" align="left"><i>trans</i></td><td class="colsep0 rowsep0" align="left">racemic</td><td class="colsep0 rowsep0" align="left">1.58</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>(±)-20b</b></td><td class="colsep0 rowsep0" align="left"><i>cis</i></td><td class="colsep0 rowsep0" align="left">racemic</td><td class="colsep0 rowsep0" align="left">15.51</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20aa</b></td><td class="colsep0 rowsep0" align="left">(3<i>S</i>,3a<i>S</i>)</td><td class="colsep0 rowsep0" align="left">99.97%</td><td class="colsep0 rowsep0" align="left">0.40</td><td class="colsep0 rowsep0" align="left">0.125</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20ab</b></td><td class="colsep0 rowsep0" align="left">(3<i>R</i>,3a<i>R</i>)</td><td class="colsep0 rowsep0" align="left">99.94%</td><td class="colsep0 rowsep0" align="left">>32</td><td class="colsep0 rowsep0" align="left">>64</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">linezolid</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">0.88</td><td class="colsep0 rowsep0" align="left">0.125</td></tr></tbody></table></div></div><div class="NLM_p">After confirming <b>20aa</b>, the 3<i>S</i>, 3a<i>S</i>-isomer, as the most potent compound, we conducted extensive SAR studies on the phenyl ring and C5 side chain. The target compounds were evaluated for their activities against a series of bacteria including Mtb, Gram-positive and Gram-negative strains (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Keeping fluoro substitution at R<sub>2</sub>, compounds with R<sub>1</sub> as aryl group showed more potent <i>in vitro</i> anti-TB activity (<b>20aa</b>, <b>30</b>, <b>31</b>, and <b>35</b>), whether R<sub>3</sub> was H or an acetyl group. In contrast, when R<sub>1</sub> was morpholinyl, compounds <b>32</b> and <b>36</b> had no activity. For Gram-positive bacteria, compounds <b>20aa</b> and <b>35</b> containing an aryl group at R<sub>1</sub> displayed equal or more potent activity (MIC = 0.125 μg/mL) compared to the reference linezolid (MIC = 0.125–0.25 μg/mL). Compound <b>36</b> bearing a morpholine motif showed moderate antibacterial activity but lower than compound <b>20aa</b>. Fluorine on the phenyl ring has been illustrated to have a beneficial effect on the antibacterial activity for linezolid analogues;<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> thus we assessed the activities of the fluoride-free compounds (<b>33</b>, <b>37</b> and <b>34</b>, <b>38</b>). As illustrated in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>, compounds <b>33</b> and <b>37</b> containing a pyridine group displayed significantly reduced anti-TB activity, while compounds <b>34</b> and <b>38</b> bearing a morpholine group totally lost anti-TB activity. Although compound <b>37</b> showed good activity against Gram-positive pathogens (<i>S. aureus</i> and <i>B. subtilis</i>), its activity was lower compared to <b>20aa</b>. These results implied that fluorine on the phenyl ring of this novel tricyclic fused oxazolidinone was not only essential for the anti-TB activity but also critical for its antibacterial activity. The effect of fluorination on anti-TB activity was consistent with benzo[1,4]oxazinyloxazolidinones;<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22,23)</a> however, for antibacterial activity, the effect was contrary to that previously reported.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Subsequently, we investigated the effect on the activity by switching the F and pyridine (or morpholine) positions. Obviously, compounds <b>(±)-45</b>–<b>48</b> with F at the R<sub>1</sub> position resulted in a complete loss of antitubercular activity (MIC > 32 μg/mL); <b>(±)-45</b> and <b>(±)-47</b> even with a pyridine group at R<sub>2</sub> displayed no antibacterial activity (MIC > 64 μg/mL), indicating that the positions of the substituents on the B ring also have an important effect on activity. Unsurprisingly, all these compounds were inactive against Gram-negative bacteria <i>E. coli</i> similar to the reference linezolid.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Antibacterial Activities of Target Compounds</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/medium/jm0c02153_0013.gif" alt="" id="GRAPHIC-d7e1596-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/medium/jm0c02153_0014.gif" alt="" id="gr12" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last"><i>Staphylococcus aureus</i> 29213.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last"><i>Bacillus subtilis</i> 168.</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last"><i>Escherichia coli</i> 25922.</p></div></div><div></div></div><div class="NLM_p">Prompted by two promising compounds <b>20aa</b> and <b>35</b> which displayed significant potency against Mtb H37Rv and Gram-positive bacteria, we subsequently concentrated on evaluating these two compounds for their activities against drug-resistant TB strains and drug-resistant Gram-positive strains (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). We were pleased to find that compounds <b>20aa</b> and <b>35</b> displayed equivalent potency against two clinically isolated strains 13946 and 14862 (extensively drug-resistant TB) compared with the drug-sensitive strain. Meanwhile, as displayed in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>, <b>20aa</b> and <b>35</b> exhibited excellent antibacterial activity against all tested Gram-positive drug-resistant bacteria, with MIC values of 0.25–0.5 μg/mL (<b>20aa</b>) and 0.5–4 μg/mL (<b>35</b>) against MRSA, 1 μg/mL (<b>20aa</b> and <b>35</b>) against MRSE, 0.25 μg/mL (<b>20aa</b>) and 0.5 μg/mL (<b>35</b>) against VISA, and 0.25 μg/mL (<b>20aa</b> and <b>35</b>) against VRE. Furthermore, we investigated the activities of compounds <b>20aa</b> and <b>35</b> against linezolid-resistant bacteria (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). Although <b>20aa</b> (MIC = 3.63 μg/mL) and <b>35</b> (MIC = 2.32 μg/mL) exhibited some activity against linezolid-resistant TB strain, for drug-sensitive strain Mtb H37Rv, these two compounds displayed reduced activity as about 3- to 7-fold increase in MIC values (<b>20aa</b> 0.48 μg/mL and <b>35</b> 0.54 μg/mL). In addition, we evaluated the activities of <b>20aa</b> and <b>35</b> against linezolid-resistant <i>Enterococcus</i> and <i>Staphylococcus</i> strains. The results showed that <b>20aa</b> and <b>35</b> exhibited superior activities against linezolid-resistant <i>Enterococcus</i> (MIC = 1–2 μg/mL) and linezolid-resistant <i>Staphylococcus</i> (MIC = 2–4 μg/mL). However, the antibacterial activity of <b>20aa</b> and <b>35</b> against linezolid-resistant Gram-positive bacteria was substantially inferior compared to that against the standard strains. The results were similar to antituberculosis activities of compounds <b>20aa</b> and <b>35</b> against linezolid-resistant TB strain, indicating that this novel benzo[1,3]oxazinyloxazolidinone scaffold might have a similar mode of action as linezolid.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Activities against Drug-Resistant Bacteria of Compounds <b>20aa</b> and <b>35</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="6" align="center">MIC (μg/mL)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">Mtb 13946<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">Mtb 14862<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">MRSA<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">MRSE<a class="ref internalNav" href="#t4fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center">VISA<a class="ref internalNav" href="#t4fn5" aria-label="e">e</a></th><th class="colsep0 rowsep0" align="center">VRE<a class="ref internalNav" href="#t4fn6" aria-label="f">f</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20aa</b></td><td class="colsep0 rowsep0" align="left">0.48</td><td class="colsep0 rowsep0" align="left">0.82</td><td class="colsep0 rowsep0" align="left">0.25–0.5</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">0.25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>35</b></td><td class="colsep0 rowsep0" align="left">0.39</td><td class="colsep0 rowsep0" align="left">0.85</td><td class="colsep0 rowsep0" align="left">0.5–4</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">0.25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">INH</td><td class="colsep0 rowsep0" align="left">2.38</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">RIF</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ampicillin</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">>32</td><td class="colsep0 rowsep0" align="left">>32</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">vancomycin</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">0.5–1</td><td class="colsep0 rowsep0" align="left"><2</td><td class="colsep0 rowsep0" align="left">>32</td><td class="colsep0 rowsep0" align="left">>32</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Resistance to isoniazid (INH), streptomycin (SM), rifampicin (RFP), ethambutol (EMB), rifabutin (RBT), <i>p</i>-aminosalicylate (PAS), and ofloxacin (OLFX).</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">Resistance to INH, SM, RFP, EMB, PAS, prothionamide (1321), and capreomycin (CPM).</p></div><div class="footnote" id="t4fn3"><sup><sup>c</sup></sup><p class="last">Methicillin resistant <i>Staphylococcus aureus</i>, four strains.</p></div><div class="footnote" id="t4fn4"><sup><sup>d</sup></sup><p class="last">Methicillin resistant <i>Staphylococcus epidermidis</i>.</p></div><div class="footnote" id="t4fn5"><sup><sup>e</sup></sup><p class="last">Vancomycin intermediate <i>Staphylococcus aureus</i>.</p></div><div class="footnote" id="t4fn6"><sup><sup>f</sup></sup><p class="last">Vancomycin resistant <i>Enterococcus</i>.</p></div></div></div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Activities Against Linezolid-Resistant Bacteria of Compounds <b>20aa</b> and <b>35</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">MIC (μg/mL)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">linezolid</th><th class="colsep0 rowsep0" align="center"><b>20aa</b></th><th class="colsep0 rowsep0" align="center"><b>35</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Mtb</td><td class="colsep0 rowsep0" align="left">14.54</td><td class="colsep0 rowsep0" align="left">3.63</td><td class="colsep0 rowsep0" align="left">2.32</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">E. f<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">0.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">E. f<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">4–8</td><td class="colsep0 rowsep0" align="left">1–2</td><td class="colsep0 rowsep0" align="left">1–2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">E. f<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">E. f<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">S. c<a class="ref internalNav" href="#t5fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">16 to >16</td><td class="colsep0 rowsep0" align="left">2–4</td><td class="colsep0 rowsep0" align="left">2–4</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last"><i>E. faecalis</i> ATCC 29212.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">Linezolid-resistant <i>E. faecalis</i>, six strains.</p></div><div class="footnote" id="t5fn3"><sup><sup>c</sup></sup><p class="last"><i>E. faecium</i> ATCC 49624.</p></div><div class="footnote" id="t5fn4"><sup><sup>d</sup></sup><p class="last">Linezolid-resistant <i>E. faecium</i> 13549.</p></div><div class="footnote" id="t5fn5"><sup><sup>e</sup></sup><p class="last">Linezolid-resistant <i>S. capitis</i>, five strains.</p></div></div></div><div class="NLM_p">As we desired to assess the druggability of the most potent compounds, their safety profile should be conducted as the first pass assessment. Compound <b>20aa</b> was selected for evaluation on <i>in vitro</i> toxicity, due to its highly potent antibacterial activity, particularly against MRSA. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>, compound <b>20aa</b> showed no cytotoxicity against Vero cell lines (IC<sub>50</sub> > 64 μg/mL). Its low hERG K<sup>+</sup> channel inhibition precluded its low QT prolongation risk. Compound <b>20aa</b> showed comparable mitochondrial protein synthesis (MPS) inhibition compared to linezolid (IC<sub>50</sub> = 9.28 μM).<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> This suggests that compound <b>20aa</b> has a similar safety profile as linezolid in terms of myelosuppression risk. Monoamine oxidase (MAO) inhibition is one of the adverse effects of oxazolidinone during long-term dosing; therefore, the MAO-A and MAO-B inhibition profiles of compound <b>20aa</b> were evaluated to assess the potential risk of toxicity. Compound <b>20aa</b> showed no activity against MAO-A and moderate activity against MAO-B, which implies that compound <b>20aa</b> could have an improved safety property. Bearing good safety profile, compound <b>20aa</b> was subsequently tested for its metabolic stability. It was noted that this compound showed excellent stability against mouse and human liver microsomes. This further demonstrated that this novel tricyclic fused benzo[1,3]oxazinyloxazolidinone scaffold may have an acceptable PK profile for further development.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Representative Properties of Compound <b>20aa</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">MLM<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">HLM<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="rowsep1 colsep0" colspan="4" align="center" char=".">IC<sub>50</sub> (μM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">substrate remaining (%)<a class="ref internalNav" href="#t6fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char=".">stability<a class="ref internalNav" href="#t6fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center" char=".">substrate remaining (%)<a class="ref internalNav" href="#t6fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char=".">stability<a class="ref internalNav" href="#t6fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center" char=".">Vero cytotoxicity, IC<sub>50</sub> (μg/mL)</th><th class="colsep0 rowsep0" align="center" char=".">hERG K<sup>+</sup> inhibition</th><th class="colsep0 rowsep0" align="center" char=".">MPS<a class="ref internalNav" href="#t6fn5" aria-label="e">e</a>inhibition</th><th class="colsep0 rowsep0" align="center" char=".">MAO-A<a class="ref internalNav" href="#t6fn6" aria-label="f">f</a></th><th class="colsep0 rowsep0" align="center" char=".">MAO-B<a class="ref internalNav" href="#t6fn6" aria-label="f">f</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20aa</b></td><td class="colsep0 rowsep0" align="char" char=".">95.5</td><td class="colsep0 rowsep0" align="char" char=".">108</td><td class="colsep0 rowsep0" align="char" char=".">118</td><td class="colsep0 rowsep0" align="char" char=".">106</td><td class="colsep0 rowsep0" align="char" char=".">>64</td><td class="colsep0 rowsep0" align="char" char=".">17.82</td><td class="colsep0 rowsep0" align="char" char=".">1.63</td><td class="colsep0 rowsep0" align="char" char=".">>50</td><td class="colsep0 rowsep0" align="char" char=".">6.07</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">Mouse liver microsome.</p></div><div class="footnote" id="t6fn2"><sup><sup>b</sup></sup><p class="last">Human liver microsome.</p></div><div class="footnote" id="t6fn3"><sup><sup>c</sup></sup><p class="last">Substrate concentrations were determined in incubations with NADPH after 30 min and normalized to concentrations at time zero.</p></div><div class="footnote" id="t6fn4"><sup><sup>d</sup></sup><p class="last">Stability was determined without the NADPH cofactor.</p></div><div class="footnote" id="t6fn5"><sup><sup>e</sup></sup><p class="last">Mitochondrial protein synthesis.</p></div><div class="footnote" id="t6fn6"><sup><sup>f</sup></sup><p class="last">Positive control, leflunomide (IC<sub>50</sub>): 9.40 μM for MAO-A, 5.58 μM for MAO-B.</p></div></div></div><div class="NLM_p">The aforementioned results encouraged us to further investigate the pharmacokinetic properties of compound <b>20aa</b> in BALB/c mice by following a single oral administration (dose, 10 mg/kg) and an intravenous injection (dose, 1 mg/kg). As illustrated in <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>, compound <b>20aa</b> exhibited excellent PK profiles with high plasma exposure (AUC<sub>0–∞</sub> = 78 669 h·ng/mL), high maximal plasma concentration (<i>C</i><sub>max</sub> = 10 253 ng/mL), appropriate half-life (<i>t</i><sub>1/2</sub> = 3.76 h), and excellent oral bioavailability (128%). Furthermore, compound <b>20aa</b> was rapidly absorbed after oral administration, with 8290 ng/mL plasma concentration after 15 min, and remained at 1730 ng/mL after 12 h (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>, <a href="/doi/suppl/10.1021/acs.jmedchem.0c02153/suppl_file/jm0c02153_si_001.pdf" class="ext-link">Supporting Information Table S1</a>). The high plasma concentration and quick absorption indicated that compound <b>20aa</b> could be an excellent antibacterial agent in a clinical setting.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Mouse PK Properties of Compound <b>20aa</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">parameter</th><th class="colsep0 rowsep0" align="center">unit</th><th class="colsep0 rowsep0" align="center">iv (1 mg/kg)</th><th class="colsep0 rowsep0" align="center">po (10 mg/kg)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub><a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">h</td><td class="colsep0 rowsep0" align="left">4.08</td><td class="colsep0 rowsep0" align="left">3.76</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>max</sub></td><td class="colsep0 rowsep0" align="left">h</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">1.33</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>0</sub>/<i>C</i><sub>max</sub></td><td class="colsep0 rowsep0" align="left">ng/mL</td><td class="colsep0 rowsep0" align="left">1791</td><td class="colsep0 rowsep0" align="left">10253</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>(0–<i>t</i>)</sub><a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">h·ng/mL</td><td class="colsep0 rowsep0" align="left">6080</td><td class="colsep0 rowsep0" align="left">77649</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>(0–∞)</sub></td><td class="colsep0 rowsep0" align="left">h·ng/mL</td><td class="colsep0 rowsep0" align="left">6162</td><td class="colsep0 rowsep0" align="left">78669</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MRT<sub>(0–∞)</sub><a class="ref internalNav" href="#t7fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">h</td><td class="colsep0 rowsep0" align="left">4.71</td><td class="colsep0 rowsep0" align="left">5.86</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>V</i><a class="ref internalNav" href="#t7fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">L/kg</td><td class="colsep0 rowsep0" align="left">0.762</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CL<a class="ref internalNav" href="#t7fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">(mL/min)/kg</td><td class="colsep0 rowsep0" align="left">2.71</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>F</i><a class="ref internalNav" href="#t7fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="left">%</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">128</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">Plasma elimination half-life.</p></div><div class="footnote" id="t7fn2"><sup><sup>b</sup></sup><p class="last">Plasma exposure.</p></div><div class="footnote" id="t7fn3"><sup><sup>c</sup></sup><p class="last">Mean residence time.</p></div><div class="footnote" id="t7fn4"><sup><sup>d</sup></sup><p class="last">Apparent volume of distribution.</p></div><div class="footnote" id="t7fn5"><sup><sup>e</sup></sup><p class="last">Clearance rate.</p></div><div class="footnote" id="t7fn6"><sup><sup>f</sup></sup><p class="last">Oral bioavailability.</p></div></div></div><figure id="fig4" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/medium/jm0c02153_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/large/jm0c02153_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Mean blood concentration–time profiles of compound <b>20aa</b> in mouse after oral administration (10 mg/kg) and intravenous injection (1 mg/kg) of compound <b>20aa</b> (<i>n</i> = 3). The data are presented as the means ± SD (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02153/suppl_file/jm0c02153_si_001.pdf" class="ext-link">Table S1</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/large/jm0c02153_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02153&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53734" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53734" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, we have developed a series of novel oxazolidinones containing the benzo[<i>e</i>]oxazolo[4,3-<i>b</i>][1,3]oxazin-1-one scaffold and assessed them as highly potent antibacterial agents against both Gram-positive strains and <i>M. tuberculosis</i>. It was found that a (3<i>S</i>,3a<i>S</i>) absolute configuration for the novel tricyclic fused oxazolidinone is required for potency. The systematic SAR evaluation exhibited that these new oxazolidinones differ from the previously described benzo[1,4]oxazinyloxazolidinones. Fluorine on the phenyl ring was not only essential for anti-TB activity but also significant for antibacterial activity. Compounds with heteroaromatic substituents at the para-position relative to the oxygen of benzo[1,3]oxazinyl framework exhibited relatively high potency against <i>M. tuberculosis</i> and Gram-positive strains; however, the compounds bearing a morpholine group lost antituberculosis activity and displayed moderate activity against <i>S. aureus</i> and <i>B. subtilis</i>. Two compounds, <b>20aa</b> and <b>35</b>, displayed good to excellent <i>in vitro</i> antibacterial activity including against drug-resistant TB strains, MRSA, MRSE, VISA, and VRE, as well as certain activities to some linezolid-resistant strains. The most superior compound <b>20aa</b> exhibited good druggability exemplified by potent antibacterial activity, excellent microsomal stability, no cytotoxicity against Vero cells, low hERG K<sup>+</sup> channel inhibition, comparable MPS inhibition, and acceptable inhibitory activity of MAO. Moreover, compound <b>20aa</b> exhibited an excellent mouse PK profile with high plasma exposure, high maximal plasma concentration, appropriate half-life, and excellent oral bioavailability after oral administration. Thus, we believe that <b>20aa</b> is a promising lead compound for further investigation and subsequent development. This novel conformationally constrained benzo[1,3]oxazinyloxazolidinone scaffold could provide new insight into the identification of new generation oxazolidinone for the treatment of serious infection caused by drug-resistant bacteria, which is still the unmet medical needs worldwide.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76055" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76055" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Chemistry. General</h3><div class="NLM_p last">All solvents and reagents were obtained commercially and used without further purification unless otherwise stated. <sup>1</sup>H NMR or <sup>13</sup>C NMR spectra were recorded on Varian 400 or 500 MHz spectrometer using CDCl<sub>3</sub>, DMSO-<i>d</i><sub>6</sub>, or acetone-<i>d</i><sub>6</sub> as solvent and tetramethylsilane (TMS) as an internal standard. Chemical shifts (δ) were referenced to the residual solvent peak and reported in ppm, and all coupling constantd (<i>J</i>) were given in Hz. The following multiplicity abbreviations are used: (s) singlet, (d) doublet, (t) triplet, (q) quartet, (m) multiplet, and (brs) broad. High-resolution mass spectra were recorded using a Thermo Exactive Orbitrap plus mass spectrometer (ESI). TLC was performed on silica gel plates (GF254) with visualization of components by UV light (254 nm). Silica gel 300–400 mesh was used for all flash column chromatography experiments. Melting points were determined on Yanaco MP-J3 microscope melting point apparatus. The purity of all final compounds (≥95%) was established by high-performance liquid chromatography (HPLC), which was carried out on a Thermo Fisher Accela HPLC system with an Agilent Zorbax SB-C18 column (5 μm, 2.1 mm × 50 mm), a column temperature of 40 °C, detection wavelength at 254 nm, flow rate = 0.3 mL/min, and a gradient of 5–95% MeCN in water (both containing 0.1 vol% of HCOOH) in 10 min.</div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Synthetic Procedure for Compounds <b>(±)-20a</b> and <b>(±)-20b</b></h3><div id="sec5_1_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> Benzyl 6-Bromo-7-fluoro-2-(3-(4-methoxybenzyl)-2-oxooxazolidin-5-yl)-2<i>H</i>-benzo[<i>e</i>][1,3]oxazine-3(4<i>H</i>)-carboxylate (<b>(±)-15a</b>) and (<b>(±)-15b</b>)</h4><div class="NLM_p last">A mixture of compound <b>14</b> (9.2 g, 39.1 mmol), <b>10a</b> (5.5 g, 15.5 mmol), and <i>p</i>-toluenesulfonic acid monohydrate (0.3 g, 1.6 mmol) in toluene (80 mL) was refluxed under continuous removal of water using Dean–Stark apparatus for 6 h. After cooling down to room temperature, the mixture was washed with water and dried over sodium sulfate. The products of <b>(±)-15a</b> and <b>(±)-15b</b> were obtained by chromatography eluting with petroleum/ethyl acetate. <b>(±)-15a</b> (4.4 g, yield: 49%), white solid. Mp: 150–152 °C. LC–MS (ESI) <i>m</i>/<i>z</i> [M + H]<sup>+</sup>: 571.0879 and 573.0859. <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>) δ: 7.52 (d, <i>J</i> = 7.6 Hz, 1 H), 7.45–7.34 (m, 5 H), 7.21 (d, <i>J</i> = 8.0 Hz, 2 H), 6.89 (d, <i>J</i> = 8.4 Hz, 2 H), 6.78 (d, <i>J</i> = 9.6 Hz, 1 H), 6.05 (d, <i>J</i> = 8.4 Hz, 1 H), 5.23 (d, <i>J</i> = 12.4 Hz, 1 H), 5.19 (d, <i>J</i> = 12.4 Hz, 1 H), 5.07 (d, <i>J</i> = 17.6 Hz, 1 H), 4.86 (td, <i>J</i> = 5.2, 8.4 Hz, 1 H), 4.46 (d, <i>J</i> = 17.2 Hz, 1 H), 4.38 (d, <i>J</i> = 14.4 Hz, 1 H), 4.32 (d, <i>J</i> = 14.8 Hz, 1 H), 3.78 (s, 3 H), 3.62 (t, <i>J</i> = 9.2 Hz, 1 H), 3.49 (dd, <i>J</i> = 5.2, 9.2 Hz, 1 H). <b>(±)-15b</b> (2.2 g, yield: 24.7%), colorless oil. LC–MS (ESI) <i>m</i>/<i>z</i> [M + H]<sup>+</sup>: 571.0879 and 573.0859. <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>) δ: 7.47 (d, <i>J</i> = 7.6 Hz, 1 H), 7.41–7.34 (m, 5 H), 7.23 (d, <i>J</i> = 8.4 Hz, 2 H), 6.93 (d, <i>J</i> = 8.4 Hz, 2 H), 6.80 (d, <i>J</i> = 9.6 Hz, 1 H), 6.08 (d, <i>J</i> = 6.8 Hz, 1 H), 5.22 (d, <i>J</i> = 12.4 Hz, 1 H), 5.17 (d, <i>J</i> = 12.4 Hz, 1 H), 5.05 (d, <i>J</i> = 17.2 Hz, 1 H), 4.95–4.89 (m, 1 H), 4.45 (d, <i>J</i> = 17.2 Hz, 1 H), 4.33 (d, <i>J</i> = 14.8 Hz, 1 H), 4.28 (d, <i>J</i> = 15.2 Hz, 1 H), 3.79 (s, 3 H), 3.66 (t, <i>J</i> = 8.8 Hz, 1 H), 3.36 (dd, <i>J</i> = 6.0, 9.2 Hz, 1 H).</div></div><div id="sec5_1_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> Benzyl 6-Bromo-7-fluoro-2-(-2-oxooxazolidin-5-yl)-2<i>H</i>-benzo[<i>e</i>][1,3]oxazine-3(4<i>H</i>)-carboxylate (<b>(±)-16a</b>)</h4><div class="NLM_p last">To a mixed solvent (MeCN/H<sub>2</sub>O = 85.0 mL:9.5 mL) were added <b>(±)-15a</b> (3.4 g, 5.9 mmol) and CAN (12.9 g, 23.6 mmol). The mixture was stirred for 2 h at room temperature and then poured into water (200 mL). The resulting solution was extracted with DCM (100 mL × 3). The combined organic layer was washed with water, brine and dried over sodium sulfate. The crude product was purified by chromatography (DCM/MeOH = 100:1) to afford <b>(±)-16a</b> as a white solid (2.1 g, 78%). Mp: 85–87 °C. LC–MS (ESI) <i>m</i>/<i>z</i> [M + H]<sup>+</sup>: 451.0318 and 453.0296. <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>) δ: 7.55 (d, <i>J</i> = 7.6 Hz, 1 H), 7.45–7.42 (m, 2 H), 7.39–7.33 (m, 3 H), 6.83 (d, <i>J</i> = 10.0 Hz, 1 H), 6.69 (s, 1 H), 6.18 (d, <i>J</i> = 8.4 Hz, 1H), 5.25 (d, <i>J</i> = 12.4 Hz, 1 H), 5.21 (d, <i>J</i> = 12.8 Hz, 1 H), 5.10 (d, <i>J</i> = 17.2 Hz, 1 H), 4.95 (td, <i>J</i> = 5.6, 8.8 Hz, 1 H), 4.49 (d, <i>J</i> = 17.2 Hz, 1 H), 3.77 (td, <i>J</i> = 0.8, 9.2 Hz, 1 H), 3.70–3.66 (m, 1 H).</div></div><div id="sec5_1_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> Benzyl 6-Bromo-7-fluoro-2-(-2-oxooxazolidin-5-yl)-2<i>H</i>-benzo[<i>e</i>][1,3]oxazine-3(4<i>H</i>)-carboxylate (<b>(±)-16b</b>)</h4><div class="NLM_p last">Compound <b>(±)-16b</b> (1.6 g, 76%) was prepared from <b>(±)-15b</b> (2.5 g, 4.3 mmol) according to the procedure described for <b>(±)-16a</b>. Mp: 80–82 °C. LC–MS (ESI) <i>m</i>/<i>z</i> [M + H]<sup>+</sup>: 451.0280 and 453.0260. <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>) δ: 7.49 (d, <i>J</i> = 7.6 Hz, 1 H), 7.45–7.34 (m, 5H), 6.88 (d, <i>J</i> = 10.0 Hz, 1 H), 6.61 (s, 1 H), 6.12 (d, <i>J</i> = 7.2 Hz, 1 H), 5.24 (s, 2 H), 5.09 (d, <i>J</i> = 17.2 Hz, 1 H), 5.04–4.98 (m, 1 H), 4.48 (d, <i>J</i> = 17.2 Hz, 1 H), 3.80 (t, <i>J</i> = 9.2 Hz, 1 H), 3.47 (dd, <i>J</i> = 6.4, 9.2 Hz,1 H).</div></div><div id="sec5_1_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> Benzyl 6-Bromo-2-(-3-(<i>tert</i>-butoxycarbonyl)-2-oxooxazolidin-5-yl)-7-fluoro-2<i>H</i>-benzo[<i>e</i>][1,3]oxazine-3(4<i>H</i>)-carboxylate (<b>(±)-17a</b>)</h4><div class="NLM_p last">A mixture of <b>(±)-16a</b> (2.2 g, 4.8 mmol), TEA (1.0 mL, 7.3 mmol), (Boc)<sub>2</sub>O (1.2 g, 5.7 mmol), DMAP (49.0 mg, 0.1 mmol) in DCM (20.0 mL) was stirred at room temperature for 2 h. The solution was washed with water and brine, dried over sodium sulfate, filtered, and concentrated. The residue was purified by chromatography (PE/DCM = 6:4) to give <b>(±)-17a</b> as a white solid (2.1 g, 78%). LC–MS (ESI) <i>m</i>/<i>z</i> [M + Na]<sup>+</sup>: 573.0637 and 575.0617. Mp: 161–163 °C. <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>) δ: 7.56 (d, <i>J</i> = 7.6 Hz, 1 H), 7.44–7.41 (m, 2 H), 7.40–7.32 (m, 3 H), 6.88 (d, <i>J</i> = 9.6 Hz, 1 H), 6.28 (d, <i>J</i> = 8.8 Hz, 1 H), 5.25 (d, <i>J</i> = 12.4 Hz, 1 H), 5.21 (d, <i>J</i> = 12.8 Hz, 1 H), 5.11 (d, <i>J</i> = 17.2 Hz, 1 H), 4.98–4.92 (m, 1 H), 4.50 (d, <i>J</i> = 16.8 Hz, 1 H), 4.16–4.08 (m, 2 H), 1.50 (s, 9 H).</div></div><div id="sec5_1_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> Benzyl 6-Bromo-2-(-3-(<i>tert</i>-butoxycarbonyl)-2-oxooxazolidin-5-yl)-7-fluoro-2<i>H</i>-benzo[<i>e</i>][1,3]oxazine-3(4<i>H</i>)-carboxylate (<b>(±)-17b</b>)</h4><div class="NLM_p last">In a similar manner to <b>(±)-17a</b>, compound <b>(±)-17b</b> (1.4 g, 82%) was prepared from <b>(±)-16b</b> (1.4 g, 3.1 mmol). Mp: 92–94 °C. LC–MS (ESI) <i>m</i>/<i>z</i> [M + Na]<sup>+</sup>: 573.0620 and 575.0604. <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>) δ: 7.51 (d, <i>J</i> = 7.6 Hz, 1 H), 7.45–7.43 (m, 2 H), 7.40–7.34 (m, 3 H), 6.88(d, <i>J</i> = 10.0 Hz, 1 H), 6.24 (d, <i>J</i> = 7.2 Hz, 1 H), 5.25 (s, 2 H), 5.10 (d, <i>J</i> = 16.8 Hz, 1 H), 5.04–4.98 (m, 1 H), 4.52 (d, <i>J</i> = 17.2 Hz, 1 H), 4.19 (dd, <i>J</i> = 8.8, 10.4 Hz, 1 H), 3.86 (dd, <i>J</i> = 6.4, 10.4 Hz, 1 H), 1.49 (s, 9 H).</div></div><div id="sec5_1_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> <i>tert</i>-Butyl ((7-Bromo-6-fluoro-1-oxo-3,3a-dihydro-1<i>H</i>,9<i>H</i>-benzo[<i>e</i>]oxazolo[4,3-<i>b</i>][1,3]oxazin-3-yl)methyl)carbamate (<b>(±)-18a</b>)</h4><div class="NLM_p last">To a solution of MeOH (20 mL) containing <b>(±)-17a</b> (2.1 g, 3.8 mmol) was added Cs<sub>2</sub>CO<sub>3</sub>(4.5 g, 7.6 mmol). The mixture was stirred for 3 h at room temperature, then poured into water (100 mL). The precipitate was filtered and washed with water and dried to afford <b>(±)-18a</b> as a white solid (1.4 g, 89%). Mp: 182–184 °C. LC–MS (ESI) <i>m</i>/<i>z</i> [M + Na]<sup>+</sup>: 439.0265 and 441.0246. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 7.26 (d, <i>J</i> = 7.2 Hz, 1 H), 6.70 (d, <i>J</i> = 8.8 Hz, 1 H), 5.45 (s, 1 H), 4.89 (brs, 1 H), 4.77 (d, <i>J</i> = 16.8 Hz, 1 H), 4.63 (t, <i>J</i> = 4.8 Hz, 1 H), 4.37 (d, <i>J</i> = 16.8 Hz, 1 H), 3.62–3.48 (m, 2 H), 1.44 (s, 9 H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ: 158.3 (d, <i>J</i><sub>C–F</sub> = 247.0 Hz), 156.3, 156.2, 152.4 (d, <i>J</i><sub>C–F</sub> = 11.0 Hz), 130.8 (d, <i>J</i><sub>C–F</sub> = 1.0 Hz), 116.2 (d, <i>J</i><sub>C–F</sub> = 4.0 Hz), 106.6 (d, <i>J</i><sub>C–F</sub> = 26.0 Hz), 102.1 (d, <i>J</i><sub>C–F</sub> = 21.0 Hz), 83.6, 80.5, 78.9, 41.4, 39.8, 28.3.</div></div><div id="sec5_1_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> <i>tert</i>-Butyl ((7-Bromo-6-fluoro-1-oxo-3,3a-dihydro-1<i>H</i>,9<i>H</i>-benzo[<i>e</i>]oxazolo[4,3-<i>b</i>][1,3]oxazin-3-yl)methyl)carbamate (<b>(±)-18b</b>)</h4><div class="NLM_p last">Compound <b>(±)-18b</b> (1.1 g, 91%) was prepared from <b>(±)-17b</b> (1.6 g, 2.9 mmol) according to the procedure described for <b>(±)-18a</b>. Mp: 88–90 °C. LC–MS (ESI) <i>m</i>/<i>z</i> [M + Na]<sup>+</sup>: 439.0258 and 441.0236. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 7.28 (d, <i>J</i> = 7.2 Hz, 1 H), 6.72 (d, <i>J</i> = 9.2 Hz, 1 H), 5.43 (d, <i>J</i> = 5.2 Hz,1 H), 4.91 (brs, 1 H), 4.83–4.77 (m, 2 H), 4.41 (d, <i>J</i> = 16.4 Hz, 1 H), 3.85–3.78 (m, 1 H), 3.62–3.55 (m, 1 H),1.46 (s, 9 H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ: 158.3 (d, <i>J</i><sub>C–F</sub> = 247.0 Hz), 156.3, 155.8, 152.1 (d, <i>J</i><sub>C–F</sub> = 11.0 Hz), 130.9 (d, <i>J</i><sub>C–F</sub> = 2.0 Hz), 116.2 (d, <i>J</i><sub>C–F</sub> = 4.0 Hz), 106.7 (d, <i>J</i><sub>C–F</sub> = 25.0 Hz), 102.4 (d, <i>J</i><sub>C–F</sub> = 22.0 Hz), 82.0, 80.3, 75.8, 40.0, 39.0, 28.4.</div></div><div id="sec5_1_2_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> <i>tert</i>-Butyl ((7-(6-Cyanopyridin-3-yl)-6-fluoro-1-oxo-3,3a-dihydro-1<i>H</i>,9<i>H</i>-benzo[<i>e</i>]oxazolo[4,3-<i>b</i>][1,3]oxazin-3-yl)methyl)carbamate (<b>(±)-19a</b>)</h4><div class="NLM_p last">To a three-necked bottle containing <b>(±)-18a</b> (270 mg, 0.65 mmol), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)picolinonitrile (194 mg, 0.84 mmol), Pd(PPh<sub>3</sub>)<sub>4</sub>(74.8 mg, 0.06 mmol), Na<sub>2</sub>CO<sub>3</sub>(137.3 mg, 1.30 mmol) was added solvent (DMSO/H<sub>2</sub>O = 9.0 mL: 1.5 mL) under an atmosphere of argon. The reaction was stirred for 5 h at 100 °C and then cooled to room temperature. The resulting mixture was poured into water (30 mL) and extracted with DCM (15 mL × 3). The combined organic layer was washed with water and brine, dried over sodium sulfate, filtered, and concentrated. The residue was purified by chromatography (DCM/MeOH = 100:1) to afford <b>(±)-19a</b> as an off-white solid (240 mg, yield: 84%). Mp: 167–169 °C. LC–MS (ESI) <i>m</i>/<i>z</i> [M + H]<sup>+</sup>: 441.1558. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 8.83 (s, 1 H), 7.97–7.94 (m, 1 H), 7.77 (dd, <i>J</i> = 0.8, 8.0 Hz, 1 H), 7.17 (d, <i>J</i> = 8.0 Hz, 1 H), 6.79 (d, <i>J</i> = 11.2 Hz, 1 H), 5.56 (s, 1 H), 4.90 (brs, 1 H), 4.86 (d, <i>J</i> = 16.8 Hz, 1 H), 4.67 (t, <i>J</i> = 4.8 Hz, 1 H), 4.47 (d, <i>J</i> = 16.4 Hz, 1 H), 3.65–3.50 (m, 2 H), 1.45 (s, 9 H).</div></div><div id="sec5_1_2_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> <i>tert</i>-Butyl ((7-(6-Cyanopyridin-3-yl)-6-fluoro-1-oxo-3,3a-dihydro-1<i>H</i>,9<i>H</i>-benzo[<i>e</i>]oxazolo[4,3-<i>b</i>][1,3]oxazin-3-yl)methyl)carbamate (<b>(±)-19b</b>)</h4><div class="NLM_p last">Compound <b>(±)-19b</b> (155 mg, 81%) was prepared from <b>(±)-18b</b> (200 mg, 0.48 mmol) in the same manner as described for <b>(±)-19a</b>. Mp: 98–100 °C. LC–MS (ESI) <i>m</i>/<i>z</i> [M + H]<sup>+</sup>: 441.1562. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 8.83 (s, 1 H), 7.97–7.94 (m, 1 H), 7.77 (dd, <i>J</i> = 0.8, 8.0 Hz, 1 H), 7.19 (d, <i>J</i> = 8.4 Hz, 1 H), 6.81 (d, <i>J</i> = 11.2 Hz, 1 H), 5.52 (d, <i>J</i> = 4.8 Hz, 1 H), 4.94–4.88 (m, 2 H), 4.84–4.80 (m, 1 H), 4.51 (d, <i>J</i> = 16.8 Hz, 1 H), 3.90–3.82 (m, 1 H), 3.65–3.59 (m, 1 H), 1.47 (s, 9 H).</div></div><div id="sec5_1_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> <i>N</i>-((7-(6-Cyanopyridin-3-yl)-6-fluoro-1-oxo-3,3a-dihydro-1<i>H</i>,9<i>H</i>-benzo[<i>e</i>]oxazolo[4,3-<i>b</i>][1,3]oxazin-3-yl)methyl)acetamide (<b>(±)-20a</b>)</h4><div class="NLM_p last">Trifluoroacetic acid (7.0 mL) was added to a solution of compound <b>(±)-19a</b> (404.4 mg, 0.91 mmol) in DCM (20 mL). The reaction mixture was stirred for 2 h at room temperature and then neutralized with saturated sodium bicarbonate aqueous solution. The resulting mixture was extracted with DCM (10 mL × 3). The combined organic layer was wash with water, brine, dried over sodium sulfate, and filtered. To this filtered solution were added TEA (190.0 μL, 1.4 mmol) and acetyl chloride (84.0 μL, 1.2 mmol) sequentially. The mixture was stirred for 2 h at 0 °C. Then the solution was washed with water and brine, dried over sodium sulfate, filtered, and concentrated. The residue was purified by chromatography (DCM/MeOH = 100:1) to give <b>(±)-20a</b> as an off-white solid (305 mg, 87%). Mp: 210–212 °C. HRMS (ESI) <i>m</i>/<i>z</i> [M + H]<sup>+</sup>: calcd for C<sub>19</sub>H<sub>16</sub>FN<sub>4</sub>O<sub>4</sub> 383.1156, found 383.1144. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 8.82 (s, 1 H), 7.95 (dt, <i>J</i> = 1.6, 8.0 Hz, 1 H), 7.76 (dd, <i>J</i> = 0.4, 8.0 Hz, 1 H), 7.16 (d, <i>J</i> = 8.0 Hz, 1 H), 6.79 (d, <i>J</i> = 11.2 Hz, 1 H), 6.05 (t, <i>J</i> = 6.4 Hz,1 H), 5.51 (d, <i>J</i> = 1.2 Hz, 1 H), 4.84 (d, <i>J</i> = 16.4 Hz, 1 H), 4.70 (t, <i>J</i> = 4.8 Hz, 1 H), 4.49 (d, <i>J</i> = 16.4 Hz, 1 H), 3.71 (t, <i>J</i> = 5.6 Hz, 2 H), 2.04 (s, 3 H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ: 171.1, 159.1 (d, <i>J</i><sub>C–F</sub> = 250.0 Hz), 156.2, 154.2 (d, <i>J</i><sub>C–F</sub> = 12.0 Hz), 150.6 (d, <i>J</i><sub>C–F</sub> = 3.0 Hz),136.7 (d, <i>J</i><sub>C–F</sub> = 4.0 Hz), 134.2 (d, <i>J</i><sub>C–F</sub> = 2.0 Hz), 132.5, 128.2, 128.1 (d, <i>J</i><sub>C–F</sub> = 4.0 Hz), 118.7 (d, <i>J</i><sub>C–F</sub> = 15.0 Hz), 117.2, 115.8 (d, <i>J</i><sub>C–F</sub> = 4.0 Hz), 106.5 (d, <i>J</i><sub>C–F</sub> = 25.0 Hz), 83.8, 78.9, 40.2, 40.1, 23.1.</div></div><div id="sec5_1_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> <i>N</i>-((7-(6-Cyanopyridin-3-yl)-6-fluoro-1-oxo-3,3a-dihydro-1<i>H</i>,9<i>H</i>-benzo[<i>e</i>]oxazolo[4,3-<i>b</i>][1,3]oxazin-3-yl)methyl)acetamide (<b>(±)-20b</b>)</h4><div class="NLM_p last">Compound <b>(±)-20b</b> (154 mg, 80%) was prepared from <b>(±)-19b</b> (222 mg, 0.50 mmol) in the same manner as described for <b>(±)-20a</b>. Mp: 204–206 °C. HRMS (ESI) <i>m</i>/<i>z</i> [M + H]<sup>+</sup>: calcd for C<sub>19</sub>H<sub>16</sub>FN<sub>4</sub>O<sub>4</sub> 383.1156, found 383.1141. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 8.83 (s, 1 H), 7.97–7.94 (m, 1 H), 7.77 (dd, <i>J</i> = 0.8, 8.0 Hz, 1H), 7.20 (d, <i>J</i> = 8.4 Hz, 1 H), 6.81 (d, <i>J</i> = 10.8 Hz, 1 H), 5.94 (t, <i>J</i> = 6.8 Hz, 1 H), 5.53 (d, <i>J</i> = 4.8 Hz, 1 H), 4.90 (d, <i>J</i> = 16.4 Hz, 1 H), 4.86–4.81 (m, 1 H), 4.52 (d, <i>J</i> = 16.8 Hz, 1 H), 4.20–4.14 (m, 1 H), 3.57–3.50 (m, 1 H), 2.06 (s, 3 H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ: 170.7, 159.2 (d, <i>J</i><sub>C–F</sub> = 250.0 Hz), 156.2, 153.9 (d, <i>J</i><sub>C–F</sub> = 12.0 Hz), 150.6 (d, <i>J</i><sub>C–F</sub> = 3.0 Hz), 136.7 (d, <i>J</i><sub>C–F</sub> = 4.0 Hz), 134.1, 132.6, 128.2, 128.1, 119.0 (d, <i>J</i><sub>C–F</sub> = 14.0 Hz), 117.1, 115.8 (d, <i>J</i><sub>C–F</sub> = 4.0 Hz), 106.6 (d, <i>J</i><sub>C–F</sub> = 26.0 Hz), 82.1, 75.8, 40.2, 38.1, 23.2.</div></div><div id="sec5_1_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> <i>N</i>-(((3<i>S</i>,3a<i>S</i>)-7-(6-Cyanopyridin-3-yl)-6-fluoro-1-oxo-3,3a-dihydro-1<i>H</i>,9<i>H</i>-benzo[<i>e</i>]oxazolo[4,3-<i>b</i>][1,3]oxazin-3-yl)methyl)acetamide (<b>20aa</b>) and <i>N</i>-(((3<i>R</i>,3a<i>R</i>)-7-(6-Cyanopyridin-3-yl)-6-fluoro-1-oxo-3,3a-dihydro-1<i>H</i>,9<i>H</i>-benzo[<i>e</i>]oxazolo[4,3-<i>b</i>][1,3]oxazin-3-yl)methyl)acetamide (<b>20ab</b>)</h4><div class="NLM_p last">Chiral resolution of racemic <b>(±)-20a</b> afforded <b>20aa</b> and <b>20ab</b>. HPLC separation condition: CHIRALPAK IA column, MeOH/EtOAc = 80:20, 1 mL/min, λ = 254 nm, 25 °C. Rt (<b>20aa</b>) = 2.95 min, Rt (<b>20ab</b>) = 3.52 min. [α]<sub>D</sub><sup>29</sup> (<b>20aa</b>) = −298.8 (<i>c</i> 0.332, CHCl<sub>3</sub>), [α]<sub>D</sub><sup>29</sup> (<b>20ab</b>) = +268.9 (<i>c</i> 0.238, CHCl<sub>3</sub>).</div></div></div><div id="sec5_1_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> Synthetic Procedure for Compound <b>(±)-24</b></h3><div id="sec5_1_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> Benzyl 6-Bromo-2-(3-(4-methoxybenzyl)-2-oxooxazolidin-5-yl)-2<i>H</i>-benzo[<i>e</i>][1,3]oxazine-3(4<i>H</i>)-carboxylate (<b>(±)-21</b>)</h4><div class="NLM_p last">Compound <b>(±)-21</b> (3.7 g, 50%) was prepared from <b>10b</b> and <b>14</b> in the same manner as described for <b>(±)-15a</b>. Mp: 134–136 °C. LC–MS (ESI) <i>m</i>/<i>z</i> [M + Na]<sup>+</sup>: 575.0792 and 577.0781. <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>) δ: 7.42–7.25 (m, 7 H), 7.19 (d, <i>J</i> = 8.0 Hz, 2 H), 6.85 (d, <i>J</i> = 8.0 Hz, 2 H), 6.74 (d, <i>J</i> = 8.8 Hz, 1 H), 5.98 (d, <i>J</i> = 8.8 Hz, 1 H), 5.21 (d, <i>J</i> = 12.4 Hz, 1 H), 5.16 (d, <i>J</i> = 12.4 Hz, 1 H), 5.03 (d, <i>J</i> = 17.2 Hz, 1 H), 4.83–4.77 (m, 1 H), 4.46 (d, <i>J</i> = 16.8 Hz, 1 H), 4.35 (d, <i>J</i> = 14.8 Hz, 1 H), 4.28 (d, <i>J</i> = 15.2 Hz, 1 H), 3.75 (s, 3 H), 3.57 (t, <i>J</i> = 9.2 Hz, 1 H), 3.49–3.43 (m, 1 H).</div></div><div id="sec5_1_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> Benzyl 6-Bromo-2-(2-oxooxazolidin-5-yl)-2<i>H</i>-benzo[<i>e</i>][1,3]oxazine-3(4<i>H</i>)-carboxylate (<b>(±)-22</b>)</h4><div class="NLM_p last">Compound <b>(±)-22</b> (1.9 g, 76%) was prepared from <b>(±)-21</b> (3.2 g, 5.7 mmol) in the same manner as described for <b>(±)-16a</b>. Mp: 72–74 °C. LC–MS (ESI) <i>m</i>/<i>z</i> [M + H]<sup>+</sup>: 433.0388 and 435.0368. <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>) δ: 7.45–7.30 (m, 6 H), 6.83 (d, <i>J</i> = 8.8 Hz, 1 H), 6.67 (s, 1 H), 6.14 (d, <i>J</i> = 8.4 Hz, 1 H), 5.25 (d, <i>J</i> = 12.4 Hz, 1 H), 5.21 (d, <i>J</i> = 12.4 Hz, 1 H), 5.08 (d, <i>J</i> = 17.2 Hz, 1H), 4.95–4.89 (m, 1 H), 4.52 (d, <i>J</i> = 17.6 Hz, 1 H), 3.77–3.65 (m, 2 H).</div></div><div id="sec5_1_4_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> Benzyl 6-Bromo-2-(3-(<i>tert</i>-butoxycarbonyl)-2-oxooxazolidin-5-yl)-2<i>H</i>-benzo[<i>e</i>][1,3]oxazine-3(4<i>H</i>)-carboxylate (<b>(±)-23</b>)</h4><div class="NLM_p last">Compound <b>(±)-23</b> (2.0 g, 90%) was prepared from <b>(±)-22</b> (1.8 g, 4.1 mmol) in the same manner as described for <b>(±)-17a</b>. Mp: 135–137 °C. LC–MS (ESI) <i>m</i>/<i>z</i> [M + H]<sup>+</sup>: 555.0742 and 557.0724. <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>) δ: 7.44–7.33 (m, 7 H), 6.87 (d, <i>J</i> = 8.4 Hz, 1 H), 6.23 (d, <i>J</i> = 8.8 Hz, 1 H), 5.25 (d, <i>J</i> = 12.4 Hz, 1 H), 5.22 (d, <i>J</i> = 12.4 Hz, 1 H), 5.10 (d, <i>J</i> = 17.2 Hz, 1 H), 5.00–4.85 (m, 1 H), 4.53 (d, <i>J</i> = 17.2 Hz, 1 H), 4.10 (d, <i>J</i> = 7.2 Hz, 2 H), 1.50 (s, 9 H).</div></div><div id="sec5_1_4_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> <i>tert</i>-Butyl ((7-Bromo-1-oxo-3,3a-dihydro-1<i>H</i>,9<i>H</i>-benzo[<i>e</i>]oxazolo[4,3-<i>b</i>][1,3]oxazin-3-yl)methyl)carbamate (<b>(±)-24</b>)</h4><div class="NLM_p last">Compound <b>(±)-24</b> (1.2 g, 84%) was prepared from <b>(±)-23</b> (1.9 g, 3.5 mmol) in the same manner as described for <b>(±)-18a</b>. Mp: 165–167 °C. LC–MS (ESI) <i>m</i>/<i>z</i> [M + Na]<sup>+</sup>: 421.0364 and 423.0343. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 7.28 (dd, <i>J</i> = 2.4, 8.8 Hz, 1 H), 7.21 (d, <i>J</i> = 2.0 Hz, 1 H), 6.78 (d, <i>J</i> = 8.8 Hz, 1 H), 5.40 (s, 1 H), 4.91 (brs, 1 H), 4.77 (d, <i>J</i> = 16.8 Hz, 1 H), 4.63 (t, <i>J</i> = 4.8 Hz, 1 H), 4.39 (d, <i>J</i> = 16.8 Hz, 1 H), 3.61–3.49 (m, 2 H), 1.44 (s, 9 H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ: 156.4, 156.1, 151.3, 131.5, 129.4, 120.8, 119.8, 114.9, 83.4, 80.4, 79.0, 41.5, 40.2, 28.3.</div></div></div><div id="sec5_1_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> Synthetic Procedure for Compounds <b>20aa</b> and <b>35</b>–<b>38</b></h3><div id="sec5_1_5_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> <i>tert</i>-Butyl (((3<i>S</i>,3a<i>S</i>)-7-bromo-6-fluoro-1-oxo-3,3a-dihydro-1<i>H</i>,9<i>H</i>-benzo[e] oxazolo[4,3-<i>b</i>][1,3]oxazin-3-yl)methyl)carbamate (<b>18a</b>)</h4><div class="NLM_p last">Chiral resolution of <b>(±)-18a</b> afforded <b>18a</b>. HPLC condition: CHIRALPAK AD-H column, MeOH = 100%, 1.0 mL/min, λ = 214 nm, 35 °C. Rt: 5.5 min. Mp: 130–132 °C. [α]<sub>D</sub><sup>29</sup> = −204.9 (<i>c</i> 0.287, CHCl<sub>3</sub>).</div></div><div id="sec5_1_5_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> <i>tert</i>-Butyl (((3<i>S</i>,3a<i>S</i>)-7-Bromo-1-oxo-3,3a-dihydro-1<i>H</i>,9<i>H</i>-benzo[<i>e</i>]oxazolo[4,3-<i>b</i>][1,3]oxazin-3-yl)methyl)carbamate (<b>24</b>)</h4><div class="NLM_p last">Chiral resolution of <b>(±)-24</b> afforded <b>24</b>. HPLC condition: CHIRALPAK IA column, hexane/EtOH = 50:50, 1.0 mL/min, λ = 254 nm, 25 °C. Rt: 9.3 min. Mp: 114–115 °C. [α]<sub>D</sub><sup>29</sup> = −200.7 (<i>c</i> 0.300, CHCl<sub>3</sub>).</div></div><div id="sec5_1_5_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> <i>tert</i>-Butyl (((3<i>S</i>,3a<i>S</i>)-7-(6-Cyanopyridin-3-yl)-6-fluoro-1-oxo-3,3a-dihydro-1<i>H</i>,9<i>H</i>-benzo[<i>e</i>]oxazolo[4,3-<i>b</i>][1,3]oxazin-3-yl)methyl)carbamate (<b>25</b>)</h4><div class="NLM_p last">Compound <b>25</b> (185 mg, 88%) was prepared from <b>18a</b> (200 mg, 0.48 mmol) according to the procedure described for <b>(±)-19a</b>. Mp: 148–150 °C. LC–MS (ESI) <i>m</i>/<i>z</i> [M + H]<sup>+</sup>: 441.1573.</div></div><div id="sec5_1_5_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> <i>tert</i>-Butyl (((3<i>S</i>,3a<i>S</i>)-6-Fluoro-7-(6-(2-methyl-2<i>H</i>-tetrazol-5-yl)pyridin-3-yl)-1-oxo-3,3a-dihydro-1<i>H</i>,9<i>H</i>-benzo[<i>e</i>]oxazolo[4,3-<i>b</i>][1,3]oxazin-3-yl)methyl)carbamate (<b>26</b>)</h4><div class="NLM_p last">Compound <b>26</b> (150 mg, 57%) was prepared from <b>18a</b> (220 mg, 0.53 mmol) and 2-(2-methyl-2<i>H</i>-tetrazol-5-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (181.6 mg, 0.63 mmol) according to the procedure described for <b>(±)-19a</b>. Mp: 95–97 °C. LC–MS (ESI) <i>m</i>/<i>z</i> [M + H]<sup>+</sup>: 498.1878. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 8.87 (s, 1 H), 8.30 (d, <i>J</i> = 8.0 Hz,1 H), 7.98 (dt, <i>J</i> = 8.0, 1.6 Hz, 1 H), 7.20 (d, <i>J</i> = 8.0 Hz, 1 H), 6.79 (d, <i>J</i> = 11.2 Hz, 1 H), 5.54 (s, 1 H), 4.92–4.85 (m, 2 H), 4.67 (td, <i>J</i> = 1.2, 4.8 Hz, 1 H), 4.48 (d, <i>J</i> = 16.4 Hz, 1 H), 4.47 (s, 3 H), 3.64–3.51 (m, 2 H), 1.45 (s, 9 H).</div></div><div id="sec5_1_5_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> <i>tert</i>-Butyl (((3<i>S</i>,3a<i>S</i>)-6-Fluoro-7-morpholino-1-oxo-3,3a-dihydro-1<i>H</i>,9<i>H</i>-benzo[<i>e</i>]oxazolo[4,3-<i>b</i>][1,3]oxazin-3-yl)methyl)carbamate (<b>27</b>)</h4><div class="NLM_p last">To a three necked-bottle containing <b>18a</b> (300 mg, 0.72 mmol), morpholine (125.0 mg, 1.44 mmol), X-PHOS (103.0 mg, 0.22 mmol), Pd(OAc)<sub>2</sub> (24.2 g, 0.11 mmol), and Cs<sub>2</sub>CO<sub>3</sub>(351.6 mg, 1.08 mmol) was added toluene (15.0 mL) under an atmosphere of argon. The mixture was stirred at 100 °C for 6 h and then filtered. The filtered solution was concentrated and purified by chromatography (PE/EtOAc = 3:1) to give <b>27</b> as an off-white solid (134 mg, 44%). Mp: 89–91 °C. LC–MS (ESI) <i>m</i>/<i>z</i> [M + H]<sup>+</sup>: 424.1880. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 6.67–6.62 (m, 2 H), 5.38 (s, 1 H), 4.87 (s, 1 H), 4.73 (d, <i>J</i> = 16.4 Hz, 1 H), 4.61 (t, <i>J</i> = 4.8 Hz, 1 H), 4.37 (d, <i>J</i> = 16.4 Hz, 1 H), 3.88–3.86 (m, 4 H), 3.56–3.49 (m, 2 H), 3.02–3.0 (m, 4 H), 1.44 (s, 9 H).</div></div><div id="sec5_1_5_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> <i>tert</i>-Butyl (((3<i>S</i>,3a<i>S</i>)-7-(6-Cyanopyridin-3-yl)-1-oxo-3,3a-dihydro-1<i>H</i>,9<i>H</i>-benzo[<i>e</i>]oxazolo[4,3-<i>b</i>][1,3]oxazin-3-yl)methyl)carbamate (<b>28</b>)</h4><div class="NLM_p last">Compound <b>28</b> (187 mg, 89%) was prepared from <b>24</b> (200 mg, 0.5 mmol) according to the procedure described for <b>25</b>. Mp: 151–153 °C. LC–MS (ESI) <i>m</i>/<i>z</i> [M + H]<sup>+</sup>: 423.1658. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 8.88 (dd, <i>J</i> = 0.8, 2.4 Hz, 1 H), 7.94 (dd, <i>J</i> = 2.4, 8.0 Hz, 1 H), 7.75 (dd, <i>J</i> = 0.8, 8.4 Hz, 1 H), 7.43 (dd, <i>J</i> = 2.0, 8.4 Hz, 1 H), 7.32 (d, <i>J</i> = 2.4 Hz,1 H), 7.05 (d, <i>J</i> = 8.4 Hz, 1 H), 5.52 (s, 1 H), 4.91–4.87 (m, 2 H), 4.68 (td, <i>J</i> = 4.8, 1.2 Hz, 1 H), 4.52 (d, <i>J</i> = 17.2 Hz, 1 H), 3.65–3.51 (m, 2 H), 1.45 (s, 9 H).</div></div><div id="sec5_1_5_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> <i>tert</i>-Butyl (((3<i>S</i>,3a<i>S</i>)-7-Morpholino-1-oxo-3,3a-dihydro-1<i>H</i>,9<i>H</i>-benzo[<i>e</i>]oxazolo[4,3-<i>b</i>][1,3]oxazin-3-yl)methyl)carbamate (<b>29</b>)</h4><div class="NLM_p last">Compound <b>29</b> (283 mg, 66%) was prepared from <b>24</b> (400 mg, 1 mmol) according to the procedure described for <b>27</b>. Mp: 85–87 °C. LC–MS (ESI) <i>m</i>/<i>z</i> [M + H]<sup>+</sup>: 406.1983. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 6.84 (d, <i>J</i> = 8.8 Hz, 1 H), 6.79 (dd, <i>J</i> = 2.8, 8.8 Hz, 1 H), 6.59 (d, <i>J</i> = 2.8 Hz, 1 H), 5.33 (s, 1 H), 4.87 (brs, 1 H), 4.76 (d, <i>J</i> = 16.4 Hz, 1 H), 4.61 (td, <i>J</i> = 1.2, 4.8 Hz, 1 H), 4.40 (d, <i>J</i> = 16.4 Hz, 1 H), 3.86–3.84 (m, 4 H), 3.55–3.52 (m, 2 H), 3.07–3.05 (m, 4 H), 1.44 (s, 9 H).</div></div><div id="sec5_1_5_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> 5-((3<i>S</i>,3a<i>S</i>)-3-(Aminomethyl)-6-fluoro-1-oxo-3,3a-dihydro-1<i>H</i>,9<i>H</i>-benzo[<i>e</i>]oxazolo[4,3-<i>b</i>][1,3]oxazin-7-yl)picolinonitrile (<b>30</b>)</h4><div class="NLM_p last">Trifluoroacetic acid (4.0 mL) was added to a solution of compound <b>25</b> (240 mg, 0.54 mmol) in DCM (15 mL). The reaction mixture was stirred for 2 h at room temperature and then neutralized with saturated sodium bicarbonate aqueous solution. The resulting mixture was extracted with DCM (15 mL × 3). The combined organic layer was washed with water, brine, dried over sodium sulfate, filtered, and concentrated. The residue was purified by chromatography (DCM/MeOH/NH<sub>4</sub>OH = 100:2:0.5) to afford <b>30</b> as a white solid (175 mg, 94%). Mp: 157–159 °C. HRMS (ESI) <i>m</i>/<i>z</i> [M + H]<sup>+</sup>: calcd for C<sub>17</sub>H<sub>14</sub>FN<sub>4</sub>O<sub>3</sub> 341.1050, found 341.1039. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 8.84 (s, 1 H), 7.96 (dt, <i>J</i> = 2.0, 8.0 Hz, 1 H), 7.76 (dd, <i>J</i> = 0.8, 8.4 Hz, 1 H), 7.19 (d, <i>J</i> = 8.0 Hz, 1 H), 6.80 (d, <i>J</i> = 11.2 Hz, 1 H), 5.41 (d, <i>J</i> = 1.2 Hz,1 H), 4.86 (d, <i>J</i> = 16.4 Hz, 1 H), 4.61 (td, <i>J</i> = 1.2, 5.2 Hz, 1 H), 4.52 (d, <i>J</i> = 16.4 Hz, 1 H), 3.18–3.06 (m, 2 H), 1.29 (brs, 2 H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ: 159.1 (d, <i>J</i><sub>C–F</sub> = 250 Hz), 156.2, 154.4 (d, <i>J</i><sub>C–F</sub> = 12.5 Hz), 150.6, 136.7, 134.3, 132.5, 128.2, 118.6 (d, <i>J</i><sub>C–F</sub> = 13.8 Hz), 117.2, 116.0, 106.4 (d, <i>J</i><sub>C–F</sub> = 25 Hz), 84.0, 81.0, 42.7, 39.9.</div></div><div id="sec5_1_5_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> (3<i>S</i>,3a<i>S</i>)-3-(Aminomethyl)-6-fluoro-7-(6-(2-methyl-2<i>H</i>-tetrazol-5-yl)pyridin-3-yl)-3,3a-dihydro-1<i>H</i>,9<i>H</i>-benzo[<i>e</i>]oxazolo[4,3-<i>b</i>][1,3]oxazin-1-one (<b>31</b>)</h4><div class="NLM_p last">Compound <b>31</b> (85 mg, 63%) was prepared from <b>26</b> (170 mg, 0.34 mmol) according to the procedure described for <b>30</b>. Mp: 125–127 °C. HRMS (ESI) <i>m</i>/<i>z</i> [M + H]<sup>+</sup>: calcd for C<sub>18</sub>H<sub>17</sub>FN<sub>7</sub>O<sub>3</sub> 398.1377, found 398.1353. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 8.88 (s, 1 H), 8.30 (dd, <i>J</i> = 0.8, 8.0 Hz, 1 H), 7.99 (dt, <i>J</i> = 8.0, 1.6 Hz, 1 H), 7.22 (d, <i>J</i> = 8.0 Hz, 1 H), 6.79 (d, <i>J</i> = 10.8 Hz, 1 H), 5.40 (d, <i>J</i> = 1.6 Hz, 1 H), 4.87 (d, <i>J</i> = 16.4 Hz, 1 H), 4.61 (td, <i>J</i> = 1.2, 5.6 Hz, 1 H), 4.53 (d, <i>J</i> = 16.4 Hz, 1 H), 4.47 (s, 3 H), 3.17–3.05 (m, 2 H), 1.34 (brs, 2 H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ: 164.8, 159.2 (d, <i>J</i><sub>C–F</sub> = 248.0 Hz), 156.4, 153.6 (d, <i>J</i><sub>C–F</sub> = 12.0 Hz), 149.9 (d, <i>J</i><sub>C–F</sub> = 4.0 Hz), 145.7, 137.1, 132.1, 128.2 (d, <i>J</i><sub>C–F</sub> = 4.0 Hz), 122.1, 119.9 (d, <i>J</i><sub>C–F</sub> = 15.0 Hz), 115.7, 106.3 (d, <i>J</i><sub>C–F</sub> = 25.0 Hz), 84.0, 81.1, 42.9, 40.1, 39.8.</div></div><div id="sec5_1_5_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> (3<i>S</i>,3a<i>S</i>)-3-(Aminomethyl)-6-fluoro-7-morpholino-3,3a-dihydro-1<i>H</i>,9<i>H</i>-benzo[<i>e</i>]oxazolo[4,3-<i>b</i>][1,3]oxazin-1-one (<b>32</b>)</h4><div class="NLM_p last">Compound <b>32</b> (75 mg, 70%) was prepared from <b>27</b> (140 mg, 0.33 mmol) according to the procedure described for <b>30</b>. Mp: 152–157 °C. HRMS (ESI) <i>m</i>/<i>z</i> [M + H]<sup>+</sup>: calcd for C<sub>15</sub>H<sub>19</sub>FN<sub>3</sub>O<sub>4</sub> 324.1360, found 324.1347. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 6.66–6.62 (m, 2 H), 5.25 (d, <i>J</i> = 1.6 Hz, 1 H), 4.74 (d, <i>J</i> = 16.4 Hz, 1 H), 4.55 (td, <i>J</i> = 1.2, 4.8 Hz, 1 H), 4.41 (d, <i>J</i> = 16.4 Hz,1 H), 3.87–3.85 (m, 4 H), 3.14–2.98 (m, 6 H), 1.37 (brs, 2 H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ: 156.5, 155.0 (d, <i>J</i><sub>C–F</sub> = 247.0 Hz), 147.5 (d, <i>J</i><sub>C–F</sub> = 12.0 Hz), 135.7 (d, <i>J</i><sub>C–F</sub> = 10.0 Hz), 116.3 (d, <i>J</i><sub>C–F</sub> = 4.0 Hz), 114.4 (d, <i>J</i><sub>C–F</sub> = 4.0 Hz), 106.4 (d, <i>J</i><sub>C–F</sub> = 24.0 Hz), 83.6, 81.0, 67.0, 51.4, 51.3, 42.9, 40.2.</div></div><div id="sec5_1_5_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> 5-((3<i>S</i>,3a<i>S</i>)-3-(Aminomethyl)-1-oxo-3,3a-dihydro-1<i>H</i>,9<i>H</i>-benzo[<i>e</i>]oxazolo[4,3-<i>b</i>][1,3]oxazin-7-yl)picolinonitrile (<b>33</b>)</h4><div class="NLM_p last">Compound <b>33</b> (98 mg, 69%) was prepared from <b>28</b> (187 mg, 0.44 mmol) according to the procedure described for <b>30</b>. Mp: 154–156 °C. HRMS (ESI) <i>m</i>/<i>z</i> [M + H]<sup>+</sup>: calcd for C<sub>17</sub>H<sub>15</sub>N<sub>4</sub>O<sub>3</sub> 323.1144, found 323.1130. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 8.89 (s, 1 H), 7.94 (d, <i>J</i> = 8.0 Hz, 1 H), 7.75 (d, <i>J</i> = 8.0 Hz, 1 H), 7.44 (d, <i>J</i> = 7.6 Hz, 1 H), 7.34 (s, 1 H), 7.06 (d, <i>J</i> = 8.8 Hz, 1 H), 5.39 (s, 1 H), 4.90 (d, <i>J</i> = 16.8 Hz, 1 H), 4.64–4.55 (m, 2 H), 3.18–3.06 (m, 2 H), 1.32 (brs, 2 H). <sup>13</sup>C NMR (400 MHz, CDCl<sub>3</sub>) δ: 156.4, 153.6, 149.3, 138.8, 134.5, 132.1, 130.2, 128.5, 127.4, 125.8, 120.1, 119.3, 117.4, 83.9, 81.1, 42.9, 40.4.</div></div><div id="sec5_1_5_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> (3<i>S</i>,3a<i>S</i>)-3-(Aminomethyl)-7-morpholino-3,3a-dihydro-1<i>H</i>,9<i>H</i>-benzo[<i>e</i>]oxazolo[4,3-<i>b</i>][1,3]oxazin-1-one (<b>34</b>)</h4><div class="NLM_p last">Compound <b>34</b> (154 mg, 77%) was prepared from <b>29</b> (267 mg, 0.66 mmol) according to the procedure described for <b>30</b>. Mp: 173–175 °C. LC–MS (ESI) <i>m</i>/<i>z</i> [M + H]<sup>+</sup>: 306.1148. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 6.84 (d, <i>J</i> = 8.8 Hz, 1 H), 6.79 (dd, <i>J</i> = 2.8, 8.8 Hz, 1 H), 6.60 (d, <i>J</i> = 2.8 Hz, 1 H), 5.23 (d, <i>J</i> = 1.2 Hz, 1 H), 4.75 (d, <i>J</i> = 16.4 Hz, 1 H), 4.59–4.56 (td, <i>J</i> = 1.6, 4.8 Hz, 1 H), 4.44 (d, <i>J</i> = 16.8 Hz, 1 H), 3.86–3.84 (m, 4 H), 3.15–3.02 (m, 6 H), 1.57 (brs, 2 H). <sup>13</sup>C NMR (400 MHz, CDCl<sub>3</sub>) δ: 156.6, 147.0, 146.1, 119.5, 118.6, 117.0, 113.7, 83.6, 81.1, 66.9, 50.3, 43.0, 40.8.</div></div><div id="sec5_1_5_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> <i>N</i>-(((3<i>S</i>,3a<i>S</i>)-7-(6-Cyanopyridin-3-yl)-6-fluoro-1-oxo-3,3a-dihydro-1<i>H</i>,9<i>H</i>-benzo[<i>e</i>]oxazolo[4,3-<i>b</i>][1,3]oxazin-3-yl)methyl)acetamide (<b>20aa</b>)</h4><div class="NLM_p last">To a solution of <b>30</b> (75 mg, 0.22 mmol) in DCM (10.0 mL) were added TEA (45.9 μL, 0.33 mmol) and acetyl chloride (20.4 μL, 0.29 mmol) sequentially. The mixture was stirred for 2 h at 0 °C. Then the solution was washed with water and brine, dried over sodium sulfate, filtered, and concentrated. The residue was purified by chromatography (DCM/MeOH = 100:1) to give <b>20aa</b> as an off-white solid (66.0 mg, 78%). Mp: 159–161 °C. [α]<sub>D</sub><sup>19</sup> = −294.8 (<i>c</i> 0.384, CHCl<sub>3</sub>). HRMS (ESI) <i>m</i>/<i>z</i> [M + H]<sup>+</sup>: calcd for C<sub>19</sub>H<sub>16</sub>FN<sub>4</sub>O<sub>4</sub> 383.1156, found 383.1146. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 8.83 (s, 1 H), 7.95 (dt, <i>J</i> = 1.6, 8.0 Hz, 1 H), 7.76 (d, <i>J</i> = 8.0 Hz, 1 H), 7.16 (d, <i>J</i> = 8.0 Hz, 1 H), 6.79 (d, <i>J</i> = 11.2 Hz, 1 H), 5.91 (t, <i>J</i> = 5.6 Hz, 1 H), 5.51 (s, 1 H), 4.85 (d, <i>J</i> = 16.4 Hz, 1 H), 4.70 (t, <i>J</i> = 4.8 Hz,1 H), 4.49 (d, <i>J</i> = 16.8 Hz, 1 H), 3.72 (t, <i>J</i> = 5.2 Hz, 2 H), 2.05 (s, 3 H).</div></div><div id="sec5_1_5_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> <i>N</i>-(((3<i>S</i>,3a<i>S</i>)-6-Fluoro-7-(6-(2-methyl-2<i>H</i>-tetrazol-5-yl)pyridin-3-yl)-1-oxo-3,3a-dihydro-1<i>H</i>,9<i>H</i>-benzo[<i>e</i>]oxazolo[4,3-<i>b</i>][1,3]oxazin-3-yl)methyl)acetamide (<b>35</b>)</h4><div class="NLM_p last">Compound <b>35</b> (44 mg, 89%) was prepared from <b>31</b> (45 mg, 0.11 mmol) according to the procedure described for <b>20aa</b>. Mp: 108–110 °C. HRMS (ESI) <i>m</i>/<i>z</i> [M + H]<sup>+</sup>: calcd for C<sub>20</sub>H<sub>19</sub>FN<sub>7</sub>O<sub>4</sub> 440.1483, found 440.1455. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 8.87 (s, 1 H), 8.30 (d, <i>J</i> = 8.4 Hz, 1 H), 7.98 (dt, <i>J</i> = 1.6, 8.0 Hz, 1 H), 7.20 (d, <i>J</i> = 8.0 Hz, 1 H), 6.77 (d, <i>J</i> = 10.8 Hz, 1 H), 6.05 (t, <i>J</i> = 6.4 Hz, 1 H), 5.48 (d, <i>J</i> = 1.2 Hz, 1 H), 4.84 (d, <i>J</i> = 16.4 Hz, 1 H), 4.70 (t, <i>J</i> = 4.4 Hz, 1 H), 4.50 (d, <i>J</i> = 16.4 Hz, 1 H), 4.47 (s, 3 H), 3.73–3.70 (m, 2 H), 2.05 (s, 3 H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ: 171.1, 164.7, 159.2 (d, <i>J</i><sub>C–F</sub> = 249.0 Hz), 156.3, 153.4 (d, <i>J</i><sub>C–F</sub> = 12.0 Hz), 149.9, 145.7, 137.1 (d, <i>J</i><sub>C–F</sub> = 3.0 Hz), 132.0, 128.1 (d, <i>J</i><sub>C–F</sub> = 5.0 Hz), 122.0, 120.0 (d, <i>J</i><sub>C–F</sub> = 15.0 Hz), 115.5 (d, <i>J</i><sub>C–F</sub> = 4.0 Hz), 106.2 (d, <i>J</i><sub>C–F</sub> = 25.0 Hz), 83.7, 78.9, 40.3, 40.2, 39.8, 23.1.</div></div><div id="sec5_1_5_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> <i>N</i>-(((3<i>S</i>,3a<i>S</i>)-6-Fluoro-7-morpholino-1-oxo-3,3a-dihydro-1<i>H</i>,9<i>H</i>-benzo[<i>e</i>]oxazolo[4,3-<i>b</i>][1,3]oxazin-3-yl)methyl)acetamide (<b>36</b>)</h4><div class="NLM_p last">Compound <b>36</b> (58.4 mg, 86%) was prepared from <b>32</b> (60 mg, 0.14 mmol) according to the procedure described for <b>20aa</b>. Mp: 118–120 °C. HRMS (ESI) <i>m</i>/<i>z</i> [M + H]<sup>+</sup>: calcd for C<sub>17</sub>H<sub>21</sub>FN<sub>3</sub>O<sub>5</sub> 366.1465, found 366.1453. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 6.65–6.59 (m, 2 H), 6.32 (brs, 1 H), 5.32 (d, <i>J</i> = 1.2 Hz, 1 H), 4.70 (d, <i>J</i> = 16.4 Hz, 1 H), 4.63 (t, <i>J</i> = 5.2 Hz, 1 H), 4.38 (d, <i>J</i> = 16.4 Hz, 1 H), 3.86–3.84 (m, 4 H), 3.67 (t, <i>J</i> = 5.6 Hz, 2 H), 2.99–2.97 (m, 4 H), 2.02 (s, 3 H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ: 171.2, 156.6, 155.1 (d, <i>J</i><sub>C–F</sub> = 246.0 Hz), 147.4 (d, <i>J</i><sub>C–F</sub> = 11.0 Hz), 135.9 (d, <i>J</i><sub>C–F</sub> = 9.0 Hz), 116.3 (d, <i>J</i><sub>C–F</sub> = 4.0 Hz), 114.3 (d, <i>J</i><sub>C–F</sub> = 3.0 Hz), 106.5 (d, <i>J</i><sub>C–F</sub> = 24.0 Hz), 83.5, 79.0, 67.0, 51.4, 51.3, 40.4, 40.3, 23.1.</div></div><div id="sec5_1_5_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> <i>N</i>-(((3<i>S</i>,3a<i>S</i>)-7-(6-Cyanopyridin-3-yl)-1-oxo-3,3a-dihydro-1<i>H</i>,9<i>H</i>-benzo[<i>e</i>]oxazolo[4,3-<i>b</i>][1,3]oxazin-3-yl)methyl)acetamide (<b>37</b>)</h4><div class="NLM_p last">Compound <b>37</b> (81 mg, 93%) was prepared from <b>33</b> (77 mg, 0.24 mmol) according to the procedure described for <b>20aa</b>. Mp: 229–231 °C. HRMS (ESI) <i>m</i>/<i>z</i> [M + H]<sup>+</sup>: calcd for C<sub>19</sub>H<sub>17</sub>N<sub>4</sub>O<sub>4</sub> 365.1250, found 365.1240. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 8.88 (d, <i>J</i> = 1.6 Hz, 1 H), 7.94 (dd, <i>J</i> = 2.4, 8.0 Hz, 1 H), 7.75 (d, <i>J</i> = 8.0 Hz, 1 H), 7.43 (dd, <i>J</i> = 2.4, 8.8 Hz, 1 H), 7.32 (d, <i>J</i> = 2.4 Hz, 1 H), 7.05 (d, <i>J</i> = 8.8 Hz, 1 H), 5.93 (t, <i>J</i> = 6.4 Hz, 1 H), 5.46 (d, <i>J</i> = 1.2 Hz, 1 H), 4.88 (d, <i>J</i> = 16.8 Hz, 1 H), 4.71 (t, <i>J</i> = 4.4 Hz, 1 H), 4.54 (d, <i>J</i> = 16.8 Hz, 1 H), 3.75–3.67 (m, 2 H), 2.05 (s, 3 H). <sup>13</sup>C NMR (400 MHz, CDCl<sub>3</sub>) δ: 171.2, 156.3, 153.4, 149.3, 138. 8, 134.5, 132.2, 130.4, 128.5, 127.5, 125.7, 119.9, 119.3, 117.3, 83.6, 78.94, 40.6, 40.3, 23.2.</div></div><div id="sec5_1_5_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> <i>N</i>-(((3<i>S</i>,3a<i>S</i>)-7-Morpholino-1-oxo-3,3a-dihydro-1<i>H</i>,9<i>H</i>-benzo[<i>e</i>]oxazolo[4,3-<i>b</i>][1,3]oxazin-3-yl)methyl)acetamide (<b>38</b>)</h4><div class="NLM_p last">Compound <b>38</b> (82 mg, 99%) was prepared from <b>34</b> (74 mg, 0.24 mmol) according to the procedure described for <b>20aa</b>. Mp: 160–162 °C. HRMS (ESI) <i>m</i>/<i>z</i> [M + H]<sup>+</sup>: calcd for C<sub>17</sub>H<sub>22</sub>N<sub>3</sub>O<sub>5</sub> 348.1560, found 348.1554. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 6.85–6.79 (m, 2 H), 6.59 (s, 1 H), 5.94 (t, <i>J</i> = 6.0 Hz, 1 H), 5.27 (d, <i>J</i> = 1.6 Hz, 1 H), 4.75 (d, <i>J</i> = 16.4 Hz, 1 H), 4.65–4.62 (m, 1 H), 4.42 (d, <i>J</i> = 16.8 Hz, 1 H), 3.87–3.85 (m, 4 H), 3.76–3.70 (m, 1 H), 3.65–3.58 (m, 1 H), 3.07–3.05 (m, 4 H), 2.03 (s, 3 H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ: 170.8, 156.5, 119.3, 118.7, 117.2, 113.70, 83.4, 78.9, 66.9, 50.3, 40.9, 40.4, 23.2.</div></div></div><div id="sec5_1_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> Synthetic Procedure for Compounds <b>(±)-47</b> and <b>(±)-48</b></h3><div id="sec5_1_6_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> Benzyl 7-Bromo-6-fluoro-2-(3-(4-methoxybenzyl)-2-oxooxazolidin-5-yl)-2<i>H</i>-benzo[<i>e</i>][1,3]oxazine-3(4<i>H</i>)-carboxylate (<b>(±)-39</b>)</h4><div class="NLM_p last">Compound <b>(±)-39</b> (3.2 g, 51%) was prepared from <b>10c</b> (3.9 g, 11.0 mmol) according to the procedure described for <b>(±)-15a</b>. Mp: 110–112 °C. LC–MS (ESI) <i>m</i>/<i>z</i> [M + H]<sup>+</sup>: 571.0892 and 573.0837. <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>) δ: 7.45–7.32 (m, 5 H), 7.22–7.19 (m, 3 H), 7.10 (d, <i>J</i> = 6.0 Hz, 1 H), 6.88 (d, <i>J</i> = 8.0 Hz, 2 H), 6.02 (d, <i>J</i> = 8.8 Hz, 1 H), 5.22 (d, <i>J</i> = 12.0 Hz, 1 H), 5.19 (d, <i>J</i> = 12.4 Hz, 1 H), 5.05 (d, <i>J</i> = 17.6 Hz, 1 H), 4.86–4.80 (m, 1 H), 4.45 (d, <i>J</i> = 17.6 Hz, 1 H), 4.37 (d, <i>J</i> = 14.8 Hz, 1 H), 4.31 (d, <i>J</i> = 14.8 Hz, 1 H), 3.78 (s, 3 H), 3.61 (t, <i>J</i> = 9.2 Hz, 1 H), 3.50–3.45 (m, 1 H).</div></div><div id="sec5_1_6_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> Benzyl 7-Bromo-6-fluoro-2-(2-oxooxazolidin-5-yl)-2<i>H</i>-benzo[<i>e</i>][1,3]oxazine-3(4<i>H</i>)-carboxylate (<b>(±)-40</b>)</h4><div class="NLM_p last">Compound <b>(±)-40</b> (1.9 g, 67%) was prepared from <b>(±)-39</b> (3.6 g, 6.3 mmol) according to the procedure described for <b>(±)-16a</b>. Mp: 150–152 °C. LC–MS (ESI) <i>m</i>/<i>z</i> [M + H]<sup>+</sup>: 451.0299 and 453.0280. <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>) δ: 7.45–7.42 (m, 2 H), 7.39–7.33 (m, 3 H), 7.22 (d, <i>J</i> = 8.8 Hz, 1 H), 7.16 (d, <i>J</i> = 6.0 Hz, 1 H), 6.67 (s, 1 H), 6.15 (d, <i>J</i> = 8.8 Hz, 1 H), 5.25 (d, <i>J</i> = 12.4 Hz, 1 H), 5.21 (d, <i>J</i> = 12.4 Hz, 1 H), 5.08 (d, <i>J</i> = 17.6 Hz, 1 H), 4.95–4.90 (m, 1 H), 4.48 (d, <i>J</i> = 17.2 Hz, 1 H), 3.76 (t, <i>J</i> = 8.8 Hz, 1 H), 3.69–3.65 (m, 1 H).</div></div><div id="sec5_1_6_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> Benzyl 7-Bromo-2-(3-(<i>tert</i>-butoxycarbonyl)-2-oxooxazolidin-5-yl)-6-fluoro-2<i>H</i>-benzo[<i>e</i>][1,3]oxazine-3(4<i>H</i>)-carboxylate (<b>(±)-41</b>)</h4><div class="NLM_p last">Compound <b>(±)-41</b> (3.2 g, 74%) was prepared from <b>(±)-40</b> (3.4 g, 7.6 mmol) according to the procedure described for <b>(±)-17a</b>. Mp: 170–172 °C. LC–MS (ESI) <i>m</i>/<i>z</i> [M + Na]<sup>+</sup>: 573.0613 and 575.0594. <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>) δ: 7.44–7.32 (m, 5 H), 7.24–7.21 (m, 2 H), 6.24 (d, <i>J</i> = 8.8 Hz, 1 H), 5.25 (d, <i>J</i> = 12.4 Hz, 1 H), 5.21 (d, <i>J</i> = 12.4 Hz, 1 H), 5.08 (d, <i>J</i> = 17.6 Hz, 1 H), 4.96–4.90 (m, 1 H), 4.50 (d, <i>J</i> = 17.6 Hz, 1 H), 4.16–4.08 (m, 2 H), 1.50 (s, 9 H).</div></div><div id="sec5_1_6_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> <i>tert</i>-Butyl ((6-Bromo-7-fluoro-1-oxo-3,3a-dihydro-1<i>H</i>,9<i>H</i>-benzo[<i>e</i>]oxazolo[4,3-<i>b</i>][1,3]oxazin-3-yl)methyl)carbamate (<b>(±)-42</b>)</h4><div class="NLM_p last">Compound <b>(±)-42</b> (2.2 g, 82%) was prepared from <b>(±)-41</b> (3.7 g, 6.7 mmol) according to the procedure described for <b>(±)-18a</b>. Mp: 107–109 °C. LC–MS (ESI) <i>m</i>/<i>z</i> [M + Na]<sup>+</sup>: 439.0256 and 441.0236. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 7.11 (d, <i>J</i> = 6.0 Hz,1 H), 6.86 (d, <i>J</i> = 8.0 Hz,1 H), 5.40 (s,1 H), 4.88 (brs, 1 H), 4.75 (d, <i>J</i> = 16.8 Hz, 1 H), 4.62 (td, <i>J</i> = 1.2, 5.2 Hz,1 H), 4.35 (d, <i>J</i> = 17.2 Hz, 1 H), 3.60–3.48 (m, 2 H), 1.44 (s, 9 H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ: 156.3, 156.1, 154.5 (d, <i>J</i><sub>C–F</sub> = 242.0 Hz), 148.6 (d, <i>J</i><sub>C–F</sub> = 2.0 Hz), 122.7, 119.2 (d, <i>J</i><sub>C–F</sub> = 7.0 Hz), 113.6 (d, <i>J</i><sub>C–F</sub> = 24.0 Hz), 108.3 (d, <i>J</i><sub>C–F</sub> = 23.0 Hz), 83.6, 80.5, 79.0, 41.4, 40.4, 40.3, 28.3.</div></div><div id="sec5_1_6_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> <i>tert</i>-Butyl ((6-(6-Cyanopyridin-3-yl)-7-fluoro-1-oxo-3,3a-dihydro-1<i>H</i>,9<i>H</i>-benzo[<i>e</i>]oxazolo[4,3-<i>b</i>][1,3]oxazin-3-yl)methyl)carbamate (<b>(±)-43</b>)</h4><div class="NLM_p last">Compound <b>(±)-43</b> (160 mg, 84%) was prepared from <b>(±)-42</b> (180 mg, 0.43 mmol) according to the procedure described for <b>(±)-19a</b>. Mp: 60–62 °C. LC–MS (ESI) <i>m</i>/<i>z</i> [M + H]<sup>+</sup>: 441.1574. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 8.86 (s,1 H), 8.00–7.97 (m, 1 H), 7.78 (dd, <i>J</i> = 0.8, 8.0 Hz, 1 H), 7.01–6.90 (m, 2 H), 5.49 (s, 1 H), 4.90 (s, 1 H), 4.86 (d, <i>J</i> = 17.2 Hz, 1 H), 4.66 (t, <i>J</i> = 4.8 Hz, 1 H), 4.47 (d, <i>J</i> = 17.6 Hz, 1 H), 3.64–3.52 (m, 2 H), 1.45 (s, 9 H).</div></div><div id="sec5_1_6_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> <i>tert</i>-Butyl ((7-Fluoro-6-morpholino-1-oxo-3,3a-dihydro-1<i>H</i>,9<i>H</i>-benzo[<i>e</i>]oxazolo[4,3-<i>b</i>][1,3]oxazin-3-yl)methyl)carbamate (<b>(±)-44</b>)</h4><div class="NLM_p last">Compound <b>(±)-44</b> (35 mg, 38%) was prepared from <b>(±)-42</b> (90 mg, 0.22 mmol) according to the procedure described for <b>27</b>. Mp: 135–137 °C. LC–MS (ESI) <i>m</i>/<i>z</i> [M + H]<sup>+</sup>: 424.1871. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 6.75 (d, <i>J</i> = 12.0 Hz, 1 H), 6.44 (d, <i>J</i> = 7.2 Hz, 1 H), 5.35 (s, 1 H), 4.92 (brs, 1 H), 4.70 (d, <i>J</i> = 16.4 Hz, 1 H), 4.60 (t, <i>J</i> = 4.8 Hz, 1 H), 4.3 (d, <i>J</i> = 16.4 Hz, 1 H), 3.85 (t, <i>J</i> = 4.4 Hz, 4 H), 3.55–3.51 (m, 2 H), 3.05–3.02 (m, 4 H), 1.43 (s, 9 H).</div></div><div id="sec5_1_6_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> 5-(3-(Aminomethyl)-7-fluoro-1-oxo-3,3a-dihydro-1<i>H</i>,9<i>H</i>-benzo[<i>e</i>]oxazolo[4,3-<i>b</i>][1,3]oxazin-6-yl)picolinonitrile (<b>(±)-45</b>)</h4><div class="NLM_p last">Compound <b>(±)-45</b> (91 mg, 78%) was prepared from <b>(±)-43</b> (150 mg, 0.43 mmol) according to the procedure described for <b>30</b>. Mp: 84–86 °C. HRMS (ESI) <i>m</i>/<i>z</i> [M + H]<sup>+</sup>: calcd for C<sub>17</sub>H<sub>14</sub>FN<sub>4</sub>O<sub>3</sub> 341.1050, found 341.1042. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 8.86 (s, 1 H), 8.01–7.98 (m, 1 H), 7.78 (dd, <i>J</i> = 0.8, 8.0 Hz, 1 H), 7.02–7.00 (m, 2 H), 5.35 (d, <i>J</i> = 1.2 Hz, 1 H), 4.87 (d, <i>J</i> = 17.6 Hz, 1 H), 4.60 (td, <i>J</i> = 1.6, 5.6 Hz, 1 H), 4.53 (d, <i>J</i> = 17; 2 Hz, 1 H), 3.17–3.05 (m, 2 H), 1.49 (brs, 2 H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ: 156.3, 154.7 (d, <i>J</i><sub>C–F</sub> = 244.0 Hz), 150.7 (d, <i>J</i><sub>C–F</sub> = 4.0 Hz), 148.9 (d, <i>J</i><sub>C–F</sub> = 2.0 Hz), 136.9 (d, <i>J</i><sub>C–F</sub> = 4.0 Hz), 134.1, 133.0, 128.2, 123.9, 121.8 (d, <i>J</i><sub>C–F</sub> = 8.0 Hz), 119.1 (d, <i>J</i><sub>C–F</sub> = 2.0 Hz), 117.1, 114..4 (d, <i>J</i><sub>C–F</sub> = 26.0 Hz), 83.9, 81.1, 42.8, 40.3.</div></div><div id="sec5_1_6_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> 3-(Aminomethyl)-7-fluoro-6-morpholino-3,3a-dihydro-1<i>H</i>,9<i>H</i>-benzo[<i>e</i>]oxazolo[4,3-<i>b</i>][1,3]oxazin-1-one (<b>(±)-46</b>)</h4><div class="NLM_p last">Compound <b>(±)-46</b> (72 mg, 86%) was prepared from <b>(±)-44</b> (110 mg, 0.26 mmol) according to the procedure described for <b>30</b>. Mp: 64–66 °C. HRMS (ESI) <i>m</i>/<i>z</i> [M + H]<sup>+</sup>: calcd for C<sub>15</sub>H<sub>19</sub>FN<sub>3</sub>O<sub>4</sub> 324.1360, found 324.1349. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 6.77 (d, <i>J</i> = 12.4 Hz, 1 H), 6.45 (d, <i>J</i> = 7.6 Hz, 1 H), 5.24 (d, <i>J</i> = 1.6 Hz, 1 H), 4.71 (d, <i>J</i> = 16.4 Hz, 1 H), 4.53 (td, <i>J</i> = 1.2, 5.6 Hz, 1 H), 4.38 (d, <i>J</i> = 16.4 Hz, 1 H), 3.85 (t, <i>J</i> = 4.8 Hz, 4 H), 3.12–2.99 (m, 6 H), 1.25 (brs, 2 H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ: 156.5, 151.1 (d, <i>J</i><sub>C–F</sub> = 241.0 Hz), 148.5 (d, <i>J</i><sub>C–F</sub> = 2.0 Hz), 140.1 (d, <i>J</i><sub>C–F</sub> = 10.0 Hz), 113.6 (d, <i>J</i><sub>C–F</sub> = 23.0 Hz), 111.9 (d, <i>J</i><sub>C–F</sub> = 7.0 Hz), 108.0 (d, <i>J</i><sub>C–F</sub> = 3.0 Hz), 83.7, 81.1, 66.9, 50.8, 50.7, 43.0, 40.0.</div></div><div id="sec5_1_6_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> <i>N</i>-((6-(6-Cyanopyridin-3-yl)-7-fluoro-1-oxo-3,3a-dihydro-1<i>H</i>,9<i>H</i>-benzo[<i>e</i>]oxazolo[4,3-<i>b</i>][1,3]oxazin-3-yl)methyl)acetamide (<b>(±)-47</b>)</h4><div class="NLM_p last">Compound <b>(±)-47</b> (68 mg, 76%) was prepared from <b>(±)-45</b> (80 mg, 0.24 mmol) according to the procedure described for <b>20aa</b>. Mp: 115–117 °C. HRMS (ESI) <i>m</i>/<i>z</i> [M + H]<sup>+</sup>: calcd for C<sub>19</sub>H<sub>16</sub>FN<sub>4</sub>O<sub>4</sub> 383.1156, found 383.1141. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 8.85 (s, 1 H), 7.98 (d, <i>J</i> = 8.0 Hz, 1 H), 7.78 (d, <i>J</i> = 8.0 Hz, 1 H), 7.00–6.97 (m, 2 H), 6.22 (brs, 1 H), 5.45 (s, 1 H), 4.84 (d, <i>J</i> = 17.2 Hz, 1 H), 4.69 (t, <i>J</i> = 4.8 Hz, 1 H), 4.49 (d, <i>J</i> = 17.2 Hz, 1 H), 3.72–3.69 (m, 2 H), 2.04 (s, 9 H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ: 171.2, 156.4, 154.8 (d, <i>J</i><sub>C–F</sub> = 245.0 Hz), 150.7 (d, <i>J</i><sub>C–F</sub> = 4.0 Hz), 148.8 (d, <i>J</i><sub>C–F</sub> = 2.0 Hz), 137.0 (d, <i>J</i><sub>C–F</sub> = 4.0 Hz), 134.1, 132.9, 128.2, 124.0 (d, <i>J</i><sub>C–F</sub> = 15.0 Hz), 121.6 (d, <i>J</i><sub>C–F</sub> = 8.0 Hz), 119.2 (d, <i>J</i><sub>C–F</sub> = 3.0 Hz), 117.1, 114.4 (d, <i>J</i><sub>C–F</sub> = 25.0 Hz), 83.7, 79.1, 40.5, 40.2, 23.1.</div></div><div id="sec5_1_6_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> <i>N</i>-((7-Fluoro-6-morpholino-1-oxo-3,3a-dihydro-1<i>H</i>,9<i>H</i>-benzo[<i>e</i>]oxazolo[4,3-<i>b</i>][1,3]oxazin-3-yl)methyl)acetamide (<b>(±)-48</b>)</h4><div class="NLM_p last">Compound <b>(±)-48</b> (44 mg, 86%) was prepared from <b>(±)-46</b> (45 mg, 0.14 mmol) according to the procedure described for <b>20aa</b>. Mp: 202–205 °C. HRMS (ESI) <i>m</i>/<i>z</i> [M + H]<sup>+</sup>: calcd for C<sub>17</sub>H<sub>21</sub>FN<sub>3</sub>O<sub>5</sub> 366.1465, found 366.1443. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 6.76 (d, <i>J</i> = 12.0 Hz, 1 H), 6.48 (d, <i>J</i> = 7.2 Hz, 1 H), 5.93 (brs, 1 H), 5.30 (d, <i>J</i> = 1.2 Hz, 1 H), 4.70 (d, <i>J</i> = 16.4 Hz, 1 H), 4.63 (t, <i>J</i> = 5.2 Hz, 1 H), 4.36 (d, <i>J</i> = 16.4 Hz, 1 H), 3.87 (t, <i>J</i> = 4.4 Hz, 4 H), 3.75–3.60 (m, 2 H), 3.07–3.04 (m, 4 H), 2.03 (s, 3 H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ: 170.9, 156.4, 151.1 (d, <i>J</i><sub>C–F</sub> = 241.0 Hz), 150.8, 148.3 (d, <i>J</i><sub>C–F</sub> = 2.0 Hz), 113.5 (d, <i>J</i><sub>C–F</sub> = 24.0 Hz), 111.9 (d, <i>J</i><sub>C–F</sub> = 7.0 Hz), 108.2 (d, <i>J</i><sub>C–F</sub> = 3.0 Hz), 83.5, 78.9, 66.8, 50.8, 50.7, 40.3, 40.2, 23.2.</div></div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> Minimum Inhibitory Concentration Testing (Antitubercular Activity)</h3><div class="NLM_p last">MICs of compounds against <i>M. tuberculosis</i> were determined by the microplate alamar blue assay (MABA). INH and RFP were included as positive controls. Compound stock solutions and the range of final testing concentrations were 32–0.5 μg/mL. For the active compounds, the stock concentration and final testing concentration range were lowered to 2–0.016 μg/mL. <i>M. tuberculosis</i> H37Rv or clinical isolates were grown to late log phase (70 to 100 Klett units) in Difco Middlebrook 7H9 broth supplemented with 0.2% (v/v) glycerol, 0.05% Tween 80, and 10% (v/v) albumin-dextrose-catalase (7H9-ADC-TG). Two-fold dilution of compounds was prepared in 7H9-ADC-TG in a volume of 100 μL in 96-well, black, clear-bottom microplates. <i>M. tuberculosis</i> (100 μL containing 2 × 10<sup>5</sup> CFU) was added, yielding a final testing volume of 200 μL. The plates were incubated at 37 °C, and on day 7 of incubation, 12.5 μL of 20% Tween 80 and 20 μL of alamar blue were added to all wells. After incubation at 37 °C for 16 h, the fluorescence was read at an excitation of 530 nm and an emission of 590 nm. The MIC was defined as the lowest concentration effecting a reduction in fluorescence of ≥90% relative to controls.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> Minimum Inhibitory Concentration Testing (Antibacterial Activity)</h3><div class="NLM_p last">Antimicrobial susceptibility tests were conducted in 96-well microplates using the broth microdilution procedure. Cation-adjusted Mueller–Hinton broth for all the <i>S. aureus</i> strains or brain heart infusion broth for VRE or Mueller–Hinton broth for the other strains was used in the assays. After incubation at 37 °C for 18 h, the absorbance at 600 nm was recorded using a microplate reader (Bio-Rad Laboratory Ltd., U.K.) and then the percentage of bacterial cell inhibition versus vehicles (1% DMSO) was calculated. The MIC was defined as the lowest compound concentration at which the growth of bacteria was inhibited by ≥90%. According to Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically (29th edition, M100), for <i>Enterococcus</i>, linezolid resistant MIC ≥ 8 μg/mL, linezolid intermediate MIC = 4 μg/mL, linezolid susceptible MIC ≤ 2 μg/mL; for <i>Staphylococcus</i>, linezolid resistant MIC ≥ 8 μg/mL, linezolid susceptible MIC ≤ 4 μg/mL.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> Cytotoxicity Assay</h3><div class="NLM_p last">Vero cells were cultured in RPMI1640 medium supplemented with 10% fetal bovine serum (FBS). The cells were incubated in a humidified atmosphere of 5% CO<sub>2</sub> at 37 °C. Stocks of cells were cultured in 25 cm<sup>2</sup> tissue culture flasks and subcultured two to three times per week. Cytotoxicity testing was performed in a transparent 96-well microplate. Outer perimeter wells were filled with sterile water to prevent dehydration in experimental wells. The cells were incubated at 37 °C under 5% CO<sub>2</sub> until confluent and then diluted with culture medium to 4 × 10<sup>5</sup> cells/mL. Three-fold serial dilutions of the stock solutions resulted in final concentrations of 64–0.26 μg/mL in a final volume of 100 μL. After incubation at 37 °C for 48 h, the medium was removed, and the monolayers were washed twice with 100 μL of warm Hanks’ balanced salt solution (HBSS). Warm medium (100 μL) and 10 μL of freshly made methylthiazolyldiphenyltetrazolium bromide (MTT) were added to each well, and then the plates were incubated for 4 h. The absorbance was determined at 492 nm.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> Liver Microsome Stability Assay</h3><div class="NLM_p last">The assay was performed with liver microsomes from male CD-1 mouse and pooled human. The incubation was performed as follows: microsomes in 0.05 M phosphate buffer, pH 7.4 (1 mg/mL microsomal protein), tested compounds (final concentration 0.1 μM, cosolvent (DMSO)), and then NADPH (1 mM) at 37 °C for 30 min. The reaction can be started by the addition of NADPH or the same volume of buffer. Aliquots were sampled at 0 and 30 min incubation, and enzymatic reaction was quenched by addition of acetonitrile. After centrifugation, samples were then analyzed by LC–MS. The assay evaluated the metabolic stability of compounds by measuring the substrate remaining with or without NADPH cofactor.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> Inhibition Evaluation on hERG K<sup>+</sup> Channel</h3><div class="NLM_p last">HEK 293 cells were stably transfected with human ether-à-go-go-related gene (hERG) channel. The voltage-gated hERG potassium channel current was recorded at room temperature (25 °C) from randomly selected transfected cells under whole-cell manual patch clamp systems equipped with EPC10 USB (HEKA) or Multiclamp 700B amplifier (Molecular Devices), while electrical data were digitalized by Digidata1440A with sampling frequency at 10 kHz using Patchmaster or pClamp10. hERG current inhibition in the presence of five concentrations, including 30, 10, 3.0, 1.0, and 0.3 μM, was tested for IC<sub>50</sub> determination. Dofetilide was also included as a positive control to ensure the accuracy and sensitivity of the test system.</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> Mitochondrial Protein Synthesis Inhibition</h3><div class="NLM_p last">Mitochondrial protein synthesis was measured on Cardiac (H9C2) cell line that was obtained from National Platform of Experimental Cell Resources for Sci-Tech. The H9C2 cells were kept in DMEM (Gibico) with 10% FBS (Hyclone) and 1× glutamine and NEAA at 37 °C, 5% CO<sub>2</sub>. The cell monolayer was washed with prewarmed PBS and detached using trypsin. After centrifugation (1000 rpm for 5 min at rt), the cells were resuspended with cell culture medium and seeded at 1500 cells/well into a 384-well plate. After 18 h, compounds <b>20aa</b> and <b>35</b>, with final concentrations of 200 μM, 66.67 μM, 22.22 μM, 7.41 μM, 2.47 μM, 0.82 μM, 0.27 μM, 0.09 μM, 0.03 μM, were added to the appropriate well and then incubated at 37 °C 5% CO<sub>2</sub> for 5 days. A negative control with 0.5% DMSO was performed for every compound. MPS inhibition was evaluated by MitoBiogenesis In-Cell ELISA. IC<sub>50</sub> calculation was performed using GraphPad Prism 5 software.</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> MAO Inhibition</h3><div class="NLM_p last">Test compound working solutions were made (4-fold dilution, six nonzero concentrations) from 10 mM test compound DMSO stock with DMSO. Control compound working solution was made (4-fold dilution, six nonzero concentrations) from 40 mM leflunomide DMSO stock with DMSO. 40 μM substrate working solution was made from 20 mM kynuramine DMSO stock with phosphate buffer. Thaw MAO-A and MAO-B recombinase in 37 °C water bath. 0.01 mg/mL MAO-A and 0.04 mg/mL MAO-B working solutions were made with phosphate buffer. Add 99 μL of substrate working solution into 1.1 mL incubation tubes and then add 1 μL of the test compound/control working solution or DMSO (vehicle control), mix well, and preincubate at 37 °C for 5 min. Add 100 μL of preincubated MAO-A or MAO-B working solution to incubation tubes to start the reaction, mix well, and incubate at 37 °C for 15 min. Following the incubation, immediately add 200 μL of quenching solution and vortex to mix. Centrifuge all samples at 4 °C for 15 min, then transfer 100 μL of supernatant with 100 μL of water for LC–MS/MS analysis. Corresponding metabolite 4-hydroxyquinolinol is detected. The inhibition potentials (% inhibition) are calculated using formation with test compound or control compound compared to that with the vehicle control. IC<sub>50</sub> values are calculated using GraphPad Prism.</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> Pharmacokinetic Studies in Mouse</h3><div class="NLM_p last">The animal protocol was approved by Institute Animal Care and Welfare Committee. Compound <b>20aa</b> was subjected to pharmacokinetic studies in BALB/c mouse (female) weighing 16–21 g with three mice in oral administration group and three mice in intravenous injection group. Compound <b>20aa</b> was formulated at a concentration of 5 mg/mL for a dose of 10 mg/kg given orally (po) and at 1 mg/mL for a dose of 1 mg/kg given intravenously (iv). Compound <b>20aa</b> was formulated with 0.5% carboxymethyl cellulose for po administration and with 10% DMSO/50% PEG400/40% water for iv administration. Blood samples were collected at 15 min, 30 min, 1 h, 2 h, 4 h, 8 h, 12 h, and 24 h after oral dosing and 5 min, 15 min, 30 min, 1 h, 2 h, 4 h, 8 h, 12 h, and 24 h after iv administration. Analyte quantification was performed by a LC/MS/MS Quantum Access mass spectrometer (AB Sciex 5500). Compound detection on the mass spectrometer was performed in electrospray positive ionization mode. The pharmacokinetic parameters were calculated using WinNonlin software version 6.3 based on noncompartmental analysis (Pharsight Corporation, Mountain View, USA). The oral bioavailability was calculated as the ratio between the area under the curve (AUC) following intravenous administration corrected for dose, <i>F</i> = [(AUC<sub>po</sub> × dose<sub>iv</sub>)/(AUC<sub>iv</sub> × dose<sub>po</sub>)] × 100%.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i76"><a href="/doi/suppl/10.1021/acs.jmedchem.0c02153" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05417" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05417" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c02153?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02153</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Synthesis of compounds <b>10a</b>–<b>c</b>, <b>14</b>, and <b>49</b>; NMR spectra of all compounds; chiral HPLC of compounds <b>(±)-18a</b>, <b>18a</b>, <b>(±)-20a</b>, <b>20aa</b>, <b>20ab</b>, <b>(±)-24</b>, and <b>24</b>; plasma exposure of compound <b>20aa</b> in mouse (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02153/suppl_file/jm0c02153_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02153/suppl_file/jm0c02153_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02153/suppl_file/jm0c02153_si_001.pdf">jm0c02153_si_001.pdf (6.6 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02153/suppl_file/jm0c02153_si_002.csv">jm0c02153_si_002.csv (4.04 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c02153" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83485" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83485" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dongfeng Zhang</span> - <span class="hlFld-Affiliation affiliation">Beijing
Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Peking Union Medical
College and Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Beijing 100050, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">Chinese
Academy of Medical Sciences Key Laboratory of Anti-DR TB Innovative
Drug Research, Institute of Materia Medica,
Peking Union Medical College and Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Beijing 100050, P. R. China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0870-3782" title="Orcid link">http://orcid.org/0000-0003-0870-3782</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#2e544a486e474343004f4d004d40"><span class="__cf_email__" data-cfemail="0b716f6d4b626666256a68256865">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ning Sun</span> - <span class="hlFld-Affiliation affiliation">The
State Key Laboratory of Chemical Biology and Drug Discovery, Department
of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">The
Fifth Affiliated Hospital of Guangzhou Medical University, 621 Gang Wan Road, Guangzhou 440112, P. R. China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#c0aea9aea7eeb3b5ae80a3afaeaea5a3b4eeb0afacb9b5eea8ab"><span class="__cf_email__" data-cfemail="600e090e074e13150e20030f0e0e0503144e100f0c19154e080b">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Haihong Huang</span> - <span class="hlFld-Affiliation affiliation">Beijing
Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Peking Union Medical
College and Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Beijing 100050, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">Chinese
Academy of Medical Sciences Key Laboratory of Anti-DR TB Innovative
Drug Research, Institute of Materia Medica,
Peking Union Medical College and Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Beijing 100050, P. R. China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#543e3b2d3731143d39397a35377a373a"><span class="__cf_email__" data-cfemail="85efeafce6e0c5ece8e8abe4e6abe6eb">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yongqi Wu</span> - <span class="hlFld-Affiliation affiliation">Beijing
Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Peking Union Medical
College and Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Beijing 100050, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">Chinese
Academy of Medical Sciences Key Laboratory of Anti-DR TB Innovative
Drug Research, Institute of Materia Medica,
Peking Union Medical College and Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Beijing 100050, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bin Wang</span> - <span class="hlFld-Affiliation affiliation">Beijing
Key Laboratory of Drug Resistance Tuberculosis Research, Department
of Pharmacology, Beijing Tuberculosis and Thoracic Tumor Research
Institute, Beijing Chest Hospital, Capital
Medical University, 97
Ma Chang Street, Beijing 101149, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Haijia Lu</span> - <span class="hlFld-Affiliation affiliation">Beijing
Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Peking Union Medical
College and Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Beijing 100050, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">Chinese
Academy of Medical Sciences Key Laboratory of Anti-DR TB Innovative
Drug Research, Institute of Materia Medica,
Peking Union Medical College and Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Beijing 100050, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hongyi Zhao</span> - <span class="hlFld-Affiliation affiliation">Beijing
Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Peking Union Medical
College and Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Beijing 100050, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">Chinese
Academy of Medical Sciences Key Laboratory of Anti-DR TB Innovative
Drug Research, Institute of Materia Medica,
Peking Union Medical College and Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Beijing 100050, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Beibei Yang</span> - <span class="hlFld-Affiliation affiliation">Beijing
Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Peking Union Medical
College and Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Beijing 100050, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Li Li</span> - <span class="hlFld-Affiliation affiliation">Beijing
Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Peking Union Medical
College and Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Beijing 100050, P. R. China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9496-2280" title="Orcid link">http://orcid.org/0000-0002-9496-2280</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yu Lu</span> - <span class="hlFld-Affiliation affiliation">Beijing
Key Laboratory of Drug Resistance Tuberculosis Research, Department
of Pharmacology, Beijing Tuberculosis and Thoracic Tumor Research
Institute, Beijing Chest Hospital, Capital
Medical University, 97
Ma Chang Street, Beijing 101149, P. R. China</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i77">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07452" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07452" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The research is supported by the National Natural Science Foundation of China (Grant 81502917) and the National Natural Science Foundation of China (Grant 81703333). The linezolid resistant strains are gifts from Prof. Min Li of Renji Hospital of Shanghai Jiaotong University and Dr. Wenchang Yuan of Guangzhou Medical University.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">MRSA</td><td class="NLM_def"><p class="first last">methicillin-resistant <i>Staphylococcus aureus</i></p></td></tr><tr><td class="NLM_term">VISA</td><td class="NLM_def"><p class="first last">vancomycin intermediate <i>Staphylococcus aureus</i></p></td></tr><tr><td class="NLM_term">VRE</td><td class="NLM_def"><p class="first last">vancomycin resistant <i>Enterococcus</i></p></td></tr><tr><td class="NLM_term">MRSE</td><td class="NLM_def"><p class="first last">methicillin-resistant <i>Staphylococcus epidermidis</i></p></td></tr><tr><td class="NLM_term">TB</td><td class="NLM_def"><p class="first last">tuberculosis</p></td></tr><tr><td class="NLM_term">MDR-TB</td><td class="NLM_def"><p class="first last">multidrug-resistant TB</p></td></tr><tr><td class="NLM_term">XDR-TB</td><td class="NLM_def"><p class="first last">extensively drug resistant TB</p></td></tr><tr><td class="NLM_term">CbzCl</td><td class="NLM_def"><p class="first last">benzyl chloroformate</p></td></tr><tr><td class="NLM_term">PMB</td><td class="NLM_def"><p class="first last">4-methoxybenzyl</p></td></tr><tr><td class="NLM_term">Boc</td><td class="NLM_def"><p class="first last"><i>tert</i>-butoxycarbonyl</p></td></tr><tr><td class="NLM_term">DMAP</td><td class="NLM_def"><p class="first last">4-dimethylaminopyridine</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">EtOAc</td><td class="NLM_def"><p class="first last">ethyl actate</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">CAN</td><td class="NLM_def"><p class="first last">ceric ammonium nitrate</p></td></tr><tr><td class="NLM_term">ECD</td><td class="NLM_def"><p class="first last">electrostatic circular dichroism</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">MIC</td><td class="NLM_def"><p class="first last">minimum inhibitory concentration</p></td></tr><tr><td class="NLM_term">MPS</td><td class="NLM_def"><p class="first last">mitochondrial protein synthesis</p></td></tr><tr><td class="NLM_term">MAO</td><td class="NLM_def"><p class="first last">monoamine oxidase</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">NADPH</td><td class="NLM_def"><p class="first last">nicotinamide adenine dinucleotide phosphate</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i79">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74117" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74117" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 29 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, G. D.</span></span> <span> </span><span class="NLM_article-title">Antibacterial drug discovery in the resistance era</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>529</i></span>,  <span class="NLM_fpage">336</span>– <span class="NLM_lpage">343</span>, <span class="refDoi"> DOI: 10.1038/nature17042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=10.1038%2Fnature17042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=26791724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Oisro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=529&publication_year=2016&pages=336-343&author=E.+D.+Brownauthor=G.+D.+Wright&title=Antibacterial+drug+discovery+in+the+resistance+era&doi=10.1038%2Fnature17042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Antibacterial drug discovery in the resistance era</span></div><div class="casAuthors">Brown, Eric D.; Wright, Gerard D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">529</span>
        (<span class="NLM_cas:issue">7586</span>),
    <span class="NLM_cas:pages">336-343</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The looming antibiotic resistance crisis has penetrated the consciousness of clinicians, researchers, policymakers, politicians and the public at large.  The evolution and widespread distribution of antibiotic resistance elements in bacterial pathogens has made diseases that were once easily treatable deadly again.  Unfortunately, accompanying the rise in global resistance is a failure in antibacterial drug discovery.  Lessons from the history of antibiotic discovery and fresh understanding of antibiotic action and the cell biol. of microorganisms have the potential to deliver twenty-first century medicines that are able to control infection in the resistance era.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKJH_K99a5abVg90H21EOLACvtfcHk0lg1iZ4UQFMDBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Oisro%253D&md5=62e0454601a242db039e60d77be26406</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnature17042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature17042%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DE.%2BD.%26aulast%3DWright%26aufirst%3DG.%2BD.%26atitle%3DAntibacterial%2520drug%2520discovery%2520in%2520the%2520resistance%2520era%26jtitle%3DNature%26date%3D2016%26volume%3D529%26spage%3D336%26epage%3D343%26doi%3D10.1038%2Fnature17042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">World Health Organization</span>.  <i>WHO Publishes List of Bacteria for Which
New Antibiotics Are Urgently Needed</i>; <span class="NLM_publisher-name">WHO</span>, <span class="NLM_publisher-loc">Geneva, Switzerland</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=World+Health+Organization&title=WHO+Publishes+List+of+Bacteria+for+Which%0ANew+Antibiotics+Are+Urgently+Needed"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3D%26btitle%3DWHO%2520Publishes%2520List%2520of%2520Bacteria%2520for%2520Which%250ANew%2520Antibiotics%2520Are%2520Urgently%2520Needed%26pub%3DWHO%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span> <i>Global Tuberculosis Report 2020</i>; <span class="NLM_publisher-name">World Health
Organization</span>: <span class="NLM_publisher-loc">Geneva, Switzerland</span>, <span class="NLM_year">2020</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Global+Tuberculosis+Report+2020%3B+World+Health%0AOrganization%3A+Geneva%2C+Switzerland%2C+2020."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26jtitle%3DGlobal%2520Tuberculosis%2520Report%25202020%26pub%3DWorld%2520Health%250AOrganization%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chellat, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raguz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riedl, R.</span></span> <span> </span><span class="NLM_article-title">Targeting antibiotic resistance</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">6600</span>– <span class="NLM_lpage">6626</span>, <span class="refDoi"> DOI: 10.1002/anie.201506818</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=10.1002%2Fanie.201506818" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=1%3ACAS%3A528%3ADC%252BC28Xks1Cju7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=6600-6626&author=M.+F.+Chellatauthor=L.+Raguzauthor=R.+Riedl&title=Targeting+antibiotic+resistance&doi=10.1002%2Fanie.201506818"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Antibiotic Resistance</span></div><div class="casAuthors">Chellat, Mathieu F.; Raguz, Luka; Riedl, Rainer</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6600-6626</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Finding strategies against the development of antibiotic resistance is a major global challenge for the life sciences community and for public health.  The past decades have seen a dramatic worldwide increase in human-pathogenic bacteria that are resistant to one or multiple antibiotics.  More and more infections caused by resistant microorganisms fail to respond to conventional treatment, and in some cases, even last-resort antibiotics have lost their power.  In addn., industry pipelines for the development of novel antibiotics have run dry over the past decades.  A recent world health day by the World Health Organization titled "Combat drug resistance: no action today means no cure tomorrow" triggered an increase in research activity, and several promising strategies have been developed to restore treatment options against infections by resistant bacterial pathogens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRcddMQflU3LVg90H21EOLACvtfcHk0lg1iZ4UQFMDBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xks1Cju7k%253D&md5=b8194ac5902fa3ac4da2e36de71f82b4</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1002%2Fanie.201506818&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201506818%26sid%3Dliteratum%253Aachs%26aulast%3DChellat%26aufirst%3DM.%2BF.%26aulast%3DRaguz%26aufirst%3DL.%26aulast%3DRiedl%26aufirst%3DR.%26atitle%3DTargeting%2520antibiotic%2520resistance%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26spage%3D6600%26epage%3D6626%26doi%3D10.1002%2Fanie.201506818" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barbachyn, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, C. W.</span></span> <span> </span><span class="NLM_article-title">Oxazolidinone structure-activity relationships leading to linezolid</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">2010</span>– <span class="NLM_lpage">2023</span>, <span class="refDoi"> DOI: 10.1002/anie.200200528</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=10.1002%2Fanie.200200528" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=1%3ACAS%3A528%3ADC%252BD3sXkt1Snu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2003&pages=2010-2023&author=M.+R.+Barbachynauthor=C.+W.+Ford&title=Oxazolidinone+structure-activity+relationships+leading+to+linezolid&doi=10.1002%2Fanie.200200528"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Oxazolidinone structure-activity relationships leading to linezolid</span></div><div class="casAuthors">Barbachyn, Michael R.; Ford, Charles W.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2010-2023</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The development of bacterial resistance to currently available antibacterial agents is a growing global health problem.  Of particular concern are infections caused by multidrug-resistant Gram-pos. pathogens which are responsible for significant morbidity and mortality in both the hospital and community settings.  A no. of solns. to the problem of bacterial resistance are possible.  The most common approach is to continue modifying existing classes of antibacterial agents to provide new analogs with improved attributes.  Other successful strategies are to combine existing antibacterial agents with other drugs as well as the development of improved diagnostic procedures that may lead to rapid identification of the causative pathogen and permit the use of antibacterial agents with a narrow spectrum of activity.  Finally, and most importantly, the discovery of novel classes of antibacterial agents employing new mechanisms of action has considerable promise.  Such agents would exhibit a lack of cross-resistance with existing antimicrobial drugs.  This review describes the work leading to the discovery of linezolid, the first clin. useful oxazolidinone antibacterial agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGritv1CBogyHbVg90H21EOLACvtfcHk0lg1iZ4UQFMDBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXkt1Snu7k%253D&md5=681744cbb331d9256cc32d8b60987284</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1002%2Fanie.200200528&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200200528%26sid%3Dliteratum%253Aachs%26aulast%3DBarbachyn%26aufirst%3DM.%2BR.%26aulast%3DFord%26aufirst%3DC.%2BW.%26atitle%3DOxazolidinone%2520structure-activity%2520relationships%2520leading%2520to%2520linezolid%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2003%26volume%3D42%26spage%3D2010%26epage%3D2023%26doi%3D10.1002%2Fanie.200200528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keam, S. J.</span></span> <span> </span><span class="NLM_article-title">Pretomanid: First Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">1797</span>– <span class="NLM_lpage">1803</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01207-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=10.1007%2Fs40265-019-01207-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=31583606" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=1%3ACAS%3A280%3ADC%252BB3MnkvF2gsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=1797-1803&author=S.+J.+Keam&title=Pretomanid%3A+First+Approval&doi=10.1007%2Fs40265-019-01207-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Pretomanid: First Approval</span></div><div class="casAuthors">Keam Susan J</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1797-1803</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Pretomanid, an oral nitroimidazooxazine antimycobacterial agent administered as part of the BPaL (bedaquiline, pretomanid and linezolid) and BPaMZ (bedaquiline, pretomanid, moxifloxacin and pyrazinamide) regimens, has been developed by the Global Alliance for TB Drug Development (TB Alliance) under license from Novartis, for the treatment for tuberculosis (TB).  TB Alliance has licensed Mylan to manufacture and commercialize pretomanid for use as part of the BPaMZ and BPaL regimens.  The license is non-exclusive in low- and middle-income countries and exclusive in high-income markets.  Pretomanid, as part of the BPaL regimen, was recently approved in the USA under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD) pathway for the treatment of adults with pulmonary extensively drug-resistant (XDR) or treatment-intolerant or non-responsive multidrug-resistant (MDR) TB.  Pretomanid is also under regulatory review in the EU.  This article summarizes the milestones in the development of pretomanid leading to this first regulatory approval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ32shufXmAyUNoizSOkG_FfW6udTcc2eaaTNz2anij5Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MnkvF2gsA%253D%253D&md5=5c28b82e658d5ce4aa0f1187cf2e7736</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01207-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01207-9%26sid%3Dliteratum%253Aachs%26aulast%3DKeam%26aufirst%3DS.%2BJ.%26atitle%3DPretomanid%253A%2520First%2520Approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D1797%26epage%3D1803%26doi%3D10.1007%2Fs40265-019-01207-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharaf, L. H.</span></span> <span> </span><span class="NLM_article-title">Oxazolidinone antimicrobials: a patent review (2012–2015)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">591</span>– <span class="NLM_lpage">605</span>, <span class="refDoi"> DOI: 10.1517/13543776.2016.1168807</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=10.1517%2F13543776.2016.1168807" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=26998627" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=1%3ACAS%3A528%3ADC%252BC28Xltlyhs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=591-605&author=O.+A.+Phillipsauthor=L.+H.+Sharaf&title=Oxazolidinone+antimicrobials%3A+a+patent+review+%282012%E2%80%932015%29&doi=10.1517%2F13543776.2016.1168807"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Oxazolidinone antimicrobials: a patent review (2012-2015)</span></div><div class="casAuthors">Phillips, Oludotun A.; Sharaf, Leyla H.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">591-605</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Antimicrobial resistance in Gram-pos. bacteria is a major health care issue.  This review summarizes patent publications from 2012 to 2015 that divulged novel oxazolidinones as antibacterial agents.: A total of 25 patents obtained from Espacenet, WIPO Patentscope and FreePatentsOnline, and AcclaimIP search engines were reviewed.  The patents were scrutinized based on the novelty of the compds., their antibacterial activity (MIC, μg/mL), and the process of prepn.  The oxazolidinones with promising antibacterial activity were classified according to the following structural diversities, as biaryl heterocyclic, fused heteroaryl rings contg. oxazolidinones, and others.  The biaryl heterocyclic, fused heteroaryl, benzoxazine, and the 1H-pyrazol-1-yl contg. oxazolidinone derivs. demonstrated potent antibacterial activities superior to linezolid against Gram-pos. bacteria.  Some derivs. were effective against std. strains of Gram-neg. bacteria, namely Moraxella catarrhalis ATCC A894, and Escherichia coli ATCC 25922.  In addn., a patent disclosed a structural isomer of linezolid with marginal activity against the aerobic Gram-neg. bacteria MDR Stenotrophomonas (Xanthomonas) maltophilia, while linezolid and vancomycin did not inhibit growth.  Finally, some derivs. showed activity against respiratory infectious diseases' causative agents, such as B. anthracis, B. mallei, Y. pestis, and M. pneumoniae.  Overall, there is limited in vivo data to support the potential clin. advancement of the currently reported novel derivs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprLzO8rJvUsrVg90H21EOLACvtfcHk0lhaRox5yUjCUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xltlyhs7s%253D&md5=c5582e97a91b14e1ae65b19b2f4e0343</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1517%2F13543776.2016.1168807&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2016.1168807%26sid%3Dliteratum%253Aachs%26aulast%3DPhillips%26aufirst%3DO.%2BA.%26aulast%3DSharaf%26aufirst%3DL.%2BH.%26atitle%3DOxazolidinone%2520antimicrobials%253A%2520a%2520patent%2520review%2520%25282012%25E2%2580%25932015%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2016%26volume%3D26%26spage%3D591%26epage%3D605%26doi%3D10.1517%2F13543776.2016.1168807" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barbachyn, M. R.</span></span> <span> </span><span class="NLM_article-title">The oxazolidinones</span>. <i>Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">97</span>– <span class="NLM_lpage">122</span>, <span class="refDoi"> DOI: 10.1007/7355_2017_15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=10.1007%2F7355_2017_15" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2017&pages=97-122&author=M.+R.+Barbachyn&title=The+oxazolidinones&doi=10.1007%2F7355_2017_15"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1007%2F7355_2017_15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F7355_2017_15%26sid%3Dliteratum%253Aachs%26aulast%3DBarbachyn%26aufirst%3DM.%2BR.%26atitle%3DThe%2520oxazolidinones%26jtitle%3DTop.%2520Med.%2520Chem.%26date%3D2017%26volume%3D26%26spage%3D97%26epage%3D122%26doi%3D10.1007%2F7355_2017_15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of a teraryl oxazolidinone compound (<i>S</i>)-<i>N</i>-((3-(3-fluoro-4-(4-(pyridin-2-yl)-1<i>H</i>-pyrazol-1-yl)phenyl)-2-oxooxazolidin-5-yl)methyl)acetamide phosphate as a novel antimicrobial agent with enhanced safety profile and efficacies</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">6389</span>– <span class="NLM_lpage">6409</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00152</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00152" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1altb7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=6389-6409&author=T.+Yangauthor=G.+Chenauthor=Z.+Sangauthor=Y.+Liuauthor=X.+Yangauthor=Y.+Changauthor=H.+Longauthor=W.+Angauthor=J.+Tangauthor=Z.+Wangauthor=G.+Liauthor=S.+Yangauthor=J.+Zhangauthor=Y.+Weiauthor=Y.+Luo&title=Discovery+of+a+teraryl+oxazolidinone+compound+%28S%29-N-%28%283-%283-fluoro-4-%284-%28pyridin-2-yl%29-1H-pyrazol-1-yl%29phenyl%29-2-oxooxazolidin-5-yl%29methyl%29acetamide+phosphate+as+a+novel+antimicrobial+agent+with+enhanced+safety+profile+and+efficacies&doi=10.1021%2Facs.jmedchem.5b00152"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Teraryl Oxazolidinone Compound (S)-N-((3-(3-Fluoro-4-(4-(pyridin-2-yl)-1H-pyrazol-1-yl)phenyl)-2-oxooxazolidin-5-yl)methyl)acetamide Phosphate as a Novel Antimicrobial Agent with Enhanced Safety Profile and Efficacies</span></div><div class="casAuthors">Yang, Tao; Chen, Gong; Sang, Zitai; Liu, Yuanyuan; Yang, Xiaoyan; Chang, Ying; Long, Haiyue; Wei, Ang; Tang, Jianying; Wang, Zhenling; Li, Guobo; Yang, Shengyong; Zhang, Jingren; Wei, Yuquan; Luo, Youfu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">6389-6409</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of novel teraryl oxazolidinone compds. was designed, synthesized, and evaluated for their antimicrobial activity and toxicities.  The compds. with arom. N-heterocyclic substituents at the 4-position of pyrazolyl ring showed better antibacterial activity against the tested bacteria than other compds. with different patterns of substitution.  Among all potent compds., I exhibited promising safety profile in MTT assays and in hERG K+ channel inhibition test.  Furthermore, its phosphate was found to be highly sol. in water (47.1 mg/mL), which is beneficial for the subsequent in vivo test.  In MRSA systemic infection mice models, I phosphate exerted significantly improved survival protection compared with linezolid.  The compd. also demonstrated high oral bioavailability (F = 99.1%).  Moreover, from the results of in vivo toxicol. expts., I phosphate would be predicted to have less bone marrow suppression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2zOHxUIAO2bVg90H21EOLACvtfcHk0lhaRox5yUjCUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1altb7E&md5=69b436025095d8fc3fcd25c2c7530a94</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00152%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DSang%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DChang%26aufirst%3DY.%26aulast%3DLong%26aufirst%3DH.%26aulast%3DAng%26aufirst%3DW.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DWei%26aufirst%3DY.%26aulast%3DLuo%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520a%2520teraryl%2520oxazolidinone%2520compound%2520%2528S%2529-N-%2528%25283-%25283-fluoro-4-%25284-%2528pyridin-2-yl%2529-1H-pyrazol-1-yl%2529phenyl%2529-2-oxooxazolidin-5-yl%2529methyl%2529acetamide%2520phosphate%2520as%2520a%2520novel%2520antimicrobial%2520agent%2520with%2520enhanced%2520safety%2520profile%2520and%2520efficacies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D6389%26epage%3D6409%26doi%3D10.1021%2Facs.jmedchem.5b00152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deshmukh, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, N.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and antibacterial evaluation of oxazolidinones with fused heterocyclic C-ring substructure</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1153</span>– <span class="NLM_lpage">1158</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00263</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00263" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFOjtbfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1153-1158&author=M.+S.+Deshmukhauthor=N.+Jain&title=Design%2C+synthesis%2C+and+antibacterial+evaluation+of+oxazolidinones+with+fused+heterocyclic+C-ring+substructure&doi=10.1021%2Facsmedchemlett.7b00263"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis and Antibacterial Evaluation of Oxazolidinones with Fused Heterocyclic C-Ring Substructure</span></div><div class="casAuthors">Deshmukh, Mahesh S.; Jain, Nidhi</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1153-1158</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of novel oxazolidinone antibacterials with diverse fused heteroaryl C-rings bearing hydrogen bond donor and hydrogen bond acceptor functionalities were designed and synthesized.  The compd. with benzoxazinone C-ring substructure (I) exhibited superior activity compared to linezolid against a panel of Gram-pos. and Gram-neg. bacteria.  Structural modifications at C5-side chain of I resulted in identification of several potent compds.  Selected compds. I and II showed very good microsomal stability and no CYP450 liability, thus clearing preliminary safety hurdles.  A docking model of II binding to 23S rRNA suggested that the increased potency of II is due to addnl. ligand-receptor interaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsos1yjPmoN7Vg90H21EOLACvtfcHk0lj7TvAQYLNfvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFOjtbfL&md5=5edbae88df65af2bd8264ff4755a0498</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00263%26sid%3Dliteratum%253Aachs%26aulast%3DDeshmukh%26aufirst%3DM.%2BS.%26aulast%3DJain%26aufirst%3DN.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520antibacterial%2520evaluation%2520of%2520oxazolidinones%2520with%2520fused%2520heterocyclic%2520C-ring%2520substructure%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D1153%26epage%3D1158%26doi%3D10.1021%2Facsmedchemlett.7b00263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Renslo, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaishankar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatachalam, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hackbarth, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordeev, M. F.</span></span> <span> </span><span class="NLM_article-title">Conformational constraint in oxazolidinone antibacterials. Synthesis and structure-activity studies of (azabicyclo[3.1.0]hexylphenyl)oxazolidinones</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">5009</span>– <span class="NLM_lpage">5024</span>, <span class="refDoi"> DOI: 10.1021/jm058204j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm058204j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=1%3ACAS%3A528%3ADC%252BD2MXltlGhtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=5009-5024&author=A.+R.+Rensloauthor=P.+Jaishankarauthor=R.+Venkatachalamauthor=C.+Hackbarthauthor=S.+Lopezauthor=D.+V.+Patelauthor=M.+F.+Gordeev&title=Conformational+constraint+in+oxazolidinone+antibacterials.+Synthesis+and+structure-activity+studies+of+%28azabicyclo%5B3.1.0%5Dhexylphenyl%29oxazolidinones&doi=10.1021%2Fjm058204j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure-Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones</span></div><div class="casAuthors">Renslo, Adam R.; Jaishankar, Priyadarshini; Venkatachalam, Revathy; Hackbarth, Corinne; Lopez, Sara; Patel, Dinesh V.; Gordeev, Mikhail F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5009-5024</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The oxazolidinones are a new class of synthetic antibacterials effective against a broad range of pathogenic Gram-pos. bacteria, including multi-drug-resistant strains.  Linezolid is the first drug from this class to reach the market and has become an important new option for the treatment of serious infections, particularly those caused by methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enteroccocus fecium (VRE).  In the search for novel oxazolidinones with improved potency and spectrum, conformationally constrained analogs in which the morpholine ring of linezolid is replaced with various substituted azabicyclo[3.1.0]hexyl ring systems were prepd. and their antibacterial properties evaluated.  Several classes of azabicyclic analogs were identified with activity comparable or superior to that of linezolid.  These include analogs bearing hydroxyl, amino, amido, or carboxyl groups on the azabicyclic ring.  The azabicyclic acid analog I was 4 times more potent than linezolid against key Gram-pos. and fastidious Gram-neg. pathogens (S. aureus, Streptococcus pneumoniae, and E. faecalis MICs ≤ 1 μg/mL; Haemophilus influenzae MIC = 4 μg/mL).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpn2mtgiOrrerVg90H21EOLACvtfcHk0lj7TvAQYLNfvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXltlGhtbg%253D&md5=ad963b5e48d335596bab426dc64e7b1e</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Fjm058204j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm058204j%26sid%3Dliteratum%253Aachs%26aulast%3DRenslo%26aufirst%3DA.%2BR.%26aulast%3DJaishankar%26aufirst%3DP.%26aulast%3DVenkatachalam%26aufirst%3DR.%26aulast%3DHackbarth%26aufirst%3DC.%26aulast%3DLopez%26aufirst%3DS.%26aulast%3DPatel%26aufirst%3DD.%2BV.%26aulast%3DGordeev%26aufirst%3DM.%2BF.%26atitle%3DConformational%2520constraint%2520in%2520oxazolidinone%2520antibacterials.%2520Synthesis%2520and%2520structure-activity%2520studies%2520of%2520%2528azabicyclo%255B3.1.0%255Dhexylphenyl%2529oxazolidinones%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D5009%26epage%3D5024%26doi%3D10.1021%2Fjm058204j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Utsunomiya, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shudo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuji, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwaki, T.</span></span> <span> </span><span class="NLM_article-title">Potent oxazolidinone antibacterials with heteroaromatic C-ring substructure</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1074</span>– <span class="NLM_lpage">1078</span>, <span class="refDoi"> DOI: 10.1021/ml400280z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml400280z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVyrtb%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=1074-1078&author=H.+Suzukiauthor=I.+Utsunomiyaauthor=K.+Shudoauthor=T.+Fujimuraauthor=M.+Tsujiauthor=I.+Katoauthor=T.+Aokiauthor=A.+Inoauthor=T.+Iwaki&title=Potent+oxazolidinone+antibacterials+with+heteroaromatic+C-ring+substructure&doi=10.1021%2Fml400280z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Potent Oxazolidinone Antibacterials with Heteroaromatic C-Ring Substructure</span></div><div class="casAuthors">Suzuki, Hideyuki; Utsunomiya, Iwao; Shudo, Koichi; Fujimura, Takaji; Tsuji, Masakatsu; Kato, Issei; Aoki, Toshiaki; Ino, Akira; Iwaki, Tsutomu</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1074-1078</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Novel oxazolidinone analogs bearing a condensed heteroarom. ring as the C-ring substructure were synthesized as candidate antibacterial agents.  Analogs 16 and 21 bearing imidazo-[1,2-a]-pyridine and 18 and 23 bearing [1,2,4]-triazolo-[1,5-a]-pyridine as the C-ring had excellent in vitro antibacterial activities against methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus faecalis (VRE), and penicillin-resistant Streptococcus pneumoniae (PRSP).  They also showed promising therapeutic effects in a mouse model of lethal infection.  Preliminary safety data (inhibitory effects on cytochrome P 450 isoforms and monoamine oxidases) were satisfactory.  Further evaluation of 18 and 23 is ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBYb1cLJtZI7Vg90H21EOLACvtfcHk0lj7TvAQYLNfvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVyrtb%252FM&md5=6f39a539a41ec53b3ce04733a74850d1</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fml400280z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml400280z%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DH.%26aulast%3DUtsunomiya%26aufirst%3DI.%26aulast%3DShudo%26aufirst%3DK.%26aulast%3DFujimura%26aufirst%3DT.%26aulast%3DTsuji%26aufirst%3DM.%26aulast%3DKato%26aufirst%3DI.%26aulast%3DAoki%26aufirst%3DT.%26aulast%3DIno%26aufirst%3DA.%26aulast%3DIwaki%26aufirst%3DT.%26atitle%3DPotent%2520oxazolidinone%2520antibacterials%2520with%2520heteroaromatic%2520C-ring%2520substructure%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D1074%26epage%3D1078%26doi%3D10.1021%2Fml400280z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Im, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, S.-H.</span></span> <span> </span><span class="NLM_article-title">Discovery of torezolid as a novel 5-hydroxymethyl-oxazolidinone antibacterial agent</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">1027</span>– <span class="NLM_lpage">1039</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2011.01.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=10.1016%2Fj.ejmech.2011.01.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=21292356" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsFWhsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2011&pages=1027-1039&author=W.+B.+Imauthor=S.+H.+Choiauthor=J.-Y.+Parkauthor=S.+H.+Choiauthor=J.+Finnauthor=S.-H.+Yoon&title=Discovery+of+torezolid+as+a+novel+5-hydroxymethyl-oxazolidinone+antibacterial+agent&doi=10.1016%2Fj.ejmech.2011.01.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of torezolid as a novel 5-hydroxymethyl-oxazolidinone antibacterial agent</span></div><div class="casAuthors">Im, Weon Bin; Choi, Sun Ho; Park, Ju-Young; Choi, Sung Hak; Finn, John; Yoon, Sung-Hwa</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1027-1039</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of novel substituted pyridyl Ph oxazolidinone analogs was synthesized and the structure-activity relationship (SAR) was investigated based on in vitro and in vivo antibacterial activities.  The min. inhibitory concns. (MICs) of the synthesized compds. against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) ranged from 0.12 to 2.0 μg/mL, and against Haemophilus influenzae (Hi) from 2.0 to 8.0 μg/mL.  Compared to linezolid, only four compds. I-IV showed higher in vitro antibacterial activities and better in vivo protective effects in mice.  To improve the aq. soly., various prodrugs of compd. I (DA-7157), which exerted a potency that was enhanced by 2-8-fold compared to that of linezolid, were synthesized.  Among the prodrugs, the phosphate compd. V exhibited excellent aq. soly. (>50 mg/mL in DW) and good pharmacokinetic profiles, along with better in vivo efficacy than linezolid.  This compd. V is currently undergoing clin. trials with the brand name Torezolid.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQ1ZCDnxjkULVg90H21EOLACvtfcHk0liLDo5EAV-dCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsFWhsLg%253D&md5=3b8ef97195a19c308b42a7df7f05e1d5</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2011.01.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2011.01.014%26sid%3Dliteratum%253Aachs%26aulast%3DIm%26aufirst%3DW.%2BB.%26aulast%3DChoi%26aufirst%3DS.%2BH.%26aulast%3DPark%26aufirst%3DJ.-Y.%26aulast%3DChoi%26aufirst%3DS.%2BH.%26aulast%3DFinn%26aufirst%3DJ.%26aulast%3DYoon%26aufirst%3DS.-H.%26atitle%3DDiscovery%2520of%2520torezolid%2520as%2520a%2520novel%25205-hydroxymethyl-oxazolidinone%2520antibacterial%2520agent%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2011%26volume%3D46%26spage%3D1027%26epage%3D1039%26doi%3D10.1016%2Fj.ejmech.2011.01.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gordeev, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Z. Y.</span></span> <span> </span><span class="NLM_article-title">New potent antibacterial oxazolidinone (MRX-I) with an improved class safety profile</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">4487</span>– <span class="NLM_lpage">4497</span>, <span class="refDoi"> DOI: 10.1021/jm401931e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401931e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlsFOjsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4487-4497&author=M.+F.+Gordeevauthor=Z.+Y.+Yuan&title=New+potent+antibacterial+oxazolidinone+%28MRX-I%29+with+an+improved+class+safety+profile&doi=10.1021%2Fjm401931e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">New Potent Antibacterial Oxazolidinone (MRX-I) with an Improved Class Safety Profile</span></div><div class="casAuthors">Gordeev, Mikhail F.; Yuan, Zhengyu Y.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4487-4497</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Oxazolidinones comprise an important class of antibacterial protein synthesis inhibitors.  Myelosuppression and monoamine oxidase inhibition (MAOI) are key independent causes for limiting adverse effects in therapy with the sole approved drug of this class, linezolid.  This annotation describes a novel oxazolidinone agent, (S)-5-((isoxazol-3-ylamino)methyl)-3-(2,3,5-trifluoro-4-(4-oxo-3,4-dihydropyridin-1(2H)-yl)phenyl)oxazolidin-2-one (MRX-I), I, distinguished by its high activity against Gram-pos. pathogens coupled with markedly reduced potential for myelosuppression and MAOI.  The medical need, medicinal chem. rationale, preclin. data, and phase I clin. trial summary for this new agent are reviewed herein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNWIpQP5Wgg7Vg90H21EOLACvtfcHk0liLDo5EAV-dCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlsFOjsbw%253D&md5=70b6b32e113b86ab6344cb266687f64f</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fjm401931e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401931e%26sid%3Dliteratum%253Aachs%26aulast%3DGordeev%26aufirst%3DM.%2BF.%26aulast%3DYuan%26aufirst%3DZ.%2BY.%26atitle%3DNew%2520potent%2520antibacterial%2520oxazolidinone%2520%2528MRX-I%2529%2520with%2520an%2520improved%2520class%2520safety%2520profile%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D4487%26epage%3D4497%26doi%3D10.1021%2Fjm401931e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chae, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baek, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwak, J. H.</span></span> <span> </span><span class="NLM_article-title">In vitro and in vivo activities of LCB01-0371, a new oxazolidinone</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">5359</span>– <span class="NLM_lpage">5362</span>, <span class="refDoi"> DOI: 10.1128/AAC.00723-10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=10.1128%2FAAC.00723-10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=20855730" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2msr%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2010&pages=5359-5362&author=J.+W.+Jeongauthor=S.+J.+Jungauthor=H.+H.+Leeauthor=Y.+Z.+Kimauthor=T.+K.+Parkauthor=Y.+L.+Choauthor=S.+E.+Chaeauthor=S.+Y.+Baekauthor=S.+H.+Wooauthor=H.+S.+Leeauthor=J.+H.+Kwak&title=In+vitro+and+in+vivo+activities+of+LCB01-0371%2C+a+new+oxazolidinone&doi=10.1128%2FAAC.00723-10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo activities of LCB01-0371, a new oxazolidinone</span></div><div class="casAuthors">Jeong, Ji-Woong; Jung, Sung-Ji; Lee, Hyun-Hee; Kim, Yong-Zu; Park, Tae-Kyo; Cho, Young-Lag; Chae, Sang-Eun; Baek, Sung-Yoon; Woo, Sung-Ho; Lee, Hyang-Sook; Kwak, Jin-Hwan</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5359-5362</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">LCB01-0371 is a new oxazolidinone with cyclic amidrazone.  In vitro activity of LCB01-0371 against 624 clin. isolates was evaluated and compared with those of linezolid, vancomycin, and other antibiotics.  LCB01-0371 showed good activity against Gram-pos. pathogens.  In vivo activity of LCB01-0371 against systemic infections in mice was also evaluated.  LCB01-0371 was more active than linezolid against these systemic infections.  LCB01-0371 showed bacteriostatic activity against Staphylococcus aureus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobg2lKKc8bzbVg90H21EOLACvtfcHk0liLDo5EAV-dCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2msr%252FJ&md5=27471d63f1195f29f869689c125f643e</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1128%2FAAC.00723-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00723-10%26sid%3Dliteratum%253Aachs%26aulast%3DJeong%26aufirst%3DJ.%2BW.%26aulast%3DJung%26aufirst%3DS.%2BJ.%26aulast%3DLee%26aufirst%3DH.%2BH.%26aulast%3DKim%26aufirst%3DY.%2BZ.%26aulast%3DPark%26aufirst%3DT.%2BK.%26aulast%3DCho%26aufirst%3DY.%2BL.%26aulast%3DChae%26aufirst%3DS.%2BE.%26aulast%3DBaek%26aufirst%3DS.%2BY.%26aulast%3DWoo%26aufirst%3DS.%2BH.%26aulast%3DLee%26aufirst%3DH.%2BS.%26aulast%3DKwak%26aufirst%3DJ.%2BH.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520activities%2520of%2520LCB01-0371%252C%2520a%2520new%2520oxazolidinone%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2010%26volume%3D54%26spage%3D5359%26epage%3D5362%26doi%3D10.1128%2FAAC.00723-10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, Y.</span></span> <span> </span><span class="NLM_article-title">Comparison of in vitro activity and MIC distributions between the novel oxazolidinone delpazolid and linezolid against multidrug-resistant and extensively drug-resistant <i>Mycobacterium tuberculosis</i> in China</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>62</i></span>, <span class="NLM_elocation-id">e00165-18</span> <span class="refDoi"> DOI: 10.1128/AAC.00165-18</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=10.1128%2FAAC.00165-18" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=29844043" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2018&author=Z.+Zongauthor=W.+Jingauthor=J.+Shiauthor=S.+Wenauthor=T.+Zhangauthor=F.+Huoauthor=Y.+Shangauthor=Q.+Liangauthor=H.+Huangauthor=Y.+Pang&title=Comparison+of+in+vitro+activity+and+MIC+distributions+between+the+novel+oxazolidinone+delpazolid+and+linezolid+against+multidrug-resistant+and+extensively+drug-resistant+Mycobacterium+tuberculosis+in+China&doi=10.1128%2FAAC.00165-18"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1128%2FAAC.00165-18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00165-18%26sid%3Dliteratum%253Aachs%26aulast%3DZong%26aufirst%3DZ.%26aulast%3DJing%26aufirst%3DW.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DWen%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DHuo%26aufirst%3DF.%26aulast%3DShang%26aufirst%3DY.%26aulast%3DLiang%26aufirst%3DQ.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DPang%26aufirst%3DY.%26atitle%3DComparison%2520of%2520in%2520vitro%2520activity%2520and%2520MIC%2520distributions%2520between%2520the%2520novel%2520oxazolidinone%2520delpazolid%2520and%2520linezolid%2520against%2520multidrug-resistant%2520and%2520extensively%2520drug-resistant%2520Mycobacterium%2520tuberculosis%2520in%2520China%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2018%26volume%3D62%26doi%3D10.1128%2FAAC.00165-18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barbachyn, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchinson, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brickner, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cynamon, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilburn, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klemens, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glickman, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grega, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendges, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toops, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zurenko, G. E.</span></span> <span> </span><span class="NLM_article-title">Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">680</span>– <span class="NLM_lpage">685</span>, <span class="refDoi"> DOI: 10.1021/jm950956y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm950956y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=1%3ACAS%3A528%3ADyaK28XlvVCisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1996&pages=680-685&author=M.+R.+Barbachynauthor=D.+K.+Hutchinsonauthor=S.+J.+Bricknerauthor=M.+H.+Cynamonauthor=J.+O.+Kilburnauthor=S.+P.+Klemensauthor=S.+E.+Glickmanauthor=K.+C.+Gregaauthor=S.+K.+Hendgesauthor=D.+S.+Toopsauthor=C.+W.+Fordauthor=G.+E.+Zurenko&title=Identification+of+a+novel+oxazolidinone+%28U-100480%29+with+potent+antimycobacterial+activity&doi=10.1021%2Fjm950956y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a Novel Oxazolidinone (U-100480) with Potent Antimycobacterial Activity</span></div><div class="casAuthors">Barbachyn, Michael R.; Hutchinson, Douglas K.; Brickner, Steven J.; Cynamon, Michael H.; Kilburn, James O.; Klemens, Sally P.; Glickman, Suzanne E.; Grega, Kevin C.; Hendges, Susan K.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">680-5</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A subclass of oxazolidinone antibacterial agents with esp. potent in vitro activity against mycobacteria was discovered.  The salient structural feature of these oxazolidinone analogs, U-100480 [i.e., (S)-N-[[3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide], U-101603, and U-101244 is their appended thiomorpholine moiety.  The rational design, synthesis, and evaluation of the in vitro antimycobacterial activity of these analogs was described.  Potent activity against a screening strain of Mycobacterium tuberculosis was demonstrated by U-100480 and U-101603 (min. inhibitory concns. or MIC's ≤0.125 μg/mL).  Oxazolidinones U-100480 and U-101244 exhibit MIC90 values of 0.50 μg/mL or less against a panel of organisms consisting of five drug-sensitive and five multidrug-resistant strains of M. tuberculosis, with U-100480 being the most active congener.  Potent in vitro activity against other mycobacterial species was also demonstrated by U-100480.  For example, U-100480 exhibited excellent in vitro activity against multiple clin. isolates of Mycobacterium avium complex (MIC's = 0.5-4 μg/mL).  Orally administered U-100480 displays in vivo efficacy against M. tuberculosis and M. avium similar to that of clin. comparators isoniazid and azithromycin, resp.  Consideration of these factors, along with a favorable pharmacokinetic and chronic toxicity profile in rats, suggests that U-100480 is a promising antimycobacterial agent (tuberculostatic).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAvvlFTIROHbVg90H21EOLACvtfcHk0lgzEULykCzHcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XlvVCisQ%253D%253D&md5=8636d20221390257b48f2d3dd6884b78</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm950956y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm950956y%26sid%3Dliteratum%253Aachs%26aulast%3DBarbachyn%26aufirst%3DM.%2BR.%26aulast%3DHutchinson%26aufirst%3DD.%2BK.%26aulast%3DBrickner%26aufirst%3DS.%2BJ.%26aulast%3DCynamon%26aufirst%3DM.%2BH.%26aulast%3DKilburn%26aufirst%3DJ.%2BO.%26aulast%3DKlemens%26aufirst%3DS.%2BP.%26aulast%3DGlickman%26aufirst%3DS.%2BE.%26aulast%3DGrega%26aufirst%3DK.%2BC.%26aulast%3DHendges%26aufirst%3DS.%2BK.%26aulast%3DToops%26aufirst%3DD.%2BS.%26aulast%3DFord%26aufirst%3DC.%2BW.%26aulast%3DZurenko%26aufirst%3DG.%2BE.%26atitle%3DIdentification%2520of%2520a%2520novel%2520oxazolidinone%2520%2528U-100480%2529%2520with%2520potent%2520antimycobacterial%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1996%26volume%3D39%26spage%3D680%26epage%3D685%26doi%3D10.1021%2Fjm950956y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wallis, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakubiec, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvia, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paige, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimitrova, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladutko, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedland, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitton-Fry, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, P. F.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics and whole-blood bactericidal activity against <i>Mycobacterium</i> <i>tuberculosis</i> of single doses of PNU-100480 in healthy volunteers</span>. <i>J. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>202</i></span>,  <span class="NLM_fpage">745</span>– <span class="NLM_lpage">751</span>, <span class="refDoi"> DOI: 10.1086/655471</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=10.1086%2F655471" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=20629533" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFKjsrzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=202&publication_year=2010&pages=745-751&author=R.+S.+Wallisauthor=W.+M.+Jakubiecauthor=V.+Kumarauthor=A.+M.+Silviaauthor=D.+Paigeauthor=D.+Dimitrovaauthor=X.+Liauthor=L.+Ladutkoauthor=S.+Campbellauthor=G.+Friedlandauthor=M.+Mitton-Fryauthor=P.+F.+Miller&title=Pharmacokinetics+and+whole-blood+bactericidal+activity+against+Mycobacterium+tuberculosis+of+single+doses+of+PNU-100480+in+healthy+volunteers&doi=10.1086%2F655471"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers</span></div><div class="casAuthors">Wallis, Robert S.; Jakubiec, Wesley M.; Kumar, Vikas; Silvia, Annette M.; Paige, Darcy; Dimitrova, Dessislava; Li, Xiaoxi; Ladutko, Lynn; Campbell, Sheldon; Friedland, Gerald; Mitton-Fry, Mark; Miller, Paul F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Infectious Diseases</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">202</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">745-751</span>CODEN:
                <span class="NLM_cas:coden">JIDIAQ</span>;
        ISSN:<span class="NLM_cas:issn">0022-1899</span>.
    
            (<span class="NLM_cas:orgname">University of Chicago Press</span>)
        </div><div class="casAbstract">Background: The oxazolidinone PNU-100480 is superior to linezolid against exptl. murine tuberculosis.  Two metabolites contribute to but do not fully account for its superiority.  This study examd. the safety, tolerability, pharmacokinetics, and mycobactericidal activity of single ascending doses of PNU-100480.  Methods: Nineteen healthy volunteers received 2 escalating single oral doses (35-1500 mg) of PNU-100480 or placebo.  Eight subjects received 4 daily doses of 300 mg of linezolid.  Drug concns. and bactericidal activity against Mycobacterium tuberculosis in whole-blood bactericidal culture were measured.  Results: All doses were safe and well tolerated.  PNU-100480 doses to 1000 mg were well absorbed and showed approx. proportional increases in exposures of parent and metabolites.  The geometric mean maximal concns. of PNU-100480, PNU-101603, and PNU-101244 (sulfoxide and sulfone metabolites) at 1000 mg were 839, 3558, and 54 ng/mL, resp.  The maximal whole-blood bactericidal activity (-037 ± .06 log/day) occurred at combined PNU levels ≥2 times the min. inhibitory concn.  The obsd. geometric mean maximal concn. for linezolid was 6425 ng/mL.  Its maximal whole-blood bactericidal activity also occurred at ≥2 times the min. inhibitory concn., but it was only -0.16 ± .05 log/day (P < .001).  Neither drug showed enhanced activity at higher concns.  Conclusions: Single doses of PNU-100480 to 1000 mg were well tolerated and exhibited antimycobacterial activity superior to 300 mg of linezolid at steady state.  Addnl. studies are warranted to define its role in drug-resistant tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgr7U7caSPNbVg90H21EOLACvtfcHk0lgzEULykCzHcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFKjsrzM&md5=bd6fb9cd1190593681d167471f09a06d</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1086%2F655471&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F655471%26sid%3Dliteratum%253Aachs%26aulast%3DWallis%26aufirst%3DR.%2BS.%26aulast%3DJakubiec%26aufirst%3DW.%2BM.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DSilvia%26aufirst%3DA.%2BM.%26aulast%3DPaige%26aufirst%3DD.%26aulast%3DDimitrova%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLadutko%26aufirst%3DL.%26aulast%3DCampbell%26aufirst%3DS.%26aulast%3DFriedland%26aufirst%3DG.%26aulast%3DMitton-Fry%26aufirst%3DM.%26aulast%3DMiller%26aufirst%3DP.%2BF.%26atitle%3DPharmacokinetics%2520and%2520whole-blood%2520bactericidal%2520activity%2520against%2520Mycobacterium%2520tuberculosis%2520of%2520single%2520doses%2520of%2520PNU-100480%2520in%2520healthy%2520volunteers%26jtitle%3DJ.%2520Infect.%2520Dis.%26date%3D2010%26volume%3D202%26spage%3D745%26epage%3D751%26doi%3D10.1086%2F655471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span>U.S.
National Library of Medicine. ClinicalTrials.gov. <a href="https://clinicaltrials.gov/ct2/show/NCT03758612" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03758612</a> (accessed Nov 29, <span class="NLM_year">2018</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=U.S.%0ANational+Library+of+Medicine.+ClinicalTrials.gov.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03758612+%28accessed+Nov+29%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and structure-activity relationship studies of highly potent novel benzoxazinyl-oxazolidinone antibacterial agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">7493</span>– <span class="NLM_lpage">7502</span>, <span class="refDoi"> DOI: 10.1021/jm200614t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200614t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht12ktrrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7493-7502&author=Q.+Xinauthor=H.+Fanauthor=B.+Guoauthor=H.+Heauthor=S.+Gaoauthor=H.+Wangauthor=Y.+Huangauthor=Y.+Yang&title=Design%2C+synthesis%2C+and+structure-activity+relationship+studies+of+highly+potent+novel+benzoxazinyl-oxazolidinone+antibacterial+agents&doi=10.1021%2Fjm200614t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Structure-Activity Relationship Studies of Highly Potent Novel Benzoxazinyl-Oxazolidinone Antibacterial Agents</span></div><div class="casAuthors">Xin, Qi-Sheng; Fan, Hou-Xing; Guo, Bin; He, Hui-Li; Gao, Suo; Wang, Hui; Huang, Yan-Qin; Yang, Yu-She</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">7493-7502</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of novel benzoxazinyl-oxazolidinones bearing nonarom. heterocycle or aryl groups were designed and synthesized.  Their in vitro and in vivo antibacterial activities were investigated.  Most of the (3S, 3aS) biaryl benzoxazinyl-oxazolidinones exhibited potent activity against Gram-pos. pathogens.  SAR trends were obsd.; a pyridyl C ring was preferable to other 5- or 6-member aryl C rings, while fluorine substitution on the B ring generated derivs. with reduced activity.  Various substituent group positions on the pyridyl ring were also evaluated.  The resulting compds. displayed excellent activity against linezolid-resistant strains.  Compd. I exhibited excellent in vitro activity, with a MIC value of 0.25-0.5 μg/mL against MRSA and an activity against linezolid-resistant strains of 8-16-fold higher potency than linezolid.  In a MRSA systemic infection model, compd. 45 displayed an ED50 < 5.0 mg/kg, a potency that is nearly 3-fold better than that of linezolid.  This compd. also showed excellent pharmacokinetic profiles, with a half-life of more than 5 h as well as an oral bioavailability of 81% in rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWmvFSwZGAmrVg90H21EOLACvtfcHk0ljlIXsk6My2VA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht12ktrrE&md5=c3535d090f53b2f4de9582567ab7b3e7</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm200614t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200614t%26sid%3Dliteratum%253Aachs%26aulast%3DXin%26aufirst%3DQ.%26aulast%3DFan%26aufirst%3DH.%26aulast%3DGuo%26aufirst%3DB.%26aulast%3DHe%26aufirst%3DH.%26aulast%3DGao%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DY.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520structure-activity%2520relationship%2520studies%2520of%2520highly%2520potent%2520novel%2520benzoxazinyl-oxazolidinone%2520antibacterial%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7493%26epage%3D7502%26doi%3D10.1021%2Fjm200614t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span> <span> </span><span class="NLM_article-title">Solubility-driven optimization of (pyridin-3-yl) benzoxazinyl-oxazolidinones leading to a promising antibacterial agent</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">2642</span>– <span class="NLM_lpage">2650</span>, <span class="refDoi"> DOI: 10.1021/jm4000598</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4000598" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=1%3ACAS%3A528%3ADC%252BC3sXivVyju7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=2642-2650&author=B.+Guoauthor=H.+Fanauthor=Q.+Xinauthor=W.+Chuauthor=H.+Wangauthor=Y.+Huangauthor=X.+Chenauthor=Y.+Yang&title=Solubility-driven+optimization+of+%28pyridin-3-yl%29+benzoxazinyl-oxazolidinones+leading+to+a+promising+antibacterial+agent&doi=10.1021%2Fjm4000598"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Solubility-Driven Optimization of (Pyridin-3-yl) Benzoxazinyl-oxazolidinones Leading to a Promising Antibacterial Agent</span></div><div class="casAuthors">Guo, Bin; Fan, Houxing; Xin, Qisheng; Chu, Wenjing; Wang, Hui; Huang, Yanqin; Chen, Xiaoyan; Yang, Yushe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2642-2650</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The soly.-driven structural modification of substituted (pyridin-3-yl)-contg. hydrobenzo[b]oxazolo[3,4-d][1,4]oxazinones is described, which resulted in the development of a new series of benzo[b]oxazolo[3,4-d][1,4]oxazinone analogs with high antibacterial activity against Gram-pos. pathogens, including that against linezolid-resistant strains, and low hERG inhibition.  With regard to structure-activity relationship (SAR) trends among the various substituents on the pyridyl ring, relatively small and nonbasic substituents were preferable to sterically demanding or basic substituents.  Oxazolidinone ring substitution on the pyridyl ring generated analogs with antibacterial activity superior to imidazolidinone ring.  Soly. was enhanced by the incorporation of polar groups, esp. when compds. were converted to their prodrugs.  Among the prodrugs, compd. I exhibited excellent soly. and a good pharmacokinetic profile.  In a MRSA systemic infection model, compd. I displayed an ED50 = 5.00 mg/kg, a potency that is 2-fold better than that of linezolid.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6VdLd2a4z0LVg90H21EOLACvtfcHk0ljlIXsk6My2VA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXivVyju7g%253D&md5=531c0bab630f3625674880d9dd1f5166</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm4000598&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4000598%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DB.%26aulast%3DFan%26aufirst%3DH.%26aulast%3DXin%26aufirst%3DQ.%26aulast%3DChu%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DY.%26atitle%3DSolubility-driven%2520optimization%2520of%2520%2528pyridin-3-yl%2529%2520benzoxazinyl-oxazolidinones%2520leading%2520to%2520a%2520promising%2520antibacterial%2520agent%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D2642%26epage%3D2650%26doi%3D10.1021%2Fjm4000598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span> <span> </span><span class="NLM_article-title">Discovery of fluorine-containing benzoxazinyl-oxazolidinones for the treatment of multidrug resistant tuberculosis</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">533</span>– <span class="NLM_lpage">537</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00068</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00068" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtVWltL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=533-537&author=H.+Zhaoauthor=Y.+Luauthor=L.+Shengauthor=Z.+Yuanauthor=B.+Wangauthor=W.+Wangauthor=Y.+Liauthor=C.+Maauthor=X.+Wangauthor=D.+Zhangauthor=H.+Huang&title=Discovery+of+fluorine-containing+benzoxazinyl-oxazolidinones+for+the+treatment+of+multidrug+resistant+tuberculosis&doi=10.1021%2Facsmedchemlett.7b00068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Fluorine-Containing Benzoxazinyl-oxazolidinones for the Treatment of Multidrug Resistant Tuberculosis</span></div><div class="casAuthors">Zhao, Hongyi; Lu, Yu; Sheng, Li; Yuan, Zishuo; Wang, Bin; Wang, Weiping; Li, Yan; Ma, Chen; Wang, Xiaoliang; Zhang, Dongfeng; Huang, Haihong</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">533-537</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel series of fluorine-contg. benzoxazinyl-oxazolidinones were designed and synthesized as antidrug-resistant tuberculosis agents possessing good activity and improved pharmacokinetic profiles.  Compd. I exhibited not only outstanding in vitro activity with a MIC value of 0.25-0.50 μg/mL against drug-susceptible H37Rv strain and two clin. isolated drug-resistant Mycobacterium tuberculosis strains, but also acceptable in vitro ADME/T properties.  Moreover, this compd. displayed excellent mouse pharmacokinetic profiles with an oral bioavailability of 102% and a longer elimination half-life of 4.22 h, thereby supporting further optimization and development of this promising lead series.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogwgObIiYn5rVg90H21EOLACvtfcHk0ljlIXsk6My2VA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtVWltL8%253D&md5=288fd039d5f0eb32cd751e6390733dc7</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00068%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DSheng%26aufirst%3DL.%26aulast%3DYuan%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DHuang%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520fluorine-containing%2520benzoxazinyl-oxazolidinones%2520for%2520the%2520treatment%2520of%2520multidrug%2520resistant%2520tuberculosis%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D533%26epage%3D537%26doi%3D10.1021%2Facsmedchemlett.7b00068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of a conformationally constrained oxazolidinone with improved safety and efficacy profiles for the treatment of multidrug-resistant tuberculosis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">9316</span>– <span class="NLM_lpage">9339</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00500</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00500" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtl2jtbbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=9316-9339&author=H.+Zhaoauthor=B.+Wangauthor=L.+Fuauthor=G.+Liauthor=H.+Luauthor=Y.+Liuauthor=L.+Shengauthor=Y.+Liauthor=B.+Zhangauthor=Y.+Luauthor=C.+Maauthor=H.+Huangauthor=D.+Zhangauthor=Y.+Lu&title=Discovery+of+a+conformationally+constrained+oxazolidinone+with+improved+safety+and+efficacy+profiles+for+the+treatment+of+multidrug-resistant+tuberculosis&doi=10.1021%2Facs.jmedchem.0c00500"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Conformationally Constrained Oxazolidinone with Improved Safety and Efficacy Profiles for the Treatment of Multidrug-Resistant Tuberculosis</span></div><div class="casAuthors">Zhao, Hongyi; Wang, Bin; Fu, Lei; Li, Gang; Lu, Haijia; Liu, Yuke; Sheng, Li; Li, Yan; Zhang, Baoxi; Lu, Yang; Ma, Chen; Huang, Haihong; Zhang, Dongfeng; Lu, Yu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">9316-9339</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tuberculosis (TB) remains a serious public health challenge, and the research and development of new anti-TB drugs is an essential component of the global strategy to eradicate TB.  In this work, we discovered a conformationally constrained oxazolidinone 19c(I) with improved anti-TB activity and safety profile through a focused lead optimization effort.  Compd. 19c displayed superior in vivo efficacy in a mouse TB infection model compared to linezolid and sutezolid.  The druggability of compd. 19c was demonstrated in a panel of assays including microsomal stability, cytotoxicity, cytochrome P 450 enzyme inhibition, and pharmacokinetics in animals.  Compd. 19c demonstrated an excellent safety profile in a battery of safety assays, including mitochondrial protein synthesis, hERG K+, hCav1.2, and Nav1.5 channels, monoamine oxidase, and genotoxicity.  In a 4 wk repeated dose toxicol. study in rats, 19c appeared to have less bone marrow suppression than linezolid, which has been a major liability of the oxazolidinone class.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZxjD-svNTCLVg90H21EOLACvtfcHk0lgdN2kX5VmOfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtl2jtbbP&md5=fca65a3a3fb69bc78178ae5b04c6a562</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00500%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DFu%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DLu%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DSheng%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DLu%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520a%2520conformationally%2520constrained%2520oxazolidinone%2520with%2520improved%2520safety%2520and%2520efficacy%2520profiles%2520for%2520the%2520treatment%2520of%2520multidrug-resistant%2520tuberculosis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D9316%26epage%3D9339%26doi%3D10.1021%2Facs.jmedchem.0c00500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Z.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.-H.</span></span> <span> </span><span class="NLM_article-title">A convenient and efficient H<sub>2</sub>SO<sub>4</sub>-promoted regioselective monobromination of phenol derivatives using <i>N</i>-bromosuccinimide</span>. <i>Synth. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">813</span>– <span class="NLM_lpage">822</span>, <span class="refDoi"> DOI: 10.1080/00397911.2019.1711415</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=10.1080%2F00397911.2019.1711415" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisV2ltrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2020&pages=813-822&author=Y.-Q.+Wuauthor=H.-J.+Luauthor=W.-T.+Zhaoauthor=H.-Y.+Zhaoauthor=Z.-Y.+Linauthor=D.-F.+Zhangauthor=H.-H.+Huang&title=A+convenient+and+efficient+H2SO4-promoted+regioselective+monobromination+of+phenol+derivatives+using+N-bromosuccinimide&doi=10.1080%2F00397911.2019.1711415"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">A convenient and efficient H2SO4-promoted regioselective monobromination of phenol derivatives using N-bromosuccinimide</span></div><div class="casAuthors">Wu, Yong-Qi; Lu, Hai-Jia; Zhao, Wen-Ting; Zhao, Hong-Yi; Lin, Zi-Yun; Zhang, Dong-Feng; Huang, Hai-Hong</div><div class="citationInfo"><span class="NLM_cas:title">Synthetic Communications</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">813-822</span>CODEN:
                <span class="NLM_cas:coden">SYNCAV</span>;
        ISSN:<span class="NLM_cas:issn">0039-7911</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">A convenient, rapid H2SO4-promoted regioselective monobromination reaction with N-bromosuccinimide was developed.  The desired para-monobrominated or ortho-monobrominated products of phenol derivs. e.g., I were obtained in good to excellent yields with high selectivity.  Regioselective chlorination and iodination were also achieved in the presence of H2SO4 using N-chlorosuccinimide and N-iodosuccinimide, resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQOtqSrXn3J7Vg90H21EOLACvtfcHk0lgdN2kX5VmOfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisV2ltrg%253D&md5=9846fd05e30df2862e0f8574e33872a3</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1080%2F00397911.2019.1711415&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00397911.2019.1711415%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DY.-Q.%26aulast%3DLu%26aufirst%3DH.-J.%26aulast%3DZhao%26aufirst%3DW.-T.%26aulast%3DZhao%26aufirst%3DH.-Y.%26aulast%3DLin%26aufirst%3DZ.-Y.%26aulast%3DZhang%26aufirst%3DD.-F.%26aulast%3DHuang%26aufirst%3DH.-H.%26atitle%3DA%2520convenient%2520and%2520efficient%2520H2SO4-promoted%2520regioselective%2520monobromination%2520of%2520phenol%2520derivatives%2520using%2520N-bromosuccinimide%26jtitle%3DSynth.%2520Commun.%26date%3D2020%26volume%3D50%26spage%3D813%26epage%3D822%26doi%3D10.1080%2F00397911.2019.1711415" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Osa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hikima, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takino, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ida, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirono, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagase, H.</span></span> <span> </span><span class="NLM_article-title">Convenient synthesis of oxazolidinones by the use of halomethyloxirane, primary amine, and carbonate salt</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">5737</span>– <span class="NLM_lpage">5740</span>, <span class="refDoi"> DOI: 10.1021/jo0501644</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo0501644" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=1%3ACAS%3A528%3ADC%252BD2MXltVSltbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2005&pages=5737-5740&author=Y.+Osaauthor=Y.+Hikimaauthor=Y.+Satoauthor=K.+Takinoauthor=Y.+Idaauthor=S.+Hironoauthor=H.+Nagase&title=Convenient+synthesis+of+oxazolidinones+by+the+use+of+halomethyloxirane%2C+primary+amine%2C+and+carbonate+salt&doi=10.1021%2Fjo0501644"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Convenient synthesis of oxazolidinones by the use of halomethyloxirane, primary amine, and carbonate salt</span></div><div class="casAuthors">Osa, Yumiko; Hikima, Yuka; Sato, Yoko; Takino, Kouichi; Ida, Yoshihiro; Hirono, Shuichi; Nagase, Hiroshi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5737-5740</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Primary amines reacted with carbonate salts (Na2CO3, K2CO3, Cs2CO3, and Ag2CO3) and halomethyloxiranes in the presence of a base such as DBU or TEA to give oxazolidinones in high yields.  The use of K2CO3 among these carbonate gave the best yield in this synthesis.  A reaction mechanism was proposed that the oxazolidinone was obtained from an oxazinanone intermediate via a bicyclo[2.2.1] intermediate.  The present reaction can be widely applied to convenient synthesis of useful N-substituted oxazolidinones and chiral oxazolidinones.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAzE5W-3AQ4LVg90H21EOLACvtfcHk0ljIc0Taq9mU3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXltVSltbo%253D&md5=623eccfcb67bfa938ca1d032c84d9595</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjo0501644&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo0501644%26sid%3Dliteratum%253Aachs%26aulast%3DOsa%26aufirst%3DY.%26aulast%3DHikima%26aufirst%3DY.%26aulast%3DSato%26aufirst%3DY.%26aulast%3DTakino%26aufirst%3DK.%26aulast%3DIda%26aufirst%3DY.%26aulast%3DHirono%26aufirst%3DS.%26aulast%3DNagase%26aufirst%3DH.%26atitle%3DConvenient%2520synthesis%2520of%2520oxazolidinones%2520by%2520the%2520use%2520of%2520halomethyloxirane%252C%2520primary%2520amine%252C%2520and%2520carbonate%2520salt%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2005%26volume%3D70%26spage%3D5737%26epage%3D5740%26doi%3D10.1021%2Fjo0501644" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Junquera, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merchán, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merino, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tejero, T.</span></span> <span> </span><span class="NLM_article-title">A straightforward synthesis of L-isoserinal</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">7045</span>– <span class="NLM_lpage">7052</span>, <span class="refDoi"> DOI: 10.1016/0040-4020(96)00309-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=10.1016%2F0040-4020%2896%2900309-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=1%3ACAS%3A528%3ADyaK28XjtV2qurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=1996&pages=7045-7052&author=F.+Junqueraauthor=F.+L.+Merch%C3%A1nauthor=P.+Merinoauthor=T.+Tejero&title=A+straightforward+synthesis+of+L-isoserinal&doi=10.1016%2F0040-4020%2896%2900309-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">A straightforward synthesis of L-isoserinal</span></div><div class="casAuthors">Junquera, Federico; Merchan, Francisco L.; Merino, Pedro; Tejero, Tomas</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7045-7052</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A convenient prepn. of an L-isoserinal deriv. in six steps and 32.8% overall yield employing D-glyceraldehyde acetonide as starting material is described.  The procedure is inexpensive, easily scaled up and proceeds without observable racemization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorxFSKcj6E4rVg90H21EOLACvtfcHk0ljIc0Taq9mU3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XjtV2qurg%253D&md5=bb935460ada392c2e7b3ff886cbf006b</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2F0040-4020%2896%2900309-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0040-4020%252896%252900309-2%26sid%3Dliteratum%253Aachs%26aulast%3DJunquera%26aufirst%3DF.%26aulast%3DMerch%25C3%25A1n%26aufirst%3DF.%2BL.%26aulast%3DMerino%26aufirst%3DP.%26aulast%3DTejero%26aufirst%3DT.%26atitle%3DA%2520straightforward%2520synthesis%2520of%2520L-isoserinal%26jtitle%3DTetrahedron%26date%3D1996%26volume%3D52%26spage%3D7045%26epage%3D7052%26doi%3D10.1016%2F0040-4020%2896%2900309-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zubkov, F. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikitina, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galeev, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaytsev, V. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khrustalev, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novikov, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlova, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varlamov, A. V.</span></span> <span> </span><span class="NLM_article-title">General synthetic approach towards annelated 3<i>a</i>,6-epoxyisoindoles by tandem acylation/IMDAF reaction of furylazaheterocycles. Scope and limitations</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">1659</span>– <span class="NLM_lpage">1690</span>, <span class="refDoi"> DOI: 10.1016/j.tet.2014.01.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=10.1016%2Fj.tet.2014.01.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlKmsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2014&pages=1659-1690&author=F.+I.+Zubkovauthor=E.+V.+Nikitinaauthor=T.+R.+Galeevauthor=V.+P.+Zaytsevauthor=V.+N.+Khrustalevauthor=R.+A.+Novikovauthor=D.+N.+Orlovaauthor=A.+V.+Varlamov&title=General+synthetic+approach+towards+annelated+3a%2C6-epoxyisoindoles+by+tandem+acylation%2FIMDAF+reaction+of+furylazaheterocycles.+Scope+and+limitations&doi=10.1016%2Fj.tet.2014.01.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">General synthetic approach towards annelated 3a,6-epoxyisoindoles by tandem acylation/IMDAF reaction of furylazaheterocycles. Scope and limitations</span></div><div class="casAuthors">Zubkov, Fedor I.; Nikitina, Eugenia V.; Galeev, Timur R.; Zaytsev, Vladimir P.; Khrustalev, Victor N.; Novikov, Roman A.; Orlova, Daria N.; Varlamov, Alexey V.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1659-1690</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">An efficient and versatile one-pot synthesis of 3,6a-epoxyisoindoles annelated with oxazine, oxazole, thiazine, thiazole, pyrimidine fragments and with their benzoannelated analogs is presented.  The method is based on tandem N-acylation/intramol. cycloaddn. (the intramol. Diels-Alder reaction of furan, IMDAF) reaction between α,β-unsatd. acid anhydrides and α-furyl substituted azaheterocycles.  The latter can be easily prepd. by condensation of diverse furfurals and 1,2- or 1,3-N,X-binucleophiles (aminoalcs., aminothiols, diamines).  The obsd. IMDAF reaction is stereoselective: exo-adducts are formed exclusively with large prevalence of one of the diastereoisomers.  In most cases, the condensation/N-acylation/IMDAF reaction sequence may be carried out via a one-pot domino protocol.  The scope and limitations of the proposed approach are thoroughly investigated.  The obtained Diels-Alder adducts are attractive and useful substrates for further transformations.  Fused isoindoles can be prepd. from them in one-step by aromatization of the 7-oxabicyclo[2.2.1]heptene ring.  Other transformations, including halogenation, ring cleavage, and Wagner-Meerwein skeletal rearrangement, are also demonstrated.  The spatial structures of the obtained compds. have been established by X-ray diffraction analyses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEcXepOY-ANLVg90H21EOLACvtfcHk0ljIc0Taq9mU3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlKmsbg%253D&md5=9c48727e215baecffb3a0db89d43b58e</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2014.01.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2014.01.008%26sid%3Dliteratum%253Aachs%26aulast%3DZubkov%26aufirst%3DF.%2BI.%26aulast%3DNikitina%26aufirst%3DE.%2BV.%26aulast%3DGaleev%26aufirst%3DT.%2BR.%26aulast%3DZaytsev%26aufirst%3DV.%2BP.%26aulast%3DKhrustalev%26aufirst%3DV.%2BN.%26aulast%3DNovikov%26aufirst%3DR.%2BA.%26aulast%3DOrlova%26aufirst%3DD.%2BN.%26aulast%3DVarlamov%26aufirst%3DA.%2BV.%26atitle%3DGeneral%2520synthetic%2520approach%2520towards%2520annelated%25203a%252C6-epoxyisoindoles%2520by%2520tandem%2520acylation%252FIMDAF%2520reaction%2520of%2520furylazaheterocycles.%2520Scope%2520and%2520limitations%26jtitle%3DTetrahedron%26date%3D2014%26volume%3D70%26spage%3D1659%26epage%3D1690%26doi%3D10.1016%2Fj.tet.2014.01.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span> <span> </span><span class="NLM_article-title">Efficient and stereoselective one-pot synthesis of benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-1-ones</span>. <i>RSC Adv.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">24037</span>– <span class="NLM_lpage">24044</span>, <span class="refDoi"> DOI: 10.1039/D0RA04104A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=10.1039%2FD0RA04104A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlSrsr3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2020&pages=24037-24044&author=H.+Zhaoauthor=W.+Zhaoauthor=S.+Chengauthor=H.+Luauthor=D.+Zhangauthor=H.+Huang&title=Efficient+and+stereoselective+one-pot+synthesis+of+benzo%5Bb%5Doxazolo%5B3%2C4-d%5D%5B1%2C4%5Doxazin-1-ones&doi=10.1039%2FD0RA04104A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Efficient and stereoselective one-pot synthesis of benzo[b]oxazolo[3,4-d][1,4]oxazin-1-ones</span></div><div class="casAuthors">Zhao, Hongyi; Zhao, Wenting; Cheng, Shihao; Lu, Haijia; Zhang, Dongfeng; Huang, Haihong</div><div class="citationInfo"><span class="NLM_cas:title">RSC Advances</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">24037-24044</span>CODEN:
                <span class="NLM_cas:coden">RSCACL</span>;
        ISSN:<span class="NLM_cas:issn">2046-2069</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">An efficient and mild one-pot convergent synthesis protocol has been developed for benzo[b]oxazolo[3,4-d][1,4]oxazin-1-one derivs. through the Mitsunobu reaction and sequential cyclization.  Various tricyclic fused benzoxazinyl-oxazolidinones (20 examples) were obtained in good to excellent yields and high enantioselectivities with facile operation.  Furthermore, four stereoisomers were afforded resp. in high ee values (>97.8%) via using different chiral 2,3-epoxy-4-trityloxybutanol.  This methodol. has been applied to the synthesis of key intermediates of drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFPYa3eAl2TbVg90H21EOLACvtfcHk0lhmZZOF3UALaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlSrsr3N&md5=89f2d8ace5b659d0b1511f50f72f3c20</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1039%2FD0RA04104A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FD0RA04104A%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DCheng%26aufirst%3DS.%26aulast%3DLu%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DHuang%26aufirst%3DH.%26atitle%3DEfficient%2520and%2520stereoselective%2520one-pot%2520synthesis%2520of%2520benzo%255Bb%255Doxazolo%255B3%252C4-d%255D%255B1%252C4%255Doxazin-1-ones%26jtitle%3DRSC%2520Adv.%26date%3D2020%26volume%3D10%26spage%3D24037%26epage%3D24044%26doi%3D10.1039%2FD0RA04104A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McKee, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bentley, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marks, T. A.</span></span> <span> </span><span class="NLM_article-title">Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">2042</span>– <span class="NLM_lpage">2049</span>, <span class="refDoi"> DOI: 10.1128/AAC.01411-05</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=10.1128%2FAAC.01411-05" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=16723564" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=1%3ACAS%3A528%3ADC%252BD28XlsVOitbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2006&pages=2042-2049&author=E.+E.+McKeeauthor=M.+Fergusonauthor=A.+T.+Bentleyauthor=T.+A.+Marks&title=Inhibition+of+mammalian+mitochondrial+protein+synthesis+by+oxazolidinones&doi=10.1128%2FAAC.01411-05"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones</span></div><div class="casAuthors">McKee, E. E.; Ferguson, M.; Bentley, A. T.; Marks, T. A.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2042-2049</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The effects of a variety of oxazolidinones, with different antibacterial potencies, including linezolid, on mitochondrial protein synthesis were detd. in intact mitochondria isolated from rat heart and liver and rabbit heart and bone marrow.  The results demonstrate that a general feature of the oxazolidinone class of antibiotics is the inhibition of mammalian mitochondrial protein synthesis.  Inhibition was similar in mitochondria from all tissues studied.  Further, oxazolidinones that were very potent as antibiotics were uniformly potent in inhibiting mitochondrial protein synthesis.  These results were compared to the inhibitory profiles of other antibiotics that function by inhibiting bacterial protein synthesis.  Of these, chloramphenicol and tetracycline were significant inhibitors of mammalian mitochondrial protein synthesis while the macrolides, lincosamides, and aminoglycosides were not.  Development of future antibiotics from the oxazolidinone class will have to evaluate potential mitochondrial toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYWXrB0u0817Vg90H21EOLACvtfcHk0lhmZZOF3UALaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlsVOitbo%253D&md5=4dce4c12ad8fddadae1fd90953a596d1</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1128%2FAAC.01411-05&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01411-05%26sid%3Dliteratum%253Aachs%26aulast%3DMcKee%26aufirst%3DE.%2BE.%26aulast%3DFerguson%26aufirst%3DM.%26aulast%3DBentley%26aufirst%3DA.%2BT.%26aulast%3DMarks%26aufirst%3DT.%2BA.%26atitle%3DInhibition%2520of%2520mammalian%2520mitochondrial%2520protein%2520synthesis%2520by%2520oxazolidinones%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2006%26volume%3D50%26spage%3D2042%26epage%3D2049%26doi%3D10.1128%2FAAC.01411-05" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 2 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Qianqian Zhao, Liang Xin, Yuzhi Liu, Chengyuan Liang, Jingyi Li, Yanlin Jian, Han Li, Zhenfeng Shi, Hong Liu, <span class="NLM_string-name hlFld-ContribAuthor">Wenqiang Cao</span>. </span><span class="cited-content_cbyCitation_article-title">Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021</strong>, Article ASAP.</span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00480&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00480%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DCurrent%252BLandscape%252Band%252BFuture%252BPerspective%252Bof%252BOxazolidinone%252BScaffolds%252BContaining%252BAntibacterial%252BDrugs%26aulast%3DZhao%26aufirst%3DQianqian%26date%3D2021%26date%3D2021%26date%3D16032021%26volume%3D0%26issue%3D0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Claudia  Foti</span>, <span class="hlFld-ContribAuthor ">Anna  Piperno</span>, <span class="hlFld-ContribAuthor ">Angela  Scala</span>, <span class="hlFld-ContribAuthor ">Ottavia  Giuffrè</span>. </span><span class="cited-content_cbyCitation_article-title">Oxazolidinone Antibiotics: Chemical, Biological and Analytical Aspects. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2021,</strong> <em>26 </em>
                                    (14)
                                     , 4280. <a href="https://doi.org/10.3390/molecules26144280" title="DOI URL">https://doi.org/10.3390/molecules26144280</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules26144280&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules26144280%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DOxazolidinone%252BAntibiotics%25253A%252BChemical%25252C%252BBiological%252Band%252BAnalytical%252BAspects%26aulast%3DFoti%26aufirst%3DClaudia%26date%3D2021%26date%3D2021%26volume%3D26%26issue%3D14%26spage%3D4280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/medium/jm0c02153_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/large/jm0c02153_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02153&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/medium/jm0c02153_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/large/jm0c02153_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Representative structure modifications of linezolid focused on the C-ring and C5 side chain.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/large/jm0c02153_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02153&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/medium/jm0c02153_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/large/jm0c02153_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Design of novel conformational constraint oxazolidinones.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/large/jm0c02153_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02153&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/medium/jm0c02153_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/large/jm0c02153_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Benzo[1,3]oxazinyloxazolidinone Intermediates <b>(±)-18a</b> and <b>(±)-18b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/large/jm0c02153_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02153&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NBS, conc H<sub>2</sub>SO<sub>4</sub>, MeCN, rt, 1 h, 84%; (b) (i) conc H<sub>2</sub>SO<sub>4</sub>, MeOH, reflux, 32 h; (ii) NH<sub>4</sub>OH, MeOH, 55 °C, 6 h, 83% of two steps; (c) (i) BH<sub>3</sub>, THF, reflux, 5 h; (ii) CbzCl, NaHCO<sub>3</sub>, THF/H<sub>2</sub>O = 5:1, rt, 3 h, 72% of two steps; (d) K<sub>2</sub>CO<sub>3</sub>, TEA, MeOH, reflux, 12 h, 60%; (e) (COCl)<sub>2</sub>, DMSO, TEA, THF, −78 °C to rt, 90%; (f) TsOH·H<sub>2</sub>O, toluene, reflux, 6 h, 49% for <b>(±)-15a</b>, 25% for <b>(±)-15b</b>; (g) ceric ammonium nitrate (CAN), MeCN/H<sub>2</sub>O = 9:1, rt, 2 h, 78% for <b>(±)-16a</b>, 76% for <b>(±)-16b</b>; (h) (Boc)<sub>2</sub>O, TEA, DMAP, DCM, rt, 2 h, 78% for <b>(±)-17a</b>, 82% for <b>(±)-17b</b>; (i) Cs<sub>2</sub>CO<sub>3</sub>, MeOH, rt, 3h, 89% for <b>(±)-18a</b>, 91% for <b>(±)-18b</b>.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/medium/jm0c02153_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/large/jm0c02153_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>(±)-20a</b> and <b>(±)-20b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/large/jm0c02153_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02153&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)picolinonitrile, Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub>, DMSO/H<sub>2</sub>O = 6:1, 100 °C, 5 h, 84% for <b>(±)-19a</b>, 81% for <b>(±)-19b</b>; (b) (i) TFA, DCM, rt, 2 h; (ii) acetyl chloride, TEA, DCM, 0 °C, 2 h, 87% for <b>(±)-20a</b>, 80% for <b>(±)-20b</b>.</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/medium/jm0c02153_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/large/jm0c02153_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Separation of Compound <b>(±)-20a</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/large/jm0c02153_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02153&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) CHIRALPAK IA column, MeOH/EtOAc = 80:20, 1.0 mL/min, λ = 254 nm, 25 °C.</p></p></figure><figure data-id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/medium/jm0c02153_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/large/jm0c02153_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. ECD spectra of compounds <b>20aa</b> and <b>20ab</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/large/jm0c02153_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02153&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/medium/jm0c02153_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/large/jm0c02153_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Compound <b>(±)-24</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/large/jm0c02153_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02153&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (i) BH<sub>3</sub>, THF, reflux, 5 h; (ii) CbzCl, NaHCO<sub>3</sub>, THF/H<sub>2</sub>O = 5:1, rt, 3 h, 72% of two steps; (b) TsOH·H<sub>2</sub>O, toluene, reflux, 6 h, 50%; (c) CAN, MeCN/H<sub>2</sub>O = 9:1, rt, 2 h, 76%; (d) (Boc)<sub>2</sub>O, TEA, DMAP, DCM, rt, 2 h, 90%; (e) Cs<sub>2</sub>CO<sub>3</sub>, MeOH, rt, 3 h, 84%.</p></p></figure><figure data-id="sch5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/medium/jm0c02153_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/large/jm0c02153_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Target Compounds <b>20aa</b> and <b>30</b>–<b>38</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/large/jm0c02153_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02153&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) CHIRALPAK AD-H column, MeOH = 100%, 1.0 mL/min, λ = 214 nm, 35 °C, for <b>18a</b>; CHIRALPAK IA column, hexane/EtOH = 50:50, 1.0 mL/min, λ = 254 nm, 25 °C, for <b>24</b>; (b) (i) arylboronic acid ester, Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub>, DMSO/H<sub>2</sub>O = 6:1, 100 °C, 5 h, 57–89%, for <b>25</b>, <b>26</b>, and <b>28</b>; (ii) morpholine, X-PHOS, Pd(OAc)<sub>2</sub>, Cs<sub>2</sub>CO<sub>3</sub>, toluene, reflux, 100 °C, 6 h, 44–66%, for <b>27</b> and <b>29</b>; (c) TFA, DCM, rt, 3 h, 63–94%; (d) acetyl chloride, TEA, DCM, 0 °C, 2 h, 78–99%.</p></p></figure><figure data-id="sch6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/medium/jm0c02153_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/large/jm0c02153_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Target Compounds <b>(±)-45</b>–<b>48</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/large/jm0c02153_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02153&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (i) BH<sub>3</sub>, THF, reflux, 5 h; (ii) CbzCl, NaHCO<sub>3</sub>, THF/H<sub>2</sub>O = 5:1, rt, 3 h, 71% of two steps; (b) TsOH·H<sub>2</sub>O, toluene, reflux, 6 h, 51%; (c) CAN, MeCN/H<sub>2</sub>O = 9:1, rt, 2 h, 67%; (d) (Boc)<sub>2</sub>O, TEA, DMAP, DCM, rt, 2 h, 74%; (e) Cs<sub>2</sub>CO<sub>3</sub>, MeOH, rt, 3h, 82%; (f) (i) 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)picolinonitrile, Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub>, DMSO/H<sub>2</sub>O = 6:1, 100 °C, 5 h, 84%, for (±)-<b>43</b>; (ii) morpholine, X-PHOS, Pd(OAc)<sub>2</sub>, Cs<sub>2</sub>CO<sub>3</sub>, toluene, reflux, 100 °C, 6 h, 38%, for (±)-<b>44</b>; (g) TFA, DCM, rt, 3 h, 78–86%; (h) acetyl chloride, TEA, DCM, 0 °C, 2 h, 76–86%.</p></p></figure><figure data-id="fig4" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/medium/jm0c02153_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/large/jm0c02153_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Mean blood concentration–time profiles of compound <b>20aa</b> in mouse after oral administration (10 mg/kg) and intravenous injection (1 mg/kg) of compound <b>20aa</b> (<i>n</i> = 3). The data are presented as the means ± SD (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02153/suppl_file/jm0c02153_si_001.pdf" class="ext-link">Table S1</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02153/20210319/images/large/jm0c02153_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02153&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i79">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24631" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24631" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 29 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, G. D.</span></span> <span> </span><span class="NLM_article-title">Antibacterial drug discovery in the resistance era</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>529</i></span>,  <span class="NLM_fpage">336</span>– <span class="NLM_lpage">343</span>, <span class="refDoi"> DOI: 10.1038/nature17042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=10.1038%2Fnature17042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=26791724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Oisro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=529&publication_year=2016&pages=336-343&author=E.+D.+Brownauthor=G.+D.+Wright&title=Antibacterial+drug+discovery+in+the+resistance+era&doi=10.1038%2Fnature17042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Antibacterial drug discovery in the resistance era</span></div><div class="casAuthors">Brown, Eric D.; Wright, Gerard D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">529</span>
        (<span class="NLM_cas:issue">7586</span>),
    <span class="NLM_cas:pages">336-343</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The looming antibiotic resistance crisis has penetrated the consciousness of clinicians, researchers, policymakers, politicians and the public at large.  The evolution and widespread distribution of antibiotic resistance elements in bacterial pathogens has made diseases that were once easily treatable deadly again.  Unfortunately, accompanying the rise in global resistance is a failure in antibacterial drug discovery.  Lessons from the history of antibiotic discovery and fresh understanding of antibiotic action and the cell biol. of microorganisms have the potential to deliver twenty-first century medicines that are able to control infection in the resistance era.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKJH_K99a5abVg90H21EOLACvtfcHk0ljQsFqLqaIefA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Oisro%253D&md5=62e0454601a242db039e60d77be26406</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnature17042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature17042%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DE.%2BD.%26aulast%3DWright%26aufirst%3DG.%2BD.%26atitle%3DAntibacterial%2520drug%2520discovery%2520in%2520the%2520resistance%2520era%26jtitle%3DNature%26date%3D2016%26volume%3D529%26spage%3D336%26epage%3D343%26doi%3D10.1038%2Fnature17042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">World Health Organization</span>.  <i>WHO Publishes List of Bacteria for Which
New Antibiotics Are Urgently Needed</i>; <span class="NLM_publisher-name">WHO</span>, <span class="NLM_publisher-loc">Geneva, Switzerland</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=World+Health+Organization&title=WHO+Publishes+List+of+Bacteria+for+Which%0ANew+Antibiotics+Are+Urgently+Needed"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3D%26btitle%3DWHO%2520Publishes%2520List%2520of%2520Bacteria%2520for%2520Which%250ANew%2520Antibiotics%2520Are%2520Urgently%2520Needed%26pub%3DWHO%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span> <i>Global Tuberculosis Report 2020</i>; <span class="NLM_publisher-name">World Health
Organization</span>: <span class="NLM_publisher-loc">Geneva, Switzerland</span>, <span class="NLM_year">2020</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Global+Tuberculosis+Report+2020%3B+World+Health%0AOrganization%3A+Geneva%2C+Switzerland%2C+2020."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26jtitle%3DGlobal%2520Tuberculosis%2520Report%25202020%26pub%3DWorld%2520Health%250AOrganization%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chellat, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raguz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riedl, R.</span></span> <span> </span><span class="NLM_article-title">Targeting antibiotic resistance</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">6600</span>– <span class="NLM_lpage">6626</span>, <span class="refDoi"> DOI: 10.1002/anie.201506818</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=10.1002%2Fanie.201506818" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=1%3ACAS%3A528%3ADC%252BC28Xks1Cju7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=6600-6626&author=M.+F.+Chellatauthor=L.+Raguzauthor=R.+Riedl&title=Targeting+antibiotic+resistance&doi=10.1002%2Fanie.201506818"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Antibiotic Resistance</span></div><div class="casAuthors">Chellat, Mathieu F.; Raguz, Luka; Riedl, Rainer</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6600-6626</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Finding strategies against the development of antibiotic resistance is a major global challenge for the life sciences community and for public health.  The past decades have seen a dramatic worldwide increase in human-pathogenic bacteria that are resistant to one or multiple antibiotics.  More and more infections caused by resistant microorganisms fail to respond to conventional treatment, and in some cases, even last-resort antibiotics have lost their power.  In addn., industry pipelines for the development of novel antibiotics have run dry over the past decades.  A recent world health day by the World Health Organization titled "Combat drug resistance: no action today means no cure tomorrow" triggered an increase in research activity, and several promising strategies have been developed to restore treatment options against infections by resistant bacterial pathogens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRcddMQflU3LVg90H21EOLACvtfcHk0ljQsFqLqaIefA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xks1Cju7k%253D&md5=b8194ac5902fa3ac4da2e36de71f82b4</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1002%2Fanie.201506818&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201506818%26sid%3Dliteratum%253Aachs%26aulast%3DChellat%26aufirst%3DM.%2BF.%26aulast%3DRaguz%26aufirst%3DL.%26aulast%3DRiedl%26aufirst%3DR.%26atitle%3DTargeting%2520antibiotic%2520resistance%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26spage%3D6600%26epage%3D6626%26doi%3D10.1002%2Fanie.201506818" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barbachyn, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, C. W.</span></span> <span> </span><span class="NLM_article-title">Oxazolidinone structure-activity relationships leading to linezolid</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">2010</span>– <span class="NLM_lpage">2023</span>, <span class="refDoi"> DOI: 10.1002/anie.200200528</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=10.1002%2Fanie.200200528" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=1%3ACAS%3A528%3ADC%252BD3sXkt1Snu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2003&pages=2010-2023&author=M.+R.+Barbachynauthor=C.+W.+Ford&title=Oxazolidinone+structure-activity+relationships+leading+to+linezolid&doi=10.1002%2Fanie.200200528"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Oxazolidinone structure-activity relationships leading to linezolid</span></div><div class="casAuthors">Barbachyn, Michael R.; Ford, Charles W.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2010-2023</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The development of bacterial resistance to currently available antibacterial agents is a growing global health problem.  Of particular concern are infections caused by multidrug-resistant Gram-pos. pathogens which are responsible for significant morbidity and mortality in both the hospital and community settings.  A no. of solns. to the problem of bacterial resistance are possible.  The most common approach is to continue modifying existing classes of antibacterial agents to provide new analogs with improved attributes.  Other successful strategies are to combine existing antibacterial agents with other drugs as well as the development of improved diagnostic procedures that may lead to rapid identification of the causative pathogen and permit the use of antibacterial agents with a narrow spectrum of activity.  Finally, and most importantly, the discovery of novel classes of antibacterial agents employing new mechanisms of action has considerable promise.  Such agents would exhibit a lack of cross-resistance with existing antimicrobial drugs.  This review describes the work leading to the discovery of linezolid, the first clin. useful oxazolidinone antibacterial agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGritv1CBogyHbVg90H21EOLACvtfcHk0ljQsFqLqaIefA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXkt1Snu7k%253D&md5=681744cbb331d9256cc32d8b60987284</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1002%2Fanie.200200528&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200200528%26sid%3Dliteratum%253Aachs%26aulast%3DBarbachyn%26aufirst%3DM.%2BR.%26aulast%3DFord%26aufirst%3DC.%2BW.%26atitle%3DOxazolidinone%2520structure-activity%2520relationships%2520leading%2520to%2520linezolid%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2003%26volume%3D42%26spage%3D2010%26epage%3D2023%26doi%3D10.1002%2Fanie.200200528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keam, S. J.</span></span> <span> </span><span class="NLM_article-title">Pretomanid: First Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">1797</span>– <span class="NLM_lpage">1803</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01207-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=10.1007%2Fs40265-019-01207-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=31583606" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=1%3ACAS%3A280%3ADC%252BB3MnkvF2gsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=1797-1803&author=S.+J.+Keam&title=Pretomanid%3A+First+Approval&doi=10.1007%2Fs40265-019-01207-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Pretomanid: First Approval</span></div><div class="casAuthors">Keam Susan J</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1797-1803</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Pretomanid, an oral nitroimidazooxazine antimycobacterial agent administered as part of the BPaL (bedaquiline, pretomanid and linezolid) and BPaMZ (bedaquiline, pretomanid, moxifloxacin and pyrazinamide) regimens, has been developed by the Global Alliance for TB Drug Development (TB Alliance) under license from Novartis, for the treatment for tuberculosis (TB).  TB Alliance has licensed Mylan to manufacture and commercialize pretomanid for use as part of the BPaMZ and BPaL regimens.  The license is non-exclusive in low- and middle-income countries and exclusive in high-income markets.  Pretomanid, as part of the BPaL regimen, was recently approved in the USA under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD) pathway for the treatment of adults with pulmonary extensively drug-resistant (XDR) or treatment-intolerant or non-responsive multidrug-resistant (MDR) TB.  Pretomanid is also under regulatory review in the EU.  This article summarizes the milestones in the development of pretomanid leading to this first regulatory approval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ32shufXmAyUNoizSOkG_FfW6udTcc2eZO0xTHdLzYtrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MnkvF2gsA%253D%253D&md5=5c28b82e658d5ce4aa0f1187cf2e7736</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01207-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01207-9%26sid%3Dliteratum%253Aachs%26aulast%3DKeam%26aufirst%3DS.%2BJ.%26atitle%3DPretomanid%253A%2520First%2520Approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D1797%26epage%3D1803%26doi%3D10.1007%2Fs40265-019-01207-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharaf, L. H.</span></span> <span> </span><span class="NLM_article-title">Oxazolidinone antimicrobials: a patent review (2012–2015)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">591</span>– <span class="NLM_lpage">605</span>, <span class="refDoi"> DOI: 10.1517/13543776.2016.1168807</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=10.1517%2F13543776.2016.1168807" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=26998627" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=1%3ACAS%3A528%3ADC%252BC28Xltlyhs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=591-605&author=O.+A.+Phillipsauthor=L.+H.+Sharaf&title=Oxazolidinone+antimicrobials%3A+a+patent+review+%282012%E2%80%932015%29&doi=10.1517%2F13543776.2016.1168807"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Oxazolidinone antimicrobials: a patent review (2012-2015)</span></div><div class="casAuthors">Phillips, Oludotun A.; Sharaf, Leyla H.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">591-605</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Antimicrobial resistance in Gram-pos. bacteria is a major health care issue.  This review summarizes patent publications from 2012 to 2015 that divulged novel oxazolidinones as antibacterial agents.: A total of 25 patents obtained from Espacenet, WIPO Patentscope and FreePatentsOnline, and AcclaimIP search engines were reviewed.  The patents were scrutinized based on the novelty of the compds., their antibacterial activity (MIC, μg/mL), and the process of prepn.  The oxazolidinones with promising antibacterial activity were classified according to the following structural diversities, as biaryl heterocyclic, fused heteroaryl rings contg. oxazolidinones, and others.  The biaryl heterocyclic, fused heteroaryl, benzoxazine, and the 1H-pyrazol-1-yl contg. oxazolidinone derivs. demonstrated potent antibacterial activities superior to linezolid against Gram-pos. bacteria.  Some derivs. were effective against std. strains of Gram-neg. bacteria, namely Moraxella catarrhalis ATCC A894, and Escherichia coli ATCC 25922.  In addn., a patent disclosed a structural isomer of linezolid with marginal activity against the aerobic Gram-neg. bacteria MDR Stenotrophomonas (Xanthomonas) maltophilia, while linezolid and vancomycin did not inhibit growth.  Finally, some derivs. showed activity against respiratory infectious diseases' causative agents, such as B. anthracis, B. mallei, Y. pestis, and M. pneumoniae.  Overall, there is limited in vivo data to support the potential clin. advancement of the currently reported novel derivs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprLzO8rJvUsrVg90H21EOLACvtfcHk0lgy737u6DfU0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xltlyhs7s%253D&md5=c5582e97a91b14e1ae65b19b2f4e0343</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1517%2F13543776.2016.1168807&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2016.1168807%26sid%3Dliteratum%253Aachs%26aulast%3DPhillips%26aufirst%3DO.%2BA.%26aulast%3DSharaf%26aufirst%3DL.%2BH.%26atitle%3DOxazolidinone%2520antimicrobials%253A%2520a%2520patent%2520review%2520%25282012%25E2%2580%25932015%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2016%26volume%3D26%26spage%3D591%26epage%3D605%26doi%3D10.1517%2F13543776.2016.1168807" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barbachyn, M. R.</span></span> <span> </span><span class="NLM_article-title">The oxazolidinones</span>. <i>Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">97</span>– <span class="NLM_lpage">122</span>, <span class="refDoi"> DOI: 10.1007/7355_2017_15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=10.1007%2F7355_2017_15" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2017&pages=97-122&author=M.+R.+Barbachyn&title=The+oxazolidinones&doi=10.1007%2F7355_2017_15"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1007%2F7355_2017_15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F7355_2017_15%26sid%3Dliteratum%253Aachs%26aulast%3DBarbachyn%26aufirst%3DM.%2BR.%26atitle%3DThe%2520oxazolidinones%26jtitle%3DTop.%2520Med.%2520Chem.%26date%3D2017%26volume%3D26%26spage%3D97%26epage%3D122%26doi%3D10.1007%2F7355_2017_15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of a teraryl oxazolidinone compound (<i>S</i>)-<i>N</i>-((3-(3-fluoro-4-(4-(pyridin-2-yl)-1<i>H</i>-pyrazol-1-yl)phenyl)-2-oxooxazolidin-5-yl)methyl)acetamide phosphate as a novel antimicrobial agent with enhanced safety profile and efficacies</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">6389</span>– <span class="NLM_lpage">6409</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00152</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00152" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1altb7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=6389-6409&author=T.+Yangauthor=G.+Chenauthor=Z.+Sangauthor=Y.+Liuauthor=X.+Yangauthor=Y.+Changauthor=H.+Longauthor=W.+Angauthor=J.+Tangauthor=Z.+Wangauthor=G.+Liauthor=S.+Yangauthor=J.+Zhangauthor=Y.+Weiauthor=Y.+Luo&title=Discovery+of+a+teraryl+oxazolidinone+compound+%28S%29-N-%28%283-%283-fluoro-4-%284-%28pyridin-2-yl%29-1H-pyrazol-1-yl%29phenyl%29-2-oxooxazolidin-5-yl%29methyl%29acetamide+phosphate+as+a+novel+antimicrobial+agent+with+enhanced+safety+profile+and+efficacies&doi=10.1021%2Facs.jmedchem.5b00152"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Teraryl Oxazolidinone Compound (S)-N-((3-(3-Fluoro-4-(4-(pyridin-2-yl)-1H-pyrazol-1-yl)phenyl)-2-oxooxazolidin-5-yl)methyl)acetamide Phosphate as a Novel Antimicrobial Agent with Enhanced Safety Profile and Efficacies</span></div><div class="casAuthors">Yang, Tao; Chen, Gong; Sang, Zitai; Liu, Yuanyuan; Yang, Xiaoyan; Chang, Ying; Long, Haiyue; Wei, Ang; Tang, Jianying; Wang, Zhenling; Li, Guobo; Yang, Shengyong; Zhang, Jingren; Wei, Yuquan; Luo, Youfu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">6389-6409</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of novel teraryl oxazolidinone compds. was designed, synthesized, and evaluated for their antimicrobial activity and toxicities.  The compds. with arom. N-heterocyclic substituents at the 4-position of pyrazolyl ring showed better antibacterial activity against the tested bacteria than other compds. with different patterns of substitution.  Among all potent compds., I exhibited promising safety profile in MTT assays and in hERG K+ channel inhibition test.  Furthermore, its phosphate was found to be highly sol. in water (47.1 mg/mL), which is beneficial for the subsequent in vivo test.  In MRSA systemic infection mice models, I phosphate exerted significantly improved survival protection compared with linezolid.  The compd. also demonstrated high oral bioavailability (F = 99.1%).  Moreover, from the results of in vivo toxicol. expts., I phosphate would be predicted to have less bone marrow suppression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2zOHxUIAO2bVg90H21EOLACvtfcHk0liLd82hdvDqBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1altb7E&md5=69b436025095d8fc3fcd25c2c7530a94</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00152%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DSang%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DChang%26aufirst%3DY.%26aulast%3DLong%26aufirst%3DH.%26aulast%3DAng%26aufirst%3DW.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DWei%26aufirst%3DY.%26aulast%3DLuo%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520a%2520teraryl%2520oxazolidinone%2520compound%2520%2528S%2529-N-%2528%25283-%25283-fluoro-4-%25284-%2528pyridin-2-yl%2529-1H-pyrazol-1-yl%2529phenyl%2529-2-oxooxazolidin-5-yl%2529methyl%2529acetamide%2520phosphate%2520as%2520a%2520novel%2520antimicrobial%2520agent%2520with%2520enhanced%2520safety%2520profile%2520and%2520efficacies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D6389%26epage%3D6409%26doi%3D10.1021%2Facs.jmedchem.5b00152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deshmukh, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, N.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and antibacterial evaluation of oxazolidinones with fused heterocyclic C-ring substructure</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1153</span>– <span class="NLM_lpage">1158</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00263</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00263" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFOjtbfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1153-1158&author=M.+S.+Deshmukhauthor=N.+Jain&title=Design%2C+synthesis%2C+and+antibacterial+evaluation+of+oxazolidinones+with+fused+heterocyclic+C-ring+substructure&doi=10.1021%2Facsmedchemlett.7b00263"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis and Antibacterial Evaluation of Oxazolidinones with Fused Heterocyclic C-Ring Substructure</span></div><div class="casAuthors">Deshmukh, Mahesh S.; Jain, Nidhi</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1153-1158</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of novel oxazolidinone antibacterials with diverse fused heteroaryl C-rings bearing hydrogen bond donor and hydrogen bond acceptor functionalities were designed and synthesized.  The compd. with benzoxazinone C-ring substructure (I) exhibited superior activity compared to linezolid against a panel of Gram-pos. and Gram-neg. bacteria.  Structural modifications at C5-side chain of I resulted in identification of several potent compds.  Selected compds. I and II showed very good microsomal stability and no CYP450 liability, thus clearing preliminary safety hurdles.  A docking model of II binding to 23S rRNA suggested that the increased potency of II is due to addnl. ligand-receptor interaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsos1yjPmoN7Vg90H21EOLACvtfcHk0liLd82hdvDqBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFOjtbfL&md5=5edbae88df65af2bd8264ff4755a0498</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00263%26sid%3Dliteratum%253Aachs%26aulast%3DDeshmukh%26aufirst%3DM.%2BS.%26aulast%3DJain%26aufirst%3DN.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520antibacterial%2520evaluation%2520of%2520oxazolidinones%2520with%2520fused%2520heterocyclic%2520C-ring%2520substructure%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D1153%26epage%3D1158%26doi%3D10.1021%2Facsmedchemlett.7b00263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Renslo, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaishankar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatachalam, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hackbarth, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordeev, M. F.</span></span> <span> </span><span class="NLM_article-title">Conformational constraint in oxazolidinone antibacterials. Synthesis and structure-activity studies of (azabicyclo[3.1.0]hexylphenyl)oxazolidinones</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">5009</span>– <span class="NLM_lpage">5024</span>, <span class="refDoi"> DOI: 10.1021/jm058204j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm058204j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=1%3ACAS%3A528%3ADC%252BD2MXltlGhtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=5009-5024&author=A.+R.+Rensloauthor=P.+Jaishankarauthor=R.+Venkatachalamauthor=C.+Hackbarthauthor=S.+Lopezauthor=D.+V.+Patelauthor=M.+F.+Gordeev&title=Conformational+constraint+in+oxazolidinone+antibacterials.+Synthesis+and+structure-activity+studies+of+%28azabicyclo%5B3.1.0%5Dhexylphenyl%29oxazolidinones&doi=10.1021%2Fjm058204j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure-Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones</span></div><div class="casAuthors">Renslo, Adam R.; Jaishankar, Priyadarshini; Venkatachalam, Revathy; Hackbarth, Corinne; Lopez, Sara; Patel, Dinesh V.; Gordeev, Mikhail F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5009-5024</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The oxazolidinones are a new class of synthetic antibacterials effective against a broad range of pathogenic Gram-pos. bacteria, including multi-drug-resistant strains.  Linezolid is the first drug from this class to reach the market and has become an important new option for the treatment of serious infections, particularly those caused by methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enteroccocus fecium (VRE).  In the search for novel oxazolidinones with improved potency and spectrum, conformationally constrained analogs in which the morpholine ring of linezolid is replaced with various substituted azabicyclo[3.1.0]hexyl ring systems were prepd. and their antibacterial properties evaluated.  Several classes of azabicyclic analogs were identified with activity comparable or superior to that of linezolid.  These include analogs bearing hydroxyl, amino, amido, or carboxyl groups on the azabicyclic ring.  The azabicyclic acid analog I was 4 times more potent than linezolid against key Gram-pos. and fastidious Gram-neg. pathogens (S. aureus, Streptococcus pneumoniae, and E. faecalis MICs ≤ 1 μg/mL; Haemophilus influenzae MIC = 4 μg/mL).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpn2mtgiOrrerVg90H21EOLACvtfcHk0liLd82hdvDqBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXltlGhtbg%253D&md5=ad963b5e48d335596bab426dc64e7b1e</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Fjm058204j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm058204j%26sid%3Dliteratum%253Aachs%26aulast%3DRenslo%26aufirst%3DA.%2BR.%26aulast%3DJaishankar%26aufirst%3DP.%26aulast%3DVenkatachalam%26aufirst%3DR.%26aulast%3DHackbarth%26aufirst%3DC.%26aulast%3DLopez%26aufirst%3DS.%26aulast%3DPatel%26aufirst%3DD.%2BV.%26aulast%3DGordeev%26aufirst%3DM.%2BF.%26atitle%3DConformational%2520constraint%2520in%2520oxazolidinone%2520antibacterials.%2520Synthesis%2520and%2520structure-activity%2520studies%2520of%2520%2528azabicyclo%255B3.1.0%255Dhexylphenyl%2529oxazolidinones%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D5009%26epage%3D5024%26doi%3D10.1021%2Fjm058204j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Utsunomiya, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shudo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuji, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwaki, T.</span></span> <span> </span><span class="NLM_article-title">Potent oxazolidinone antibacterials with heteroaromatic C-ring substructure</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1074</span>– <span class="NLM_lpage">1078</span>, <span class="refDoi"> DOI: 10.1021/ml400280z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml400280z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVyrtb%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=1074-1078&author=H.+Suzukiauthor=I.+Utsunomiyaauthor=K.+Shudoauthor=T.+Fujimuraauthor=M.+Tsujiauthor=I.+Katoauthor=T.+Aokiauthor=A.+Inoauthor=T.+Iwaki&title=Potent+oxazolidinone+antibacterials+with+heteroaromatic+C-ring+substructure&doi=10.1021%2Fml400280z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Potent Oxazolidinone Antibacterials with Heteroaromatic C-Ring Substructure</span></div><div class="casAuthors">Suzuki, Hideyuki; Utsunomiya, Iwao; Shudo, Koichi; Fujimura, Takaji; Tsuji, Masakatsu; Kato, Issei; Aoki, Toshiaki; Ino, Akira; Iwaki, Tsutomu</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1074-1078</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Novel oxazolidinone analogs bearing a condensed heteroarom. ring as the C-ring substructure were synthesized as candidate antibacterial agents.  Analogs 16 and 21 bearing imidazo-[1,2-a]-pyridine and 18 and 23 bearing [1,2,4]-triazolo-[1,5-a]-pyridine as the C-ring had excellent in vitro antibacterial activities against methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus faecalis (VRE), and penicillin-resistant Streptococcus pneumoniae (PRSP).  They also showed promising therapeutic effects in a mouse model of lethal infection.  Preliminary safety data (inhibitory effects on cytochrome P 450 isoforms and monoamine oxidases) were satisfactory.  Further evaluation of 18 and 23 is ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBYb1cLJtZI7Vg90H21EOLACvtfcHk0ljcv213aeBkNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVyrtb%252FM&md5=6f39a539a41ec53b3ce04733a74850d1</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fml400280z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml400280z%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DH.%26aulast%3DUtsunomiya%26aufirst%3DI.%26aulast%3DShudo%26aufirst%3DK.%26aulast%3DFujimura%26aufirst%3DT.%26aulast%3DTsuji%26aufirst%3DM.%26aulast%3DKato%26aufirst%3DI.%26aulast%3DAoki%26aufirst%3DT.%26aulast%3DIno%26aufirst%3DA.%26aulast%3DIwaki%26aufirst%3DT.%26atitle%3DPotent%2520oxazolidinone%2520antibacterials%2520with%2520heteroaromatic%2520C-ring%2520substructure%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D1074%26epage%3D1078%26doi%3D10.1021%2Fml400280z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Im, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, S.-H.</span></span> <span> </span><span class="NLM_article-title">Discovery of torezolid as a novel 5-hydroxymethyl-oxazolidinone antibacterial agent</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">1027</span>– <span class="NLM_lpage">1039</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2011.01.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=10.1016%2Fj.ejmech.2011.01.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=21292356" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsFWhsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2011&pages=1027-1039&author=W.+B.+Imauthor=S.+H.+Choiauthor=J.-Y.+Parkauthor=S.+H.+Choiauthor=J.+Finnauthor=S.-H.+Yoon&title=Discovery+of+torezolid+as+a+novel+5-hydroxymethyl-oxazolidinone+antibacterial+agent&doi=10.1016%2Fj.ejmech.2011.01.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of torezolid as a novel 5-hydroxymethyl-oxazolidinone antibacterial agent</span></div><div class="casAuthors">Im, Weon Bin; Choi, Sun Ho; Park, Ju-Young; Choi, Sung Hak; Finn, John; Yoon, Sung-Hwa</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1027-1039</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of novel substituted pyridyl Ph oxazolidinone analogs was synthesized and the structure-activity relationship (SAR) was investigated based on in vitro and in vivo antibacterial activities.  The min. inhibitory concns. (MICs) of the synthesized compds. against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) ranged from 0.12 to 2.0 μg/mL, and against Haemophilus influenzae (Hi) from 2.0 to 8.0 μg/mL.  Compared to linezolid, only four compds. I-IV showed higher in vitro antibacterial activities and better in vivo protective effects in mice.  To improve the aq. soly., various prodrugs of compd. I (DA-7157), which exerted a potency that was enhanced by 2-8-fold compared to that of linezolid, were synthesized.  Among the prodrugs, the phosphate compd. V exhibited excellent aq. soly. (>50 mg/mL in DW) and good pharmacokinetic profiles, along with better in vivo efficacy than linezolid.  This compd. V is currently undergoing clin. trials with the brand name Torezolid.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQ1ZCDnxjkULVg90H21EOLACvtfcHk0ljcv213aeBkNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsFWhsLg%253D&md5=3b8ef97195a19c308b42a7df7f05e1d5</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2011.01.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2011.01.014%26sid%3Dliteratum%253Aachs%26aulast%3DIm%26aufirst%3DW.%2BB.%26aulast%3DChoi%26aufirst%3DS.%2BH.%26aulast%3DPark%26aufirst%3DJ.-Y.%26aulast%3DChoi%26aufirst%3DS.%2BH.%26aulast%3DFinn%26aufirst%3DJ.%26aulast%3DYoon%26aufirst%3DS.-H.%26atitle%3DDiscovery%2520of%2520torezolid%2520as%2520a%2520novel%25205-hydroxymethyl-oxazolidinone%2520antibacterial%2520agent%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2011%26volume%3D46%26spage%3D1027%26epage%3D1039%26doi%3D10.1016%2Fj.ejmech.2011.01.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gordeev, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Z. Y.</span></span> <span> </span><span class="NLM_article-title">New potent antibacterial oxazolidinone (MRX-I) with an improved class safety profile</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">4487</span>– <span class="NLM_lpage">4497</span>, <span class="refDoi"> DOI: 10.1021/jm401931e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401931e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlsFOjsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4487-4497&author=M.+F.+Gordeevauthor=Z.+Y.+Yuan&title=New+potent+antibacterial+oxazolidinone+%28MRX-I%29+with+an+improved+class+safety+profile&doi=10.1021%2Fjm401931e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">New Potent Antibacterial Oxazolidinone (MRX-I) with an Improved Class Safety Profile</span></div><div class="casAuthors">Gordeev, Mikhail F.; Yuan, Zhengyu Y.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4487-4497</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Oxazolidinones comprise an important class of antibacterial protein synthesis inhibitors.  Myelosuppression and monoamine oxidase inhibition (MAOI) are key independent causes for limiting adverse effects in therapy with the sole approved drug of this class, linezolid.  This annotation describes a novel oxazolidinone agent, (S)-5-((isoxazol-3-ylamino)methyl)-3-(2,3,5-trifluoro-4-(4-oxo-3,4-dihydropyridin-1(2H)-yl)phenyl)oxazolidin-2-one (MRX-I), I, distinguished by its high activity against Gram-pos. pathogens coupled with markedly reduced potential for myelosuppression and MAOI.  The medical need, medicinal chem. rationale, preclin. data, and phase I clin. trial summary for this new agent are reviewed herein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNWIpQP5Wgg7Vg90H21EOLACvtfcHk0ljcv213aeBkNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlsFOjsbw%253D&md5=70b6b32e113b86ab6344cb266687f64f</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fjm401931e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401931e%26sid%3Dliteratum%253Aachs%26aulast%3DGordeev%26aufirst%3DM.%2BF.%26aulast%3DYuan%26aufirst%3DZ.%2BY.%26atitle%3DNew%2520potent%2520antibacterial%2520oxazolidinone%2520%2528MRX-I%2529%2520with%2520an%2520improved%2520class%2520safety%2520profile%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D4487%26epage%3D4497%26doi%3D10.1021%2Fjm401931e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chae, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baek, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwak, J. H.</span></span> <span> </span><span class="NLM_article-title">In vitro and in vivo activities of LCB01-0371, a new oxazolidinone</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">5359</span>– <span class="NLM_lpage">5362</span>, <span class="refDoi"> DOI: 10.1128/AAC.00723-10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=10.1128%2FAAC.00723-10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=20855730" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2msr%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2010&pages=5359-5362&author=J.+W.+Jeongauthor=S.+J.+Jungauthor=H.+H.+Leeauthor=Y.+Z.+Kimauthor=T.+K.+Parkauthor=Y.+L.+Choauthor=S.+E.+Chaeauthor=S.+Y.+Baekauthor=S.+H.+Wooauthor=H.+S.+Leeauthor=J.+H.+Kwak&title=In+vitro+and+in+vivo+activities+of+LCB01-0371%2C+a+new+oxazolidinone&doi=10.1128%2FAAC.00723-10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo activities of LCB01-0371, a new oxazolidinone</span></div><div class="casAuthors">Jeong, Ji-Woong; Jung, Sung-Ji; Lee, Hyun-Hee; Kim, Yong-Zu; Park, Tae-Kyo; Cho, Young-Lag; Chae, Sang-Eun; Baek, Sung-Yoon; Woo, Sung-Ho; Lee, Hyang-Sook; Kwak, Jin-Hwan</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5359-5362</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">LCB01-0371 is a new oxazolidinone with cyclic amidrazone.  In vitro activity of LCB01-0371 against 624 clin. isolates was evaluated and compared with those of linezolid, vancomycin, and other antibiotics.  LCB01-0371 showed good activity against Gram-pos. pathogens.  In vivo activity of LCB01-0371 against systemic infections in mice was also evaluated.  LCB01-0371 was more active than linezolid against these systemic infections.  LCB01-0371 showed bacteriostatic activity against Staphylococcus aureus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobg2lKKc8bzbVg90H21EOLACvtfcHk0lj5h_xG5l0X9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2msr%252FJ&md5=27471d63f1195f29f869689c125f643e</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1128%2FAAC.00723-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00723-10%26sid%3Dliteratum%253Aachs%26aulast%3DJeong%26aufirst%3DJ.%2BW.%26aulast%3DJung%26aufirst%3DS.%2BJ.%26aulast%3DLee%26aufirst%3DH.%2BH.%26aulast%3DKim%26aufirst%3DY.%2BZ.%26aulast%3DPark%26aufirst%3DT.%2BK.%26aulast%3DCho%26aufirst%3DY.%2BL.%26aulast%3DChae%26aufirst%3DS.%2BE.%26aulast%3DBaek%26aufirst%3DS.%2BY.%26aulast%3DWoo%26aufirst%3DS.%2BH.%26aulast%3DLee%26aufirst%3DH.%2BS.%26aulast%3DKwak%26aufirst%3DJ.%2BH.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520activities%2520of%2520LCB01-0371%252C%2520a%2520new%2520oxazolidinone%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2010%26volume%3D54%26spage%3D5359%26epage%3D5362%26doi%3D10.1128%2FAAC.00723-10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, Y.</span></span> <span> </span><span class="NLM_article-title">Comparison of in vitro activity and MIC distributions between the novel oxazolidinone delpazolid and linezolid against multidrug-resistant and extensively drug-resistant <i>Mycobacterium tuberculosis</i> in China</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>62</i></span>, <span class="NLM_elocation-id">e00165-18</span> <span class="refDoi"> DOI: 10.1128/AAC.00165-18</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=10.1128%2FAAC.00165-18" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=29844043" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2018&author=Z.+Zongauthor=W.+Jingauthor=J.+Shiauthor=S.+Wenauthor=T.+Zhangauthor=F.+Huoauthor=Y.+Shangauthor=Q.+Liangauthor=H.+Huangauthor=Y.+Pang&title=Comparison+of+in+vitro+activity+and+MIC+distributions+between+the+novel+oxazolidinone+delpazolid+and+linezolid+against+multidrug-resistant+and+extensively+drug-resistant+Mycobacterium+tuberculosis+in+China&doi=10.1128%2FAAC.00165-18"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1128%2FAAC.00165-18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00165-18%26sid%3Dliteratum%253Aachs%26aulast%3DZong%26aufirst%3DZ.%26aulast%3DJing%26aufirst%3DW.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DWen%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DHuo%26aufirst%3DF.%26aulast%3DShang%26aufirst%3DY.%26aulast%3DLiang%26aufirst%3DQ.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DPang%26aufirst%3DY.%26atitle%3DComparison%2520of%2520in%2520vitro%2520activity%2520and%2520MIC%2520distributions%2520between%2520the%2520novel%2520oxazolidinone%2520delpazolid%2520and%2520linezolid%2520against%2520multidrug-resistant%2520and%2520extensively%2520drug-resistant%2520Mycobacterium%2520tuberculosis%2520in%2520China%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2018%26volume%3D62%26doi%3D10.1128%2FAAC.00165-18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barbachyn, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchinson, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brickner, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cynamon, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilburn, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klemens, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glickman, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grega, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendges, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toops, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zurenko, G. E.</span></span> <span> </span><span class="NLM_article-title">Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">680</span>– <span class="NLM_lpage">685</span>, <span class="refDoi"> DOI: 10.1021/jm950956y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm950956y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=1%3ACAS%3A528%3ADyaK28XlvVCisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1996&pages=680-685&author=M.+R.+Barbachynauthor=D.+K.+Hutchinsonauthor=S.+J.+Bricknerauthor=M.+H.+Cynamonauthor=J.+O.+Kilburnauthor=S.+P.+Klemensauthor=S.+E.+Glickmanauthor=K.+C.+Gregaauthor=S.+K.+Hendgesauthor=D.+S.+Toopsauthor=C.+W.+Fordauthor=G.+E.+Zurenko&title=Identification+of+a+novel+oxazolidinone+%28U-100480%29+with+potent+antimycobacterial+activity&doi=10.1021%2Fjm950956y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a Novel Oxazolidinone (U-100480) with Potent Antimycobacterial Activity</span></div><div class="casAuthors">Barbachyn, Michael R.; Hutchinson, Douglas K.; Brickner, Steven J.; Cynamon, Michael H.; Kilburn, James O.; Klemens, Sally P.; Glickman, Suzanne E.; Grega, Kevin C.; Hendges, Susan K.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">680-5</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A subclass of oxazolidinone antibacterial agents with esp. potent in vitro activity against mycobacteria was discovered.  The salient structural feature of these oxazolidinone analogs, U-100480 [i.e., (S)-N-[[3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide], U-101603, and U-101244 is their appended thiomorpholine moiety.  The rational design, synthesis, and evaluation of the in vitro antimycobacterial activity of these analogs was described.  Potent activity against a screening strain of Mycobacterium tuberculosis was demonstrated by U-100480 and U-101603 (min. inhibitory concns. or MIC's ≤0.125 μg/mL).  Oxazolidinones U-100480 and U-101244 exhibit MIC90 values of 0.50 μg/mL or less against a panel of organisms consisting of five drug-sensitive and five multidrug-resistant strains of M. tuberculosis, with U-100480 being the most active congener.  Potent in vitro activity against other mycobacterial species was also demonstrated by U-100480.  For example, U-100480 exhibited excellent in vitro activity against multiple clin. isolates of Mycobacterium avium complex (MIC's = 0.5-4 μg/mL).  Orally administered U-100480 displays in vivo efficacy against M. tuberculosis and M. avium similar to that of clin. comparators isoniazid and azithromycin, resp.  Consideration of these factors, along with a favorable pharmacokinetic and chronic toxicity profile in rats, suggests that U-100480 is a promising antimycobacterial agent (tuberculostatic).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAvvlFTIROHbVg90H21EOLACvtfcHk0lj5h_xG5l0X9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XlvVCisQ%253D%253D&md5=8636d20221390257b48f2d3dd6884b78</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm950956y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm950956y%26sid%3Dliteratum%253Aachs%26aulast%3DBarbachyn%26aufirst%3DM.%2BR.%26aulast%3DHutchinson%26aufirst%3DD.%2BK.%26aulast%3DBrickner%26aufirst%3DS.%2BJ.%26aulast%3DCynamon%26aufirst%3DM.%2BH.%26aulast%3DKilburn%26aufirst%3DJ.%2BO.%26aulast%3DKlemens%26aufirst%3DS.%2BP.%26aulast%3DGlickman%26aufirst%3DS.%2BE.%26aulast%3DGrega%26aufirst%3DK.%2BC.%26aulast%3DHendges%26aufirst%3DS.%2BK.%26aulast%3DToops%26aufirst%3DD.%2BS.%26aulast%3DFord%26aufirst%3DC.%2BW.%26aulast%3DZurenko%26aufirst%3DG.%2BE.%26atitle%3DIdentification%2520of%2520a%2520novel%2520oxazolidinone%2520%2528U-100480%2529%2520with%2520potent%2520antimycobacterial%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1996%26volume%3D39%26spage%3D680%26epage%3D685%26doi%3D10.1021%2Fjm950956y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wallis, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakubiec, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvia, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paige, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimitrova, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladutko, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedland, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitton-Fry, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, P. F.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics and whole-blood bactericidal activity against <i>Mycobacterium</i> <i>tuberculosis</i> of single doses of PNU-100480 in healthy volunteers</span>. <i>J. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>202</i></span>,  <span class="NLM_fpage">745</span>– <span class="NLM_lpage">751</span>, <span class="refDoi"> DOI: 10.1086/655471</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=10.1086%2F655471" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=20629533" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFKjsrzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=202&publication_year=2010&pages=745-751&author=R.+S.+Wallisauthor=W.+M.+Jakubiecauthor=V.+Kumarauthor=A.+M.+Silviaauthor=D.+Paigeauthor=D.+Dimitrovaauthor=X.+Liauthor=L.+Ladutkoauthor=S.+Campbellauthor=G.+Friedlandauthor=M.+Mitton-Fryauthor=P.+F.+Miller&title=Pharmacokinetics+and+whole-blood+bactericidal+activity+against+Mycobacterium+tuberculosis+of+single+doses+of+PNU-100480+in+healthy+volunteers&doi=10.1086%2F655471"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers</span></div><div class="casAuthors">Wallis, Robert S.; Jakubiec, Wesley M.; Kumar, Vikas; Silvia, Annette M.; Paige, Darcy; Dimitrova, Dessislava; Li, Xiaoxi; Ladutko, Lynn; Campbell, Sheldon; Friedland, Gerald; Mitton-Fry, Mark; Miller, Paul F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Infectious Diseases</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">202</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">745-751</span>CODEN:
                <span class="NLM_cas:coden">JIDIAQ</span>;
        ISSN:<span class="NLM_cas:issn">0022-1899</span>.
    
            (<span class="NLM_cas:orgname">University of Chicago Press</span>)
        </div><div class="casAbstract">Background: The oxazolidinone PNU-100480 is superior to linezolid against exptl. murine tuberculosis.  Two metabolites contribute to but do not fully account for its superiority.  This study examd. the safety, tolerability, pharmacokinetics, and mycobactericidal activity of single ascending doses of PNU-100480.  Methods: Nineteen healthy volunteers received 2 escalating single oral doses (35-1500 mg) of PNU-100480 or placebo.  Eight subjects received 4 daily doses of 300 mg of linezolid.  Drug concns. and bactericidal activity against Mycobacterium tuberculosis in whole-blood bactericidal culture were measured.  Results: All doses were safe and well tolerated.  PNU-100480 doses to 1000 mg were well absorbed and showed approx. proportional increases in exposures of parent and metabolites.  The geometric mean maximal concns. of PNU-100480, PNU-101603, and PNU-101244 (sulfoxide and sulfone metabolites) at 1000 mg were 839, 3558, and 54 ng/mL, resp.  The maximal whole-blood bactericidal activity (-037 ± .06 log/day) occurred at combined PNU levels ≥2 times the min. inhibitory concn.  The obsd. geometric mean maximal concn. for linezolid was 6425 ng/mL.  Its maximal whole-blood bactericidal activity also occurred at ≥2 times the min. inhibitory concn., but it was only -0.16 ± .05 log/day (P < .001).  Neither drug showed enhanced activity at higher concns.  Conclusions: Single doses of PNU-100480 to 1000 mg were well tolerated and exhibited antimycobacterial activity superior to 300 mg of linezolid at steady state.  Addnl. studies are warranted to define its role in drug-resistant tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgr7U7caSPNbVg90H21EOLACvtfcHk0ljDBRSPwwpLbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFKjsrzM&md5=bd6fb9cd1190593681d167471f09a06d</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1086%2F655471&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F655471%26sid%3Dliteratum%253Aachs%26aulast%3DWallis%26aufirst%3DR.%2BS.%26aulast%3DJakubiec%26aufirst%3DW.%2BM.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DSilvia%26aufirst%3DA.%2BM.%26aulast%3DPaige%26aufirst%3DD.%26aulast%3DDimitrova%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLadutko%26aufirst%3DL.%26aulast%3DCampbell%26aufirst%3DS.%26aulast%3DFriedland%26aufirst%3DG.%26aulast%3DMitton-Fry%26aufirst%3DM.%26aulast%3DMiller%26aufirst%3DP.%2BF.%26atitle%3DPharmacokinetics%2520and%2520whole-blood%2520bactericidal%2520activity%2520against%2520Mycobacterium%2520tuberculosis%2520of%2520single%2520doses%2520of%2520PNU-100480%2520in%2520healthy%2520volunteers%26jtitle%3DJ.%2520Infect.%2520Dis.%26date%3D2010%26volume%3D202%26spage%3D745%26epage%3D751%26doi%3D10.1086%2F655471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span>U.S.
National Library of Medicine. ClinicalTrials.gov. <a href="https://clinicaltrials.gov/ct2/show/NCT03758612" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03758612</a> (accessed Nov 29, <span class="NLM_year">2018</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=U.S.%0ANational+Library+of+Medicine.+ClinicalTrials.gov.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03758612+%28accessed+Nov+29%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and structure-activity relationship studies of highly potent novel benzoxazinyl-oxazolidinone antibacterial agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">7493</span>– <span class="NLM_lpage">7502</span>, <span class="refDoi"> DOI: 10.1021/jm200614t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200614t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht12ktrrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7493-7502&author=Q.+Xinauthor=H.+Fanauthor=B.+Guoauthor=H.+Heauthor=S.+Gaoauthor=H.+Wangauthor=Y.+Huangauthor=Y.+Yang&title=Design%2C+synthesis%2C+and+structure-activity+relationship+studies+of+highly+potent+novel+benzoxazinyl-oxazolidinone+antibacterial+agents&doi=10.1021%2Fjm200614t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Structure-Activity Relationship Studies of Highly Potent Novel Benzoxazinyl-Oxazolidinone Antibacterial Agents</span></div><div class="casAuthors">Xin, Qi-Sheng; Fan, Hou-Xing; Guo, Bin; He, Hui-Li; Gao, Suo; Wang, Hui; Huang, Yan-Qin; Yang, Yu-She</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">7493-7502</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of novel benzoxazinyl-oxazolidinones bearing nonarom. heterocycle or aryl groups were designed and synthesized.  Their in vitro and in vivo antibacterial activities were investigated.  Most of the (3S, 3aS) biaryl benzoxazinyl-oxazolidinones exhibited potent activity against Gram-pos. pathogens.  SAR trends were obsd.; a pyridyl C ring was preferable to other 5- or 6-member aryl C rings, while fluorine substitution on the B ring generated derivs. with reduced activity.  Various substituent group positions on the pyridyl ring were also evaluated.  The resulting compds. displayed excellent activity against linezolid-resistant strains.  Compd. I exhibited excellent in vitro activity, with a MIC value of 0.25-0.5 μg/mL against MRSA and an activity against linezolid-resistant strains of 8-16-fold higher potency than linezolid.  In a MRSA systemic infection model, compd. 45 displayed an ED50 < 5.0 mg/kg, a potency that is nearly 3-fold better than that of linezolid.  This compd. also showed excellent pharmacokinetic profiles, with a half-life of more than 5 h as well as an oral bioavailability of 81% in rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWmvFSwZGAmrVg90H21EOLACvtfcHk0ljDBRSPwwpLbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht12ktrrE&md5=c3535d090f53b2f4de9582567ab7b3e7</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm200614t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200614t%26sid%3Dliteratum%253Aachs%26aulast%3DXin%26aufirst%3DQ.%26aulast%3DFan%26aufirst%3DH.%26aulast%3DGuo%26aufirst%3DB.%26aulast%3DHe%26aufirst%3DH.%26aulast%3DGao%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DY.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520structure-activity%2520relationship%2520studies%2520of%2520highly%2520potent%2520novel%2520benzoxazinyl-oxazolidinone%2520antibacterial%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7493%26epage%3D7502%26doi%3D10.1021%2Fjm200614t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span> <span> </span><span class="NLM_article-title">Solubility-driven optimization of (pyridin-3-yl) benzoxazinyl-oxazolidinones leading to a promising antibacterial agent</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">2642</span>– <span class="NLM_lpage">2650</span>, <span class="refDoi"> DOI: 10.1021/jm4000598</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4000598" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=1%3ACAS%3A528%3ADC%252BC3sXivVyju7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=2642-2650&author=B.+Guoauthor=H.+Fanauthor=Q.+Xinauthor=W.+Chuauthor=H.+Wangauthor=Y.+Huangauthor=X.+Chenauthor=Y.+Yang&title=Solubility-driven+optimization+of+%28pyridin-3-yl%29+benzoxazinyl-oxazolidinones+leading+to+a+promising+antibacterial+agent&doi=10.1021%2Fjm4000598"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Solubility-Driven Optimization of (Pyridin-3-yl) Benzoxazinyl-oxazolidinones Leading to a Promising Antibacterial Agent</span></div><div class="casAuthors">Guo, Bin; Fan, Houxing; Xin, Qisheng; Chu, Wenjing; Wang, Hui; Huang, Yanqin; Chen, Xiaoyan; Yang, Yushe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2642-2650</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The soly.-driven structural modification of substituted (pyridin-3-yl)-contg. hydrobenzo[b]oxazolo[3,4-d][1,4]oxazinones is described, which resulted in the development of a new series of benzo[b]oxazolo[3,4-d][1,4]oxazinone analogs with high antibacterial activity against Gram-pos. pathogens, including that against linezolid-resistant strains, and low hERG inhibition.  With regard to structure-activity relationship (SAR) trends among the various substituents on the pyridyl ring, relatively small and nonbasic substituents were preferable to sterically demanding or basic substituents.  Oxazolidinone ring substitution on the pyridyl ring generated analogs with antibacterial activity superior to imidazolidinone ring.  Soly. was enhanced by the incorporation of polar groups, esp. when compds. were converted to their prodrugs.  Among the prodrugs, compd. I exhibited excellent soly. and a good pharmacokinetic profile.  In a MRSA systemic infection model, compd. I displayed an ED50 = 5.00 mg/kg, a potency that is 2-fold better than that of linezolid.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6VdLd2a4z0LVg90H21EOLACvtfcHk0ljDBRSPwwpLbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXivVyju7g%253D&md5=531c0bab630f3625674880d9dd1f5166</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm4000598&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4000598%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DB.%26aulast%3DFan%26aufirst%3DH.%26aulast%3DXin%26aufirst%3DQ.%26aulast%3DChu%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DY.%26atitle%3DSolubility-driven%2520optimization%2520of%2520%2528pyridin-3-yl%2529%2520benzoxazinyl-oxazolidinones%2520leading%2520to%2520a%2520promising%2520antibacterial%2520agent%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D2642%26epage%3D2650%26doi%3D10.1021%2Fjm4000598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span> <span> </span><span class="NLM_article-title">Discovery of fluorine-containing benzoxazinyl-oxazolidinones for the treatment of multidrug resistant tuberculosis</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">533</span>– <span class="NLM_lpage">537</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00068</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00068" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtVWltL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=533-537&author=H.+Zhaoauthor=Y.+Luauthor=L.+Shengauthor=Z.+Yuanauthor=B.+Wangauthor=W.+Wangauthor=Y.+Liauthor=C.+Maauthor=X.+Wangauthor=D.+Zhangauthor=H.+Huang&title=Discovery+of+fluorine-containing+benzoxazinyl-oxazolidinones+for+the+treatment+of+multidrug+resistant+tuberculosis&doi=10.1021%2Facsmedchemlett.7b00068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Fluorine-Containing Benzoxazinyl-oxazolidinones for the Treatment of Multidrug Resistant Tuberculosis</span></div><div class="casAuthors">Zhao, Hongyi; Lu, Yu; Sheng, Li; Yuan, Zishuo; Wang, Bin; Wang, Weiping; Li, Yan; Ma, Chen; Wang, Xiaoliang; Zhang, Dongfeng; Huang, Haihong</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">533-537</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel series of fluorine-contg. benzoxazinyl-oxazolidinones were designed and synthesized as antidrug-resistant tuberculosis agents possessing good activity and improved pharmacokinetic profiles.  Compd. I exhibited not only outstanding in vitro activity with a MIC value of 0.25-0.50 μg/mL against drug-susceptible H37Rv strain and two clin. isolated drug-resistant Mycobacterium tuberculosis strains, but also acceptable in vitro ADME/T properties.  Moreover, this compd. displayed excellent mouse pharmacokinetic profiles with an oral bioavailability of 102% and a longer elimination half-life of 4.22 h, thereby supporting further optimization and development of this promising lead series.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogwgObIiYn5rVg90H21EOLACvtfcHk0lgn_xvZ-vNIgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtVWltL8%253D&md5=288fd039d5f0eb32cd751e6390733dc7</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00068%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DSheng%26aufirst%3DL.%26aulast%3DYuan%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DHuang%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520fluorine-containing%2520benzoxazinyl-oxazolidinones%2520for%2520the%2520treatment%2520of%2520multidrug%2520resistant%2520tuberculosis%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D533%26epage%3D537%26doi%3D10.1021%2Facsmedchemlett.7b00068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of a conformationally constrained oxazolidinone with improved safety and efficacy profiles for the treatment of multidrug-resistant tuberculosis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">9316</span>– <span class="NLM_lpage">9339</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00500</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00500" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtl2jtbbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=9316-9339&author=H.+Zhaoauthor=B.+Wangauthor=L.+Fuauthor=G.+Liauthor=H.+Luauthor=Y.+Liuauthor=L.+Shengauthor=Y.+Liauthor=B.+Zhangauthor=Y.+Luauthor=C.+Maauthor=H.+Huangauthor=D.+Zhangauthor=Y.+Lu&title=Discovery+of+a+conformationally+constrained+oxazolidinone+with+improved+safety+and+efficacy+profiles+for+the+treatment+of+multidrug-resistant+tuberculosis&doi=10.1021%2Facs.jmedchem.0c00500"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Conformationally Constrained Oxazolidinone with Improved Safety and Efficacy Profiles for the Treatment of Multidrug-Resistant Tuberculosis</span></div><div class="casAuthors">Zhao, Hongyi; Wang, Bin; Fu, Lei; Li, Gang; Lu, Haijia; Liu, Yuke; Sheng, Li; Li, Yan; Zhang, Baoxi; Lu, Yang; Ma, Chen; Huang, Haihong; Zhang, Dongfeng; Lu, Yu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">9316-9339</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tuberculosis (TB) remains a serious public health challenge, and the research and development of new anti-TB drugs is an essential component of the global strategy to eradicate TB.  In this work, we discovered a conformationally constrained oxazolidinone 19c(I) with improved anti-TB activity and safety profile through a focused lead optimization effort.  Compd. 19c displayed superior in vivo efficacy in a mouse TB infection model compared to linezolid and sutezolid.  The druggability of compd. 19c was demonstrated in a panel of assays including microsomal stability, cytotoxicity, cytochrome P 450 enzyme inhibition, and pharmacokinetics in animals.  Compd. 19c demonstrated an excellent safety profile in a battery of safety assays, including mitochondrial protein synthesis, hERG K+, hCav1.2, and Nav1.5 channels, monoamine oxidase, and genotoxicity.  In a 4 wk repeated dose toxicol. study in rats, 19c appeared to have less bone marrow suppression than linezolid, which has been a major liability of the oxazolidinone class.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZxjD-svNTCLVg90H21EOLACvtfcHk0lgn_xvZ-vNIgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtl2jtbbP&md5=fca65a3a3fb69bc78178ae5b04c6a562</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00500%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DFu%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DLu%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DSheng%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DLu%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520a%2520conformationally%2520constrained%2520oxazolidinone%2520with%2520improved%2520safety%2520and%2520efficacy%2520profiles%2520for%2520the%2520treatment%2520of%2520multidrug-resistant%2520tuberculosis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D9316%26epage%3D9339%26doi%3D10.1021%2Facs.jmedchem.0c00500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Z.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.-H.</span></span> <span> </span><span class="NLM_article-title">A convenient and efficient H<sub>2</sub>SO<sub>4</sub>-promoted regioselective monobromination of phenol derivatives using <i>N</i>-bromosuccinimide</span>. <i>Synth. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">813</span>– <span class="NLM_lpage">822</span>, <span class="refDoi"> DOI: 10.1080/00397911.2019.1711415</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=10.1080%2F00397911.2019.1711415" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisV2ltrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2020&pages=813-822&author=Y.-Q.+Wuauthor=H.-J.+Luauthor=W.-T.+Zhaoauthor=H.-Y.+Zhaoauthor=Z.-Y.+Linauthor=D.-F.+Zhangauthor=H.-H.+Huang&title=A+convenient+and+efficient+H2SO4-promoted+regioselective+monobromination+of+phenol+derivatives+using+N-bromosuccinimide&doi=10.1080%2F00397911.2019.1711415"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">A convenient and efficient H2SO4-promoted regioselective monobromination of phenol derivatives using N-bromosuccinimide</span></div><div class="casAuthors">Wu, Yong-Qi; Lu, Hai-Jia; Zhao, Wen-Ting; Zhao, Hong-Yi; Lin, Zi-Yun; Zhang, Dong-Feng; Huang, Hai-Hong</div><div class="citationInfo"><span class="NLM_cas:title">Synthetic Communications</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">813-822</span>CODEN:
                <span class="NLM_cas:coden">SYNCAV</span>;
        ISSN:<span class="NLM_cas:issn">0039-7911</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">A convenient, rapid H2SO4-promoted regioselective monobromination reaction with N-bromosuccinimide was developed.  The desired para-monobrominated or ortho-monobrominated products of phenol derivs. e.g., I were obtained in good to excellent yields with high selectivity.  Regioselective chlorination and iodination were also achieved in the presence of H2SO4 using N-chlorosuccinimide and N-iodosuccinimide, resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQOtqSrXn3J7Vg90H21EOLACvtfcHk0lhSSPPrCxvXXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisV2ltrg%253D&md5=9846fd05e30df2862e0f8574e33872a3</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1080%2F00397911.2019.1711415&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00397911.2019.1711415%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DY.-Q.%26aulast%3DLu%26aufirst%3DH.-J.%26aulast%3DZhao%26aufirst%3DW.-T.%26aulast%3DZhao%26aufirst%3DH.-Y.%26aulast%3DLin%26aufirst%3DZ.-Y.%26aulast%3DZhang%26aufirst%3DD.-F.%26aulast%3DHuang%26aufirst%3DH.-H.%26atitle%3DA%2520convenient%2520and%2520efficient%2520H2SO4-promoted%2520regioselective%2520monobromination%2520of%2520phenol%2520derivatives%2520using%2520N-bromosuccinimide%26jtitle%3DSynth.%2520Commun.%26date%3D2020%26volume%3D50%26spage%3D813%26epage%3D822%26doi%3D10.1080%2F00397911.2019.1711415" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Osa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hikima, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takino, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ida, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirono, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagase, H.</span></span> <span> </span><span class="NLM_article-title">Convenient synthesis of oxazolidinones by the use of halomethyloxirane, primary amine, and carbonate salt</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">5737</span>– <span class="NLM_lpage">5740</span>, <span class="refDoi"> DOI: 10.1021/jo0501644</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo0501644" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=1%3ACAS%3A528%3ADC%252BD2MXltVSltbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2005&pages=5737-5740&author=Y.+Osaauthor=Y.+Hikimaauthor=Y.+Satoauthor=K.+Takinoauthor=Y.+Idaauthor=S.+Hironoauthor=H.+Nagase&title=Convenient+synthesis+of+oxazolidinones+by+the+use+of+halomethyloxirane%2C+primary+amine%2C+and+carbonate+salt&doi=10.1021%2Fjo0501644"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Convenient synthesis of oxazolidinones by the use of halomethyloxirane, primary amine, and carbonate salt</span></div><div class="casAuthors">Osa, Yumiko; Hikima, Yuka; Sato, Yoko; Takino, Kouichi; Ida, Yoshihiro; Hirono, Shuichi; Nagase, Hiroshi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5737-5740</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Primary amines reacted with carbonate salts (Na2CO3, K2CO3, Cs2CO3, and Ag2CO3) and halomethyloxiranes in the presence of a base such as DBU or TEA to give oxazolidinones in high yields.  The use of K2CO3 among these carbonate gave the best yield in this synthesis.  A reaction mechanism was proposed that the oxazolidinone was obtained from an oxazinanone intermediate via a bicyclo[2.2.1] intermediate.  The present reaction can be widely applied to convenient synthesis of useful N-substituted oxazolidinones and chiral oxazolidinones.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAzE5W-3AQ4LVg90H21EOLACvtfcHk0lhSSPPrCxvXXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXltVSltbo%253D&md5=623eccfcb67bfa938ca1d032c84d9595</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjo0501644&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo0501644%26sid%3Dliteratum%253Aachs%26aulast%3DOsa%26aufirst%3DY.%26aulast%3DHikima%26aufirst%3DY.%26aulast%3DSato%26aufirst%3DY.%26aulast%3DTakino%26aufirst%3DK.%26aulast%3DIda%26aufirst%3DY.%26aulast%3DHirono%26aufirst%3DS.%26aulast%3DNagase%26aufirst%3DH.%26atitle%3DConvenient%2520synthesis%2520of%2520oxazolidinones%2520by%2520the%2520use%2520of%2520halomethyloxirane%252C%2520primary%2520amine%252C%2520and%2520carbonate%2520salt%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2005%26volume%3D70%26spage%3D5737%26epage%3D5740%26doi%3D10.1021%2Fjo0501644" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Junquera, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merchán, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merino, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tejero, T.</span></span> <span> </span><span class="NLM_article-title">A straightforward synthesis of L-isoserinal</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">7045</span>– <span class="NLM_lpage">7052</span>, <span class="refDoi"> DOI: 10.1016/0040-4020(96)00309-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=10.1016%2F0040-4020%2896%2900309-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=1%3ACAS%3A528%3ADyaK28XjtV2qurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=1996&pages=7045-7052&author=F.+Junqueraauthor=F.+L.+Merch%C3%A1nauthor=P.+Merinoauthor=T.+Tejero&title=A+straightforward+synthesis+of+L-isoserinal&doi=10.1016%2F0040-4020%2896%2900309-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">A straightforward synthesis of L-isoserinal</span></div><div class="casAuthors">Junquera, Federico; Merchan, Francisco L.; Merino, Pedro; Tejero, Tomas</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7045-7052</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A convenient prepn. of an L-isoserinal deriv. in six steps and 32.8% overall yield employing D-glyceraldehyde acetonide as starting material is described.  The procedure is inexpensive, easily scaled up and proceeds without observable racemization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorxFSKcj6E4rVg90H21EOLACvtfcHk0lhSSPPrCxvXXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XjtV2qurg%253D&md5=bb935460ada392c2e7b3ff886cbf006b</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2F0040-4020%2896%2900309-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0040-4020%252896%252900309-2%26sid%3Dliteratum%253Aachs%26aulast%3DJunquera%26aufirst%3DF.%26aulast%3DMerch%25C3%25A1n%26aufirst%3DF.%2BL.%26aulast%3DMerino%26aufirst%3DP.%26aulast%3DTejero%26aufirst%3DT.%26atitle%3DA%2520straightforward%2520synthesis%2520of%2520L-isoserinal%26jtitle%3DTetrahedron%26date%3D1996%26volume%3D52%26spage%3D7045%26epage%3D7052%26doi%3D10.1016%2F0040-4020%2896%2900309-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zubkov, F. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikitina, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galeev, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaytsev, V. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khrustalev, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novikov, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlova, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varlamov, A. V.</span></span> <span> </span><span class="NLM_article-title">General synthetic approach towards annelated 3<i>a</i>,6-epoxyisoindoles by tandem acylation/IMDAF reaction of furylazaheterocycles. Scope and limitations</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">1659</span>– <span class="NLM_lpage">1690</span>, <span class="refDoi"> DOI: 10.1016/j.tet.2014.01.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=10.1016%2Fj.tet.2014.01.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlKmsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2014&pages=1659-1690&author=F.+I.+Zubkovauthor=E.+V.+Nikitinaauthor=T.+R.+Galeevauthor=V.+P.+Zaytsevauthor=V.+N.+Khrustalevauthor=R.+A.+Novikovauthor=D.+N.+Orlovaauthor=A.+V.+Varlamov&title=General+synthetic+approach+towards+annelated+3a%2C6-epoxyisoindoles+by+tandem+acylation%2FIMDAF+reaction+of+furylazaheterocycles.+Scope+and+limitations&doi=10.1016%2Fj.tet.2014.01.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">General synthetic approach towards annelated 3a,6-epoxyisoindoles by tandem acylation/IMDAF reaction of furylazaheterocycles. Scope and limitations</span></div><div class="casAuthors">Zubkov, Fedor I.; Nikitina, Eugenia V.; Galeev, Timur R.; Zaytsev, Vladimir P.; Khrustalev, Victor N.; Novikov, Roman A.; Orlova, Daria N.; Varlamov, Alexey V.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1659-1690</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">An efficient and versatile one-pot synthesis of 3,6a-epoxyisoindoles annelated with oxazine, oxazole, thiazine, thiazole, pyrimidine fragments and with their benzoannelated analogs is presented.  The method is based on tandem N-acylation/intramol. cycloaddn. (the intramol. Diels-Alder reaction of furan, IMDAF) reaction between α,β-unsatd. acid anhydrides and α-furyl substituted azaheterocycles.  The latter can be easily prepd. by condensation of diverse furfurals and 1,2- or 1,3-N,X-binucleophiles (aminoalcs., aminothiols, diamines).  The obsd. IMDAF reaction is stereoselective: exo-adducts are formed exclusively with large prevalence of one of the diastereoisomers.  In most cases, the condensation/N-acylation/IMDAF reaction sequence may be carried out via a one-pot domino protocol.  The scope and limitations of the proposed approach are thoroughly investigated.  The obtained Diels-Alder adducts are attractive and useful substrates for further transformations.  Fused isoindoles can be prepd. from them in one-step by aromatization of the 7-oxabicyclo[2.2.1]heptene ring.  Other transformations, including halogenation, ring cleavage, and Wagner-Meerwein skeletal rearrangement, are also demonstrated.  The spatial structures of the obtained compds. have been established by X-ray diffraction analyses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEcXepOY-ANLVg90H21EOLACvtfcHk0ljHrbF4U7inZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlKmsbg%253D&md5=9c48727e215baecffb3a0db89d43b58e</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2014.01.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2014.01.008%26sid%3Dliteratum%253Aachs%26aulast%3DZubkov%26aufirst%3DF.%2BI.%26aulast%3DNikitina%26aufirst%3DE.%2BV.%26aulast%3DGaleev%26aufirst%3DT.%2BR.%26aulast%3DZaytsev%26aufirst%3DV.%2BP.%26aulast%3DKhrustalev%26aufirst%3DV.%2BN.%26aulast%3DNovikov%26aufirst%3DR.%2BA.%26aulast%3DOrlova%26aufirst%3DD.%2BN.%26aulast%3DVarlamov%26aufirst%3DA.%2BV.%26atitle%3DGeneral%2520synthetic%2520approach%2520towards%2520annelated%25203a%252C6-epoxyisoindoles%2520by%2520tandem%2520acylation%252FIMDAF%2520reaction%2520of%2520furylazaheterocycles.%2520Scope%2520and%2520limitations%26jtitle%3DTetrahedron%26date%3D2014%26volume%3D70%26spage%3D1659%26epage%3D1690%26doi%3D10.1016%2Fj.tet.2014.01.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span> <span> </span><span class="NLM_article-title">Efficient and stereoselective one-pot synthesis of benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-1-ones</span>. <i>RSC Adv.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">24037</span>– <span class="NLM_lpage">24044</span>, <span class="refDoi"> DOI: 10.1039/D0RA04104A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=10.1039%2FD0RA04104A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlSrsr3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2020&pages=24037-24044&author=H.+Zhaoauthor=W.+Zhaoauthor=S.+Chengauthor=H.+Luauthor=D.+Zhangauthor=H.+Huang&title=Efficient+and+stereoselective+one-pot+synthesis+of+benzo%5Bb%5Doxazolo%5B3%2C4-d%5D%5B1%2C4%5Doxazin-1-ones&doi=10.1039%2FD0RA04104A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Efficient and stereoselective one-pot synthesis of benzo[b]oxazolo[3,4-d][1,4]oxazin-1-ones</span></div><div class="casAuthors">Zhao, Hongyi; Zhao, Wenting; Cheng, Shihao; Lu, Haijia; Zhang, Dongfeng; Huang, Haihong</div><div class="citationInfo"><span class="NLM_cas:title">RSC Advances</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">24037-24044</span>CODEN:
                <span class="NLM_cas:coden">RSCACL</span>;
        ISSN:<span class="NLM_cas:issn">2046-2069</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">An efficient and mild one-pot convergent synthesis protocol has been developed for benzo[b]oxazolo[3,4-d][1,4]oxazin-1-one derivs. through the Mitsunobu reaction and sequential cyclization.  Various tricyclic fused benzoxazinyl-oxazolidinones (20 examples) were obtained in good to excellent yields and high enantioselectivities with facile operation.  Furthermore, four stereoisomers were afforded resp. in high ee values (>97.8%) via using different chiral 2,3-epoxy-4-trityloxybutanol.  This methodol. has been applied to the synthesis of key intermediates of drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFPYa3eAl2TbVg90H21EOLACvtfcHk0ljHrbF4U7inZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlSrsr3N&md5=89f2d8ace5b659d0b1511f50f72f3c20</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1039%2FD0RA04104A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FD0RA04104A%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DCheng%26aufirst%3DS.%26aulast%3DLu%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DHuang%26aufirst%3DH.%26atitle%3DEfficient%2520and%2520stereoselective%2520one-pot%2520synthesis%2520of%2520benzo%255Bb%255Doxazolo%255B3%252C4-d%255D%255B1%252C4%255Doxazin-1-ones%26jtitle%3DRSC%2520Adv.%26date%3D2020%26volume%3D10%26spage%3D24037%26epage%3D24044%26doi%3D10.1039%2FD0RA04104A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McKee, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bentley, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marks, T. A.</span></span> <span> </span><span class="NLM_article-title">Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">2042</span>– <span class="NLM_lpage">2049</span>, <span class="refDoi"> DOI: 10.1128/AAC.01411-05</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=10.1128%2FAAC.01411-05" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=16723564" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;key=1%3ACAS%3A528%3ADC%252BD28XlsVOitbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2006&pages=2042-2049&author=E.+E.+McKeeauthor=M.+Fergusonauthor=A.+T.+Bentleyauthor=T.+A.+Marks&title=Inhibition+of+mammalian+mitochondrial+protein+synthesis+by+oxazolidinones&doi=10.1128%2FAAC.01411-05"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones</span></div><div class="casAuthors">McKee, E. E.; Ferguson, M.; Bentley, A. T.; Marks, T. A.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2042-2049</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The effects of a variety of oxazolidinones, with different antibacterial potencies, including linezolid, on mitochondrial protein synthesis were detd. in intact mitochondria isolated from rat heart and liver and rabbit heart and bone marrow.  The results demonstrate that a general feature of the oxazolidinone class of antibiotics is the inhibition of mammalian mitochondrial protein synthesis.  Inhibition was similar in mitochondria from all tissues studied.  Further, oxazolidinones that were very potent as antibiotics were uniformly potent in inhibiting mitochondrial protein synthesis.  These results were compared to the inhibitory profiles of other antibiotics that function by inhibiting bacterial protein synthesis.  Of these, chloramphenicol and tetracycline were significant inhibitors of mammalian mitochondrial protein synthesis while the macrolides, lincosamides, and aminoglycosides were not.  Development of future antibiotics from the oxazolidinone class will have to evaluate potential mitochondrial toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYWXrB0u0817Vg90H21EOLACvtfcHk0ljHrbF4U7inZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlsVOitbo%253D&md5=4dce4c12ad8fddadae1fd90953a596d1</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1128%2FAAC.01411-05&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01411-05%26sid%3Dliteratum%253Aachs%26aulast%3DMcKee%26aufirst%3DE.%2BE.%26aulast%3DFerguson%26aufirst%3DM.%26aulast%3DBentley%26aufirst%3DA.%2BT.%26aulast%3DMarks%26aufirst%3DT.%2BA.%26atitle%3DInhibition%2520of%2520mammalian%2520mitochondrial%2520protein%2520synthesis%2520by%2520oxazolidinones%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2006%26volume%3D50%26spage%3D2042%26epage%3D2049%26doi%3D10.1128%2FAAC.01411-05" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i76"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02153">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_55657"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c02153?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02153</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Synthesis of compounds <b>10a</b>–<b>c</b>, <b>14</b>, and <b>49</b>; NMR spectra of all compounds; chiral HPLC of compounds <b>(±)-18a</b>, <b>18a</b>, <b>(±)-20a</b>, <b>20aa</b>, <b>20ab</b>, <b>(±)-24</b>, and <b>24</b>; plasma exposure of compound <b>20aa</b> in mouse (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02153/suppl_file/jm0c02153_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02153/suppl_file/jm0c02153_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02153/suppl_file/jm0c02153_si_001.pdf">jm0c02153_si_001.pdf (6.6 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02153/suppl_file/jm0c02153_si_002.csv">jm0c02153_si_002.csv (4.04 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c02153%3Bwgroup%3Astring%3AACHS+website+Group%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-6%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c02153" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67994df45dda3c58","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
